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This thesis has been composed by myself.
The first two chapters are based on
personal surveys of the literature, and the
rest of the thesis is composed of clinical
studies performed with a group of colleagues
in the Departments of Anaesthetics and
Clinical Chemistry, Royal Infirmary of
Edinburgh.
I was the principal investigator in the
studies of the effect of nicardipine and
cimetidine on plasma GST concentration; in
the remaining two studies I shared the
responsibility and duties of the principal
investigator with Dr Louise Aldridge who
has kindly allowed me to include the
results of those studies in this thesis.
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ABSTRACT
On rare occasions, halothane anaesthesia is associated
with liver damage. Two forms of toxicity are now
recognised - a mild form manifest by increased serum
liver enzymes, and a rarer, fulminant form which may be
fatal. The historical background, clinical features,
morphology and epidemiology of halothane hepatitis are
presented, and animal models of halothane hepatotoxicity
are described; current perspectives on its aetiology are
reviewed.
The application of serum enzymes to the recognition of
acute liver injury is reviewed, and the limitations of
those in current use are described. The measurement of
glutathione S-transferase (GST) in plasma by specific
radioimmunoassay offers potential for the early detection
of drug-induced, hepatocellular damage. The structure,
classification, distribution and techniques for
measurement of GST are presented, and experience with
their use in various liver disorders is explored. The
influence of general anaesthesia on several liver enzymes
is examined, and the advantages of GST over conventional
liver enzymes are discussed.
The effects of halothane, enflurane and isoflurane
anaesthesia on plasma GST concentration after operation
are reported. GST concentration increased 3-6 hours
after anaesthesia with halothane and enflurane, and more
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marked increases were observed at 24 hours in some of the
patients who received these agents: GST did not increase
at any time in patients who received isoflurane. The
incidence of abnormal GST concentrations after
anaesthesia with halothane, enflurane and isoflurane
directly correlated with the incidence of reported
clinical hepatic dysfunction for these drugs.
Three of the proposed aetiologies of halothane hepatitis,
namely altered hepatocellular calcium balance, toxic
products of biotransformation and hepatic hypoxia, were
investigated subsequently in more detail. Perioperative
administration of the calcium channel blocker nicardipine
did not influence GST release after halothane
anaesthesia. Cimetidine, which reduces halothane
metabolism, did not influence GST release either. In
patients undergoing artificial ventilation, a greater
increase in GST concentration occurred at 1 hour after
anaesthesia compared with the change that occurred in
patients who breathed spontaneously.
These studies suggest that a different mechanism is
responsible for the two phases of toxicity recognised in
the 24 hours after anaesthesia: an early phase up to 6
hours may result from hepatic hypoxia or altered calcium
balance, while toxic products of metabolism may produce a
secondary phase at 24 hours. This supports the proposal
that the aetiology of the mild form of halothane-induced
liver damage is multifactorial.
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HALOTHANE HEPATITIS - A REVIEW
HISTORICAL BACKGROUND
Liver dysfunction following exposure to volatile
halogenated anaesthetics has long been established. The
first recorded case of unexplained jaundice following
chloroform anaesthesia occurred in 1848 [Defalque 1968],
only one year after its introduction into clinical
practice by Simpson. Halothane was introduced for
clinical use in 1956 and was hailed immediately as a
great advance in anaesthesia [Johnstone 1956] . Its
advantages of potency, lack of flammability and general
smoothness of administration led rapidly to widespread
use. Initial animal studies in rats [Krantz et al
1958], dogs [Raventos 1958; Virtue et al 1958] and
monkeys [Stephen et al 1958] indicated minimal or no
hepatotoxicity, and in particular no hepatic necrosis was
observed after halothane compared to chloroform or
divinyl ether [Jones, Margolis & Stephen 1958].
Early Reports
The early clinical accounts on the use of halothane in
man supported the animal studies; no liver necrosis was
recorded [Robson & Sheridan 1957; Little, Barbour & Given
1958]. Reports of postoperative liver necrosis after
the use of halothane began to appear in 1958 [Virtue &
Payne 1958; Burnap, Galla & Vandam 1958] and further
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anecdotal reports followed [Temple, Cote & Gorens 1962;
Bunker & Blumenfeld 1963; Lindenbaum & Leifer 1963; Brody
& Sweet 1963]. By 1963, five years after the widespread
international use of halothane, at least 350 cases of
"halothane hepatitis" had been recorded [Brown & Gandolfi
1987].
Retrospective Studies in Man
The general concern precipitated a number of
retrospective surveys of hepatic dysfunction following
general anaesthesia [Slater et al 1964; Henderson &
Gordon 1964; Mushin et al 1964; Allen & Metcalf 1964;
Dykes et al 1965; Trey et al 1968; Klion, Schaffner &
Popper 1968; Peters et al 1969]. These studies were
conducted in different geographical locations and
reviewed approximately 230,000 general anaesthetics of
which about 50% had included halothane. When compared
to other general anaesthetic agents there was no evidence
that halothane had caused an increased incidence of
postoperative liver damage. These reports led to the
National Halothane Study which reviewed cases of fatal
hepatic necrosis occurring within 6 weeks of anaesthesia
in 34 hospital centres in the United States of America
[National Halothane Study 1969]. Over the 4 year period
of the study, 82 cases of fatal hepatic necrosis were
collected from some 856,000 administrations of general
anaesthesia, of which about 255,000 involved halothane.
In all but nine of these cases the necrosis could be
assigned to a recognisable clinical factor. Seven of
7
these patients with unexplained liver necrosis had
received halothane, and four of the seven had received
halothane on more than one occasion within the previous 6
weeks. Thus the incidence of fatal hepatic necrosis
following halothane anaesthesia in this study was
approximately 1 in 35,000.
The result of this massive study published in 1969 was
unfortunately totally inconclusive. The intention had
been to compare the incidence of fatal, massive hepatic
necrosis within six weeks of halothane anaesthesia with
that of other general anaesthetics. In this respect
halothane compared favourably; cyclopropane was
associated with the greatest overall estimated necrosis
rate (1.7 per 10,000 anaesthetics compared with 1.02 per
10,000 anaesthetics for halothane). Furthermore, no
patient who developed jaundice after halothane and died
after a second administration, was found at post mortem
to have suffered massive or intermediate hepatic
necrosis. Weaknesses in the study design may have
prejudiced the results: the study was retrospective,
although the original intention had been to establish a
prospective survey, and reporting bias might have
occurred, as some of the institutions involved had
already published anecdotal case reports of liver
dysfunction associated with halothane. In addition,
there was no information available on post mortem
examination of the abdominal viscera in 40% of the deaths
considered in the study. It is also noteworthy that
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differences in death rates between institutions (lowest
0.27%, highest 6.41%) were greater than differences
between anaesthetics, even after adjusting the rates for
differences in operating patterns, and the age and
physical status of the institutional cohorts. The main
conclusions which emerged from this study were that
massive hepatic necrosis after anaesthesia was a rare
occurrence (approximately 1 in 10,000), although an
association with halothane could neither be confirmed nor
excluded, and that halothane had a good overall record of
safety, including use in operations involving the gall
bladder and biliary tract.
Other retrospective studies confirmed that halothane was
associated with severe liver dysfunction, with an
incidence ranging from 1 in 6,000 to 1 in 20,000 [Inman &
Mushin 1974; Bottiger, Dalen & Hallen 1976]. In
addition, it became apparent that there was a greater
problem with repeated exposure to halothane, especially
at short intervals [Moult & Sherlock 1975; Inman & Mushin
1974; Inman & Mushin 1978; Bottiger, Dalen & Hallen
1976] . In a comprehensive review, Walton and his
colleagues (1976) described 203 patients with jaundice
following anaesthesia in the United Kingdom. Full
clinical and biochemical details of these cases were
reviewed blindly by a panel of hepatologists, who
considered that the hepatitis could not be attributed to
an identifiable cause in 76 patients who had received
halothane. Of these, 95% had received multiple
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halothane anaesthetics; in 55% of cases, the repeat
exposure was within 4 weeks. Also noted was an
increased incidence in women, middle-aged and obese
patients, and a high incidence of thyroid antibodies was
found in patients whose jaundice was not related to any
identifiable cause. However, as it was not possible to
distinguish the clinical or biochemical course of
hepatitis in these patients from that in viral hepatitis,
the authors stressed that they did not attribute all of
these 76 cases to halothane hepatotoxicity.
Prospective Studies in Man
Three small, but well-controlled, prospective studies of
changes in liver biochemical tests after anaesthesia and
minor surgery have been reported from Britain [Wright et
al 1975; Trowell, Peto & Smith 1975; Fee et al 1979],
The former showed that increased serum activities of
aspartate aminotransferase (AST) occurred in 15 of 76
patients who received multiple halothane anaesthetics
compared with 4 of 76 patients who received
trichloroethylene. Trowell, Peto and Smith (1975) found
the serum activity of alanine aminotransferase (ALT) to
be greater than 100 U l-1 in 4 out of 18 patients
receiving halothane, two of whom displayed hepatocellular
necrosis on liver biopsy. None of the 21 patients who
received repeated non-halothane anaesthesia showed
similar increases. The choice of anaesthetic technique,
however, did not influence the number of patients who
developed serum activities of ALT which exceeded the
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upper limit of the reference range (9/18 halothane, 6/21
non-halothane).
Fee and colleagues (1979) analysed data from 129 patients
who underwent minor urological operations, 63 of whom
received two or more administrations of halothane, and
the remainder two or more enflurane anaesthetics.
Although no patient in this study showed overt signs of
liver dysfunction, more liver enzyme abnormalities
occurred after multiple exposures to halothane than after
repeated enflurane anaesthesia. This difference between
the groups disappeared when obese patients or those
exposed to anaesthesia in the preceding 6 weeks were
excluded. In spite of its detailed and expensive plan,
this study suffered from two fundamental limitations; the
number of patients available was too small to draw firm
conclusions, and the interval between anaesthetics was
very variable and often more than 4 weeks. This meant
that no conclusion could be drawn on the validity or
otherwise of the recommended minimum interval of 28 days
between halothane anaesthetics which pertained at that
time.
To add to the confusion, other workers had published
reports which disagreed about the effect of multiple
halothane anaesthetics on biochemical liver tests.
McEwan (1976) found a smaller frequency of disturbance of
ALT and AST in patients after repeated halothane
anaesthesia than in patients receiving non-halothane
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anaesthesia after previous halothane, while Allen and
Downing (1977) who investigated the effect of multiple
anaesthetics with either halothane or enflurane in South
African black women, found only minimal increases in
serum aminotransferases, although the gap between
re-exposures was considerably longer than 6 weeks.
In a more recent Danish study of postoperative
complications, Zaric and colleagues (1986) encountered
four cases of presumed halothane hepatitis in 2609
consecutive surgical patients, of whom 1166 were
anaesthetised with halothane; no case of hepatitis was
reported among the other patients who had received
enflurane, regional or intravenous anaesthesia. All
four implicated patients were obese, middle-aged females
who underwent non-abdominal surgery, and three of the
four had received halothane previously.
Most of these prospective studies, however, have
described only altered liver biochemical tests and not
the full clinical syndrome of halothane hepatitis.
EPIDEMIOLOGY
Several possible risk factors for the development of
halothane hepatitis have become apparent on the basis of
reported cases (Table 1.1).
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The risk of halothane hepatitis is increased greatly when
repeated halothane anaesthetics are given over a short
period [Inman & Mushin 1974; Inman & Mushin 1978; Moult &
Sherlock 1975; Bottiger, Dalen & Hallen 1976]. More
than 80% of patients who develop hepatic necrosis after
halothane have been exposed previously to the agent
[Touloukian & Kaplowitz 1981; Walton et al 1976], and up
to two-thirds of patients who develop fulminant hepatic
failure after halothane may have had a documented adverse
reaction to halothane, such as postoperative pyrexia,
nausea and jaundice [Neuberger & Williams 1984]. Inman
and Mushin (1978) reviewed 251 cases of alleged halothane
hepatotoxicity reported to the Committee on Safety of
Medicines. Of these, 82% involved multiple exposure to
halothane, and 75% of these patients had been exposed
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more than once within 28 days. Irrespective of the
interval, multiple exposure was associated with a higher
mortality (51%) than was single exposure (35%).
Although the incidence of dysfunction appeared to be
maximal when the penultimate exposure was within 28 days,
cases have been reported when the penultimate exposure
was several years previously [Inman & Mushin 1974;
Neuberger & Williams 1984]. The shorter the interval
between exposures, the more severe is the hepatic
dysfunction and the shorter is the latency before
presentation [Moult & Sherlock 1975; Inman & Mushin 1978;
Neuberger & Williams 1984].
Middle age
Middle-aged patients have a greater propensity to develop
liver damage than the young or elderly [Carney & Van Dyke
1972; Neuberger & Williams 1984; Cousins, Plummer & Hall
1989]; 70% of cases occur in patients older than 40
years, and the peak incidence occurs between 50 and 60
years. In comparison with the age distribution of
patients undergoing anaesthesia, patients with
halothane-induced liver disease are slightly older
[Bottiger, Dalen & Hallen 1976; Carney & Van Dyke 1972;
Neuberger & Williams 1984] . Severe hepatic dysfunction
after halothane anaesthesia in children was not
considered previously to be a hazard, but an increasing
number of reports indicate that it can occur [Wark 1983;
Warner et al 1984; Whitburn & Sumner 1986; Wark,
O'Halloran & Overton 1986; Kenna et al 1987]. The
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incidence in children is, however, considerably smaller
than in adults (between 1 in 82,000 [Wark 1983] and 1 in
200,000 [Warner et al 1984]). Despite its occurrence,
halothane is still particularly indicated for, even
repeated, anaesthesia in children [Walton 1986; Weis &
Engelhardt 1989].
Obesity
Hepatic dysfunction is more common in obese than in
non-obese patients [Peters et al 1969; Carney & Van Dyke
1972; Walton et al 1976]. As halothane accumulates in
adipose tisue, this could delay its excretion and,
theoretically, prolong exposure to potentially reactive
halothane metabolites, resulting in increased risk in
obese patients. In addition, obese patients metabolise
halothane more extensively than do non-obese patients
[Bentley et al 1982], which might further predispose them
to liver injury.
Female gender
Although there is no difference in exposure to halothane
between the two sexes [Carney & Van Dyke 1972], females
are at approximately double the risk than males of
developing halothane hepatitis [Neuberger & Williams
1984; Benjamin et al 1985], although male patients
apparently have a worse prognosis [Moult & Sherlock 1975;
Walton et al 1976; Bottiger, Dalen & Hallen 1976]. In a
rat model of halothane hepatotoxicity, however, halothane
is less hepatotoxic in females than in males [Plummer et
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al 1985; Jee et al 1980]. Recently, Jenner, Plummer and
Cousins (1990) have shown that reductive
biotransformation of halothane was more extensive in
females than in males undergoing routine anaesthesia,
which might explain the association between female gender
and halothane hepatotoxicity.
Genetics and ethnic origin
Susceptibility to halothane hepatitis may, to a certain
extent, be heritable. Hoft and colleagues (1981) have
reported cases of halothane hepatitis in three pairs of
closely related women of Mexican-Indian or
Mexican-Spanish descent. In addition, Farrell and
coworkers (1985) have suggested that a familial
susceptibility factor may exist. Furthermore, patients
with unexplained hepatic failure after halothane are
reported to have different human lymphocyte antigen (HLA)
frequencies to healthy controls [Otsuka et al 1985],
providing additional evidence of genetic predisposition.
Enzyme induction
The association between hepatotoxicity and repeated
exposure to halothane might be explained if halothane
anaesthesia itself induced drug metabolising enzymes.
Using antipyrine half-life or clearance as an index of
drug metabolising capacity, halothane has been shown to
cause microsomal enzyme induction in both adults [Nimmo,
Thompson & Prescott 1981] and children [Haxholdt et al
1986]. Further support for this hypothesis is provided
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in a retrospective analysis of 279 patients who underwent
brain surgery during halothane anaesthesia [Nomura et al
1986] . The incidence of halothane-induced liver injury
was greater in subjects treated with phenobarbitone
before surgery (7/100) than in those not taking
enzyme-inducing medication (1/179).
Other factors such as type of surgery and the presence of
pre-existing liver disease might also be expected to
influence the development of liver necrosis after
anaesthesia. However, no correlation between
hepatotoxicity and duration, site or severity of surgery
(including hepatobiliary procedures) has been shown in
man [Benjamin et al 1985], and in fact halothane
hepatitis may follow apparently uneventful anaesthesia
for minor surgery [Neuberger & Williams 1984].
Similarly, there is no convincing evidence that patients
with pre-existing, compensated liver disease are at any
greater risk of developing halothane hepatotoxicity than
healthy patients [Brown 1985; Cousins et al 1989; Stock &
Strunin 1985]. Radiation therapy in association with
repeated exposure to halothane was considered previously
to increase risk of hepatic damage [Hughes & Powell 1970]
but subsequent studies have not confirmed this [Allen &
Downing 1977; Wark, Clifton & Bookallil 1979].
Halothane hepatotoxicity is not restricted to patients
undergoing anaesthesia. Liver damage following
occupational exposure to halothane has been reported in
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medical personnel including anaesthetists, surgeons and
laboratory workers [Belfrage, Ahlgren & Axelson 1966;
Klatskin & Kimberg 1969; Johnston & Mendelsohn 1971;
Lund, Skulberg & Helle 1974; Neuberger et al 1981b; Lings
1988]. In two surgeons specific "halothane antibody"
was present, and three of these individuals developed
hepatitis following deliberate re-exposure to halothane,
providing compelling evidence for the existence of
halothane hepatotoxicity [Dykes 1977].
CLINICAL FEATURES
Halothane hepatitis is characterised by several
consistent clinical features (Table 1.2). Many patients
complain initially of malaise, anorexia and nonspecific
gastrointestinal symptoms such as nausea and upper
abdominal discomfort [Klion, Schaffner & Popper 1969;
Moult & Sherlock 1975]. The onset of fever is
characteristically the first sign of illness. Klion,
Schaffner and Popper (1969) found pyrexia in 37 of 42
patients with presumed halothane hepatotoxicity, but only
persistent or recurrent fever was related to the onset of
hepatitis. Moult and Sherlock (1975) described a
pattern of delayed pyrexia after exposure to halothane in
eight patients, and 75% of patients in a series from
King's College Hospital, London, developed unexplained
fever after operation [Neuberger & Williams 1984]. The
mean interval between operation and onset of fever was 7
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days after a first exposure, whereas multiple exposures
were associated with a reduced latent period of 4 days
[Bottiger, Dalen & Hallen 1976] . Not all patients
become pyrexial, however [Walton et al 1976], and the
value of unexplained postoperative fever as an indicator
of sensitisation to halothane has been questioned [Dykes
1971].
Table 1.2








Jaundice occurs almost invariably. Many studies have
shown that its appearance is delayed until the 5th or
6th day after exposure [Moult & Sherlock 1975; Inman &
Mushin 1978; Neuberger & Williams 1984], although rarely
it can be delayed by up to 4 weeks [Klion, Schaffner &
Popper 1969]. As with fever, multiple exposures to
halothane are associated with a shorter delay in
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appearance of jaundice than that after a single exposure.
In a series of 251 cases reported to the Committee on
Safety of Medicines, patients became icteric after a mean
delay of 11 days following a single exposure and about 4
to 6 days in instances of multiple exposures [Inman &
Mushin 1978].
Eosinophilia is occasionally present, its incidence
ranging from 8% to 32% [Klion, Schaffner & Popper 1969;
Moult & Sherlock 1975; Walton et al 1976; Bottiger, Dalen
& Hallen 1976]. Serum autoantibodies are often found
during the course of liver failure. Walton and
colleagues (1976) found liver kidney microsomal
antibodies in 19 of 76 patients with unexplained jaundice
after halothane, with a similarly high incidence of
thyroid antibodies. Neuberger and Williams (1984)
identified serum autoantibodies (antiliver kidney
microsomal, antismooth muscle, and antinuclear) in 44% of
their patients. A small number of patients may develop
a nonspecific rash, or arthralgia [Walton et al 1976] .
Biochemical tests of liver function generally reflect
changes which are typical of hepatocellular damage.
Serum aminotransferase activities are frequently grossly
increased (500 to 2000 U 1_1) [Klion, Schaffner & Popper;
Moult & Sherlock 1975; Bottiger, Dalen & Hallen 1976],
although the degree of increase can vary widely [Walton
et al 1976]. Alkaline phosphatase activity, although
increased, is generally less than twice the upper limit
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of normal [Walton et al 1976]. Clinically insignificant
disturbances in liver biochemical tests are common
following halothane, and, to a lesser extent, after
enflurane. These alterations are not related to acute
necrosis in an obvious spectrum, and have not been shown
to have important sequelae [Fee et al 1979].
PATHOLOGY
Light microscopy
The most notable histological feature of halothane
hepatitis is centrilobular necrosis [Slater et al 1964;
Blackburn, Ngai & Lindenbaum 1964; Klion, Schaffner &
Popper 1969; Schatzki, Kay & McGavic 1973; Wills & Walton
1978; Uzunalimoglu, Yardley & Boitnott 1970; Benjamin et
al 1985]. A spectrum of severity exists from panlobular
and multifocal spotty necrosis through to massive
necrosis. There is associated ballooning degeneration
of hepatocytes with subsequent inflammatory infiltrate,
collapse and stromal fibrosis. Fatty infiltration has
been noted also by several investigators [Lindenbaum &
Leifer 1963; Slater et al 1964; Blackburn, Ngai &
Lindenbaum 1964; Klion, Schaffner & Popper 1969; Benjamin
et al 1985]. Granulomatous aggregates are occasionally
seen [Benjamin et al 1985]. As many of these features
occur in viral hepatitis, it can be difficult to
distinguish between the two conditions on light
microscopy, although a number of authors consider that
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such distinction can be made [Peters et al 1969; Klion,
Schaffner & Popper 1969; Uzunalimoglu, Yardley & Boitnott
1970; Benjamin et al 1985].
Electron microscopy
Klion, Schaffner and Popper (1969) described
mitochondrial membrane abnormalities as the most
prominent feature seen on electron microscopy in
halothane hepatitis. Although these findings were
confirmed by Uzunalimoglu, Yardley and Boitnott (1970),
other workers have noted only very mild or less frequent
changes [Wills & Walton 1978; Schatzki, Kay & McGavic
1973]. More recently, Goldfarb and colleagues (1989)
used electron microscopy to examine liver biopsy
specimens taken during anaesthesia with halothane,
isoflurane or droperidol. No mitochondrial
abnormalities were seen, but significantly more lysosomes
were found in the hepatocytes of patients receiving
halothane than in those receiving isoflurane or
droperidol. It appears that halothane can induce
ultrastructural abnormalities very early after the
beginning of its administration, while under the same
conditions, isoflurane does not. However, as none of
these patients subsequently developed clinically obvious
liver damage, the relation of these ultrastructural




There are classically four major theories proposed to
account for halothane hepatotoxicity: toxic products of
metabolism, hypersensitivity, regional hepatic hypoxia
and genetic predisposition. To these has been added
more recently a fifth theory: that of altered
hepatocellular calcium homeostasis.
Biotransformation
Inhalation anaesthetic agents have been thought
classically to be inert and not to undergo
biotransformation in the body. This concept was not
challenged until 1964 when Van Dyke, Chenoweth and Van
Poznak (1964) demonstrated the metabolism of several
volatile anaesthetic agents including halothane. The
same group found that halothane metabolism occurred in
the microsomal fraction of the liver [Van Dyke &
Chenoweth 1965], and was increased by pretreatment with
phenobarbitone [Van Dyke 1966]. Halothane
biotransformation in man was confirmed by Stier and
colleagues (1964), and the extent of this metabolism was
found to be approximately 20% [Rehder et al 1967;
Cascorbi, Blake & Helrich 1970]. Two main pathways of
metabolism have been identified (Figure 1.1). Oxidative
metabolism is greater in the presence of high oxygen
tensions, while reductive metabolism is favoured by
hypoxic conditions and phenobarbitone pretreatment.
Both pathways exist in man, and reductive metabolism is
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known to occur in patients undergoing routine halothane
anaesthesia [Cousins et al 1987a]. Metabolism begins
soon after commencing the administration of halothane and
continues into the period immediately after anaesthesia
[Atallah & Geddes 1973; Gourlay et al 1980].
TFAA
Figure 1.1 Oxidative and reductive pathways of
halothane metabolism. Major products of
metabolism are enclosed in boxes.
Metabolic products recovered initially in urine were
predominantly bromide ion and trifluoroacetic acid (TFAA)
[Stier et al 1964; Rehder et al 1967], although later
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Cohen and colleagues (1975) demonstrated, in addition,
the formation of N-trifluoroacetyl-2-aminoethanol and
N-acetyl-S-(2-bromo-2-chloro-l,1-difluoroethyl)-L-
cysteine. All but the last of these are considered to
be products of oxidative metabolism. In 1977, Mukai and
coworkers (1977) identified two new volatile products of
reductive metabolism, 2-chloro-l,1,1-trifluoroethane
(CTF) and 2-chloro-l,1-difluoroethylene (CDF) in the
expired breath of rabbits exposed to halothane. The
formation of these products has been confirmed
subsequently in humans [Sharp, Trudell & Cohen 1979;
Gourlay et al 1980]. Van Dyke and Gandolfi (1976) had
found that fluoride ion was cleared from the halothane
molecule under reductive biotransformation; serum
fluoride, therefore, became a simple measure of reductive
metabolism of halothane.
Although none of the end products of either metabolic
pathway has been shown to be toxic per se, intermediate
products of biotransformation may be responsible for
direct hepatic injury; it has been proposed that liver
damage is mediated via reactive, free radical
intermediates, as occurs with the classical hepatotoxins
carbon tetrachloride (CC14) and chloroform (CHC13) .
Although free radicals are produced during administration
of halothane [Plummer et al 1982], there is no direct
evidence that they are responsible for halothane
hepatotoxicity. Moreover, Brown, Sipes and Sagalyn
(1974) found that halothane hepatotoxicity does not
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proceed by the same sequence of events as that caused by
chloroform, and Cohen and Chance (1990) have demonstrated
significant differences in hepatic pathology associated
with the two agents. Trifluoroethanol, a precursor of
TFAA, has been postulated as a metabolite of halothane
[Cohen 1971], although it has not been identified in
humans: there is conflicting evidence for its ability to
produce hepatic necrosis [Rosenberg & Wahlstrom 1971;
Blake et al 1969].
Using low-temperature autoradiography with labelled
halothane [Cohen & Hood 1969], Cohen (1969) demonstrated
that non-volatile metabolites were bound covalently to
liver macromolecules in mice for at least 2 weeks after
halothane exposure, although this could not be correlated
with hepatic necrosis as none was seen. Binding occurs
in the microsomal fraction of the liver [Van Dyke & Wood
1973] and depends on the transformation of volatile
agents by the mixed function oxidase-cytochrome P-450
system [Karashima et al 1977]. The extent of binding is
enhanced by inducers of cytochrome P-450, for example
phenobarbitone [Van Dyke 1973; Brown & Sipes 1977], and
is reduced by enzyme inhibitors, such as metyrapone
[Gandolfi et al 1980] and SKF 525A [Van Dyke & Wood
1973]. Covalent binding of metabolites increases under
hypoxic conditions [Uehleke, Hellmer &
Taberelli-Poplawski 1973], although oxygen is required
initially to convert halothane to the intermediate
metabolite which is bound [Van Dyke 1973]. Products
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from reductive metabolism are therefore thought to have
more hepatotoxic potential than oxidative metabolites
[Widger, Gandolfi & Van Dyke 1976; Gandolfi et al 1980].
It has been hypothesised that CF3C-HCl free radicals are
formed by cytochrome P-450, and that some of these
radicals then initiate lipid peroxidation in the
endoplasmic reticulum; the damage produced by this
process might be responsible ultimately for cell death
[de Groot & Noll 1983].
Enflurane and isoflurane undergo considerably less
metabolism than halothane during routine anaesthesia
(2.4% [Chase et al 1971] and 0.2% [Holaday et al 1975],
respectively). Neither drug is subject to reductive
metabolism, and neither produces free radicals [Plummer
et al 1982]. Because the extent of metabolism of
halothane, enflurane and isoflurane is directly related
to the incidence of reported clinical hepatic dysfunction
for these drugs, it is proposed that products of
metabolism play an integral role in the production of
halothane-induced liver injury. Furthermore, the
increased covalent binding of metabolites under hypoxic
conditions, the potential for producing free radicals as
a reactive intermediate, and the absence of effect of
deuterium substitution of halothane (which reduces
oxidative but not reductive metabolism) on the degree of
hepatotoxicity in the phenobarbitone-hypoxic rat model
[Sipes et al 1980], has focused much attention on
reductive halothane metabolism mediating hepatotoxicity.
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Immune-mediated
Several features of halothane-induced hepatotoxicity
point to hypersensitivity as a mechanism [Editorial
1986; Sherlock 1986]. These include the frequent
association with multiple exposures [Inman & Mushin 1974;
Inman & Mushin 1978; Moult & Sherlock 1975; Bottiger,
Dalen & Hallen 1976], the common history of drug allergy
or atopy [Carney & Van Dyke 1972; Walton et al 1976;
Zaric et al 1986], the association with fever and
eosinophilia [Klion, Schaffner & Popper 1968; Benjamin et
al 1985; Touloukian & Kaplowitz 1981], a history of
previous adverse reaction to halothane [Neuberger &
Williams 1984], provocation of hepatitis by deliberate
challenge in previously affected individuals [Belfrage,
Ahlgren & Axelson 1966; Klatskin & Kimberg 1969], and the
demonstration of circulating autoantibodies [Walton et al
1976; Rodriguez et al 1969; Neuberger & Williams 1984;
Sharpstone, Medley & Williams 1971]. Apart from the
positive challenge tests, however, none of these features
can be considered unique to immune involvement.
Initial studies to detect evidence of hypersensitivity
responses in patients with halothane hepatitis produced
conflicting results. Paronetto and Popper (1970)
demonstrated a positive lymphocyte transformation test in
patients with suspected halothane-induced liver disease,
but other studies failed to confirm this [Moult et al
1975; Walton et al 1973]. Following the demonstration
by Uehleke, Hellmer and Tabarelli-Poplawski (1973) that
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halothane metabolites could bind covalently to liver
macromolecules, it was postulated that a reactive
metabolite of halothane acted as a hapten which generated
an immune response. However, Reves and McCracken (1976)
could not induce hepatic necrosis in guinea pigs
sensitised to a halothane metabolite and challenged
subsequently with halothane.
In 1978, in vitro sensitisation of leucocytes to liver
homogenates prepared from rabbits exposed previously to
halothane was demonstrated in patients with halothane
hepatitis [Vergani et al 1978]. Circulating antibodies
that bound to the surface membrane of halothane-altered
rabbit hepatocytes were detected subsequently in about
75% of patients in whom fulminant hepatic failure
occurred after halothane anaesthesia [Kenna, Neuberger &
Williams 1984; Vergani et al 1980; Neuberger et al 1983].
These antibodies could not be detected in the serum of
normal healthy controls, patients with other types of
liver disease, or patients exposed to halothane with no
liver damage. The antibodies were of the IgG subclass
and not of the IgM subclass, suggesting that
sensitisation to halothane-altered liver cell components
had occurred following an earlier exposure [Neuberger et
al 1983]. The same antibodies were detected to a
similar extent (16 of 23 patients) in patients with less
severe hepatitis after halothane anaesthesia [Kenna,
Neuberger & Williams 1987]. These antibodies have been
identified as being cross-reactive with
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trifluoroacetyl-halide CF3CBrClOH (TFA-halide), bound
covalently to liver protein (anti-TFA antibody). Five
of 6 patients with halothane hepatitis had a high titre
of circulating anti-TFA antibody [Hubbard et al 1988b].
This antibody was present as early as 4 days after
exposure in one patient, and remained elevated for 3
months after halothane in another patient.
The presence of these antibodies shown by an
enzyme-linked immunosorbent assay [Kenna, Neuberger &
Williams 1984] has been proposed as a diagnostic marker
of halothane-induced liver damage. However, in some
patients the antibodies did not appear until 8 weeks
after exposure to halothane and it is not known if the
antibodies are a cause, or merely arise as a consequence,
of hepatic damage [Dienstag 1980]. Furthermore, several
problems with the assay have been discovered that were
not recognised previously [Martin, Kenna & Pohl 1990],
and Spence (1987b) has warned of the limited value of the
antibody test in diagnosing halothane hepatitis. A more
recent tiered system of laboratory methods may, however,
offer greater potential for an accurate diagnosis
[Hastings et al 1989].
The theories of biotransformation and immune-mediation
are not mutually exclusive. Halothane hepatitis may be
initiated by a reactive metabolite that alters the
surface structure of hepatocytes; in susceptible
individuals these changes may induce an immune response
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and subsequent cytotoxicity. In contrast with the
biotransformation theory which emphasises reductive
halothane metabolism, metabolism via the oxidative route
is necessary for the expression of halothane-altered
membrane antigen [Neuberger et al 1981a]. Oxidative
metabolism of halothane proceeds via trifluoroacetyl
halide [Karashima et al 1977], a reactive metabolite
which can bind covalently to cellular constituents
[Gandolfi et al 1980; Kenna et al 1988b]. Endogenous
liver protein is, in effect, changed from "self" to
"non-self", thus becoming immunogenic. Antibodies are
elicited against this "non-self" protein, creating an
immune response. Using immunohistochemical staining
with an antibody specific for the hapten, Satoh and
colleagues (1985a) detected trifluoroacetyl-conjugated
macromolecules on hepatocytes isolated from rats exposed
to halothane. They concluded that TFA-halide reacted
directly with constituents of the plasma membranes, or
with other cellular components which became incorporated
into the plasma membranes. In fact, the microsomal
fraction was found to contain the greatest concentration
of trifluoroacetyled adducts, the major component of
which was identified immunochemically as a
phenobarbitone-inducible form of cytochrome P-450. The
results suggested that TFA-halide was so reactive that it
bound predominantly to the cytochrome P-450 which
produced it [Satoh et al 1985b]. Subsequent studies,
however, have established that this is not the dominant
protein acetylated [Hubbard, Gandolfi & Brown 1988a].
31
Kenna and coworkers (1988b) have investigated the
mechanism of neoantigen generation by testing liver
microsomes from rats exposed to halothane for reactivity
with patients' sera and also with an antiserum specific
for the covalently bound TFA-halide. They characterised
the drug metabolite-tissue protein neoantigens and found
that the patients' antibodies recognised epitopes
consisting of the TFA group plus associated structural
features of the protein carriers, and not the TFA hapten
alone. In the same year, results from studies in man
indicated that humans exposed to halothane express liver
neoantigens which are analogous to the halothane
metabolite-protein neoantigens characterised previously
in halothane exposed animals [Kenna, Neuberger & Williams
1988a].
Hepatic hypoxia
There is much evidence implicating the metabolism of
halothane, especially via the reductive pathway, as the
factor principally responsible for halothane-induced
hepatotoxicity. However the following observations do
not support the metabolic theory:
(a) Enflurane and isoflurane which undergo considerably
less metabolism than halothane, and have no
reductive pathway, can cause hepatic necrosis in
phenobarbitone-pretreated, hypoxic rats [Van Dyke
1982; Shingu et al 1983].
(b) Although the products of reductive halothane
metabolism have been identified, none has been
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shown to be hepatotoxic.
(c) Hepatic necrosis occurs in rats pretreated with
triiodothyronine and then exposed to halothane
without hypoxia [Wood et al 1980; Smith et al
1983].
(d) Shingu and colleagues (1982b) found that higher
doses with shorter exposures to halothane produced
more toxicity than exposure to lower concentrations
for prolonged periods. Higher doses might produce
liver hypoxia by cardiorespiratory depression,
whereas a lengthy exposure would increase the
amount of halothane metabolic intermediates.
Considerable evidence now exists implicating a reduction
in hepatic oxygen supply, or more accurately, an
imbalance between oxygen supply and demand, in the
development of halothane-induced liver damage. Hepatic
oxygen deprivation may arise as a result of one or more
of the following: hypoxia, reduced cardiac output,
reduced hepatic blood flow, and increased hepatic oxygen
demand. Hypoxia in the absence of anaesthesia can cause
centrilobular necrosis in phenobarbitone-treated rats
similar to that seen after exposure to halothane [Shingu,
Eger & Johnson 1982a]. The region around the central
vein has the lowest oxygen tension as it is the last site
in the liver lobule to receive oxygen, and therefore
might be most influenced by hypoxia. Hypoxaemia rarely
occurs or persists during clinical anaesthesia and is
therefore unlikely to be a determinant of liver damage in
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anaesthetised humans. However, local liver hypoxia
resulting from an imbalance between oxygen supply and
demand may be relevant: factors known to increase oxygen
consumption such as barbiturate treatment and
hyperthyroidism are associated with increased halothane
hepatotoxicity in the rat [McLain, Sipes & Brown 1979;
Ross, Daggy & Cardell 1979; Wood et al 1980; Smith et al
1983],
Hepatocellular necrosis can result also from a decrease
in oxygen supply secondary to reduced hepatic perfusion.
Harper and colleagues (1982) measured hepatic injury in
phenobarbitone-induced rats following ligation of the
hepatic artery performed under thiamylal, halothane,
enflurane or isoflurane anaesthesia in oxygen. They
found that interrupting arterial flow resulted in liver
injury only in rats anaesthetised with halothane, and
that the injury was comparable to that found in the
phenobarbitone-hypoxia rat model. In addition, injury
was more severe following upper abdominal surgery than
after lower abdominal or peripheral surgery. Gelman
(1976) had shown previously that total hepatic blood flow
was reduced to a greater extent in patients undergoing
partial gastrectomy or cholecystectomy than in those
undergoing peripheral procedures such as herniorrhaphy.
These findings suggest that interference with hepatic
blood flow with consequent hepatocellular hypoxia may be
important in the production of liver injury.
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In man, total liver blood flow is derived from two
sources, the hepatic artery which supplies roughly
one-third of the total flow but 50% of the oxygen supply,
and the portal vein [Strunin & Davies 1983]. Normally
there exists reciprocity between hepatic arterial and
portal venous flows, so that total liver blood flow tends
to remain fairly constant [Richardson & Withrington
1981]. Specific volatile anaesthetic agents have
different effects on this reciprocity of flow.
Halothane has been shown to decrease both portal blood
flow and hepatic arterial blood flow in dogs [Hughes,
Campbell & Fitch 1980; Gelman, Fowler & Smith 1984a],
rats [Gelman et al 1984] and guinea pigs [Hursh, Gelman &
Bradley 1987], although the reduction in hepatic arterial
blood flow is somewhat inconsistent [Gelman 1987]; the
main determinant of portal blood flow, and to a lesser
extent, hepatic arterial blood flow during halothane
anaesthesia is cardiac output [Gelman, Fowler & Smith
1984a].
Enflurane decreases portal blood flow and, when
administered in sufficient concentration to cause a 50%
reduction in cardiac output, also impairs hepatic
arterial blood flow [Hughes, Campbell & Fitch 1980]. It
does, however, preserve liver blood flow and oxygen
supply better than halothane when used in equipotent
doses. In contrast, although isoflurane decreases
portal blood flow, hepatic arterial blood flow increases,
resulting in little change in total blood flow [Gelman,
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Fowler & Smith 1984a, 1984b]. Despite the apparent
preservation of liver blood flow, concentrations of
isoflurane sufficient to decrease mean arterial pressure
by 30% or more significantly reduced total liver blood
flow, resulting in impaired hepatic oxygen delivery,
increased hepatic oxygen consumption and a deterioration
in tissue oxygenation [Hobbhahn et al 1986]; hepatic
oxygen supply appeared to be adequate with lower
concentrations of isoflurane [Gelman, Dillard & Bradley
1987]. It would appear, therefore, that although all
three volatile agents decrease portal blood flow,
isoflurane and to a lesser extent enflurane facilitate
oxygen delivery to the liver much better than halothane,
mainly by a more effective preservation of hepatic
arterial blood flow.
Pharmacogenetics
Evidence of a genetic basis for susceptibility to
halothane hepatitis has been provided by several studies.
The extent to which an individual metabolises halothane,
particularly via the reductive pathway, may be
determined genetically. Cascorbi and colleagues (1971)
demonstrated less variation in halothane metabolism
between identical twins than between fraternal twins.
Differences in the reductive metabolism of halothane and
the susceptibility to liver damage have been reported
among three different strains of rats [Gourlay et al
1981], and there is a strong suggestion that genetic
predisposition is an important determinant in the
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aetiology of halothane-induced hepatotoxicity in the
guinea pig [Lunam, Cousins & Hall 1986].
Further evidence of possible genetic determination was
provided by a report of halothane hepatitis occurring in
three pairs of closely related women of common ethnic
origin [Hoft et al 1981]. Farrell and coworkers (1985)
reported increased susceptibility of lymphocytes to
electrophilic attack in eleven patients with halothane
hepatitis and in ten close relatives, and proposed the
existence of a predisposing, familial, constitutional
susceptibility factor. In addition, HLA frequencies
were found to be different in 38 patients with halothane
hepatitis compared with healthy controls [Otsuka et al
1985]. Available evidence seems, however, to indicate
that halothane-associated liver damage is more likely to
be of multifactorial origin, of which pharmacogenetics
constitutes, at most, one variable [Brown 1981, 1985].
Altered calcium homeostasis
A calciogenic hypothesis to account for hepatic damage
induced by volatile anaesthetic agents has been
postulated by Gelman and Van Dyke (1988). They proposed
that toxicity occurs secondary to disruption of
mechanisms which maintain cellular calcium homeostasis.
Free, ionised, intracellular calcium concentration is in
the range of 100 - 200 nmol 1~1, but that in
extracellular fluid is upwards of 1 mmol 1~1 [Rasmussen
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1986; Thomas & Reed 1989]. Maintenance of this large
chemical gradient is vital to cell viability; thus it is
conceivable that processes leading to cellular injury may
include alterations in calcium homeostasis. The
gradient is maintained by a low natural permeability of
the plasma membrane to calcium, the binding of cellular
calcium to intracellular components, and the activity of
at least two ATP-dependent transport mechanisms in the
plasma membrane [Cheung et al 1986; Landers, Becker &
Wong 1989]. In addition, both endoplasmic reticulum and
mitochondria can actively sequester calcium from the
cytosol [Becker, Fiskum & Lehninger 1980], protecting the
cell against calcium overload in times of excessive
calcium transfer into the cell [Rasmussen 1986].
Calcium ions are thought to play a major role in
mediating or propagating hepatocellular injury [Farber
1982; Thomas & Reed 1989]; it has been suggested that
increased concentrations of free intracellular calcium
constitute the final common pathway of cell injury
[Cheung et al 1986]. Several known hepatotoxins
increase cytosolic calcium [Moore et al 1985; Brattin et
al 1984; Moore 1980]. Halogenated hydrocarbons may
increase liver calcium by inhibition of a microsomal
calcium pump [Moore 1980] or by impairing the activity of
endoplasmic reticulum [Brattin et al 1984; Long & Moore
1986]. Specifically, halothane can inactivate
irreversibly calcium transport in hepatic endoplasmic
reticulum, provoking an immediate release of calcium
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[Zucker, Diamond & Berman 1982].
Animal studies have provided evidence supporting a role
for altered calcium fluxes in the mechanism of
halothane-induced liver injury. In guinea pigs, hepatic
calcium content was increased significantly, 24 hours
after exposure to halothane [Farrell et al 1988].
Subsequent changes in liver calcium were proportional to
the severity of liver necrosis, as determined
morphologically. The increase in liver calcium occurred
before hepatocellular necrosis was observed
histologically. This antecedent relationship of altered
cellular calcium homeostasis to liver necrosis is
consistent with a pathogenetic role in the production of
liver injury. Lind and coworkers (1984) administered
lipopolysaccharides to phenobarbitone-pretreated hypoxic
rats immediately after halothane anaesthesia, and found a
marked potentiation of hepatic necrosis which was related
to a significant increase in liver calcium content.
Administration of the antiendotoxin agent lactulose
reduced the hepatic damage, and prevented the observed
increase in liver calcium. More recently, it was shown
that halothane, enflurane and isoflurane each stimulated
a significant, dose-dependent release of radio-labelled
calcium from internal calcium stores in isolated rat
hepatocytes [Iaizzo et al 1990]. Halothane produced the
greatest calcium release, and isoflurane produced the
least - a pattern which is consistent with the known
ability of these anaesthetics to induce hepatic necrosis.
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Further evidence in support of the calciogenic hypothesis
of cell injury is offered by studies in which the
administration of a calcium channel blocker reduced the
extent of hepatic necrosis in animals exposed to
hepatotoxic agents, including halothane [Landon, Naukam &
Sastry 1986; Garay, Annesley & Burnette 1986; Goto et al
1990]. Calcium channel blockers most probably act by
interfering with the influx of calcium through the ionic
channel of the hepatocyte membrane, and preventing the
increase in cytosolic calcium concentration. Clearly,
calcium plays a major role in chemically induced cell
injury, although the consequences of increased cytosolic
calcium remain incompletely understood.
Current perspectives
It is now recognised that two types of halothane-induced
hepatic dysfunction exist [Brown & Gandolfi 1987;
Touloukian & Kaplowitz 1981; Pohl & Gillette 1982;
Neuberger & Williams 1984]. A mild subclinical form
manifest by abnormal biochemical indices of liver
function may occur in up to 20% of patients exposed to
halothane. This could be caused by toxic products of
halothane metabolism, possibly determined by genetic
factors, or by hepatic hypoxia resulting from an
imbalance between hepatic oxygen supply and demand;
altered hepatocellular calcium balance cannot be excluded
as a possible mechanism. A much rarer fulminant form
may occur with severe necrosis which may prove fatal.
It is probable that this form results from an immune
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reaction: an oxidative metabolite binds covalently to
liver proteins producing a hapten, which, in turn,
provokes an immune reaction and the formation of a
circulating antibody.
Hepatotoxicity following all volatile halogenated
anaesthetics may be linked by a common mechanism.
Christ and colleagues (1988b) demonstrated that enflurane
and isoflurane are converted to reactive metabolites that
form covalently bound, acylated protein adducts which are
recognised by specific anti-TFA antibodies. Halothane
formed much greater amounts of immunoreactive protein
adducts than enflurane which, in turn, formed much
greater amounts than isoflurane. Thus the degree of
anti-TFA immunoreactive adduct formation correlated
directly with the extents of metabolism and incidence of
reported clinical hepatic dysfunction for these drugs
(ie, halothane > enflurane > isoflurane).
Immunoblotting techniques used by the same group showed
that antibodies in the sera of six patients with
halothane hepatitis recognised liver microsomal antigens
formed in rats treated with enflurane or halothane
[Christ et al 1988a]. This suggested that a halide
metabolite of enflurane bound covalently to liver
proteins and could similarly provoke an immune response.
This mechanism could account also for the apparent
cross-senstisation between halothane and enflurane.
Isoflurane did not produce detectable liver antigen,
although the principal reason for this may have been
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related to the level of biotransformation in their
particular animal preparation. However, isoflurane,
enflurane and halothane all have the potential for
producing acetylating intermediates that can alter liver
proteins, rendering them immunogenic. Thus a common
mechanism for producing liver damage may exist between
the volatile halogenated anaesthetics.
ANIMAL STUDIES
Early attempts to produce an animal model of halothane
hepatitis proved disappointing. Since 1976, however,
five animal models have been developed, in each of which
massive hepatic necrosis was produced.
Polychlorinated biphenyl rat model
Sipes and Brown (1976) described a rat model in which
hepatic necrosis was induced by a single exposure to 1%
halothane in 99% oxygen following pretreatment with
Aroclor 1254, a polychlorinated biphenyl (PCB). The
lesion produced was centrilobular and multifocal, and
morphologically similar to that described in man. This
damage was apparent within 2 hours of the end of
anaesthesia [Reynolds & Moslen 1977]. PCBs are potent
inducers of a wide variety of biotransformation pathways,
but unfortunately can themselves cause liver damage




Certain strains of male rats develop hepatic necrosis
when exposed to halothane under hypoxic conditions after
phenobarbitone pretreatment [McLain, Sipes & Brown 1979;
Ross, Daggy & Cardell 1979; Cousins et al 1979]. Both
hypoxia and phenobarbitone are required to cause
necrosis. As the severity of damage correlated with the
amount of inorganic fluoride produced, it was proposed
that the liver damage was mediated through reductive
metabolism of halothane [Cousins et al 1987b]. This
hypothesis was supported by Jee and colleagues (1980),
who found that the administration of the
biotransformation inhibitors metyrapone and SKF 525A
inhibited hepatic necrosis even when administered up to 4
hours after anaesthesia. Later, Wilhelm and others
(1987) postulated that glutathione was responsible for
the detoxification of reactive intermediate products of
reductive metabolism, and found that liver damage in this
model was significantly aggravated by glutathione
depletion.
The validity of this particular model has, however, been
questioned. The reproducibility of liver damage depends
on species, sex, age, temperature and even season
variations [Gelman 1986]. Severe hypoxia (FjC^ 0.06 -
0.08) alone can cause necrosis in phenobarbitone
pretreated rats [Shingu, Eger & Johnson 1982a]. Both
isoflurane and enflurane, neither of which undergo
reductive metabolism, can cause necrosis in starved rats
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pretreated with phenobarbitone under conditions of
profound hypoxia (Fj02 0.08) [Van Dyke 1982], but not
under moderate hypoxia (Fj02 0.14) [Lind et al 1985].
Fed rats exposed to enflurane or isoflurane did not
develop liver necrosis. The effect of fasting is
unclear, although starvation is known to increase the
solubility of volatile anaesthetics in rat liver
enhancing hepatic uptake of anaesthetic [Fassoulaki &
Eger 1986].
In the phenobarbitone-hypoxia rat model, it is unclear
whether halothane initiates liver injury by reducing
hepatic blood flow thereby inducing hypoxia, or whether
products of halothane metabolism are responsible. These
variables are impossible to separate during in vivo
halothane exposure, as reductive metabolism requires
hypoxia. However, Schlieble and colleagues (1988) have
attempted to separate these effects of halothane in an in
vitro experimental system, using monolayer cultures of
rat hepatocytes to eliminate the effect of halothane on
hepatic perfusion. They found that three essential
components were necessary for the development of necrosis
in this model, namely hypoxia, phenobarbitone induction
and exposure to halothane.
Triiodothyronine rat model
Hepatic necrosis occurs in rats pretreated with
triiodothyronine (T3) and then exposed to halothane in
non-hypoxic environments [Wood et al 1980; Smith et al
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1983]. Because the necrosis is caused in the absence of
hypoxia, reductive metabolism is not implicated. Both
enflurane and isoflurane can also cause necrosis in this
model [Berman et al 1983]. In contrast to the
phenobarbitone-hypoxia model, it appears that a mechanism
other than reduction of halothane may be involved in the
T3 model [Uetrecht et al 1983]. It is proposed that
hypoxic damage to the hypermetabolic centrilobular cells
resulting from depression of splanchnic blood flow is
responsible for the liver cell necrosis [Berman et al
1983].
Isoniazid rat model
Rice and colleagues (1987) treated Fischer 344 rats with
isoniazid or saline for 7 days, and then exposed them to
either halothane in air, or air alone. Hepatocellular
necrosis occurred only in rats administered halothane;
the most severe lesions were observed in the isoniazid
treated animals, mirroring increases in serum
aminotransferase activities. Hypoxia was not required
for lesion development, and as isoniazid treatment
enhanced oxidative but not reductive halothane
biotransformation, it was suggested that oxidative
metabolism was responsible for hepatotoxicity in this
model.
Guinea pig model
Recently, a model has been described in which halothane
produced hepatic damage in an outbred strain of guinea
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pig [Lunam, Cousins & Hall 1985]. Neither enzyme
induction nor hypoxia was required for this effect.
Subsequently, liver necrosis was described in certain
other strains of guinea pig [Lind et al 1987]. Unlike
other animal models in which all animals developed severe
centrilobular necrosis within hours of exposure, only 30%
of guinea pigs show a similar degree of severity. In
addition, the development of necrosis is delayed for
48-72 hours, and both sexes are affected. Although both
reductive and oxidative metabolism of halothane occur in
the guinea pig, it is the oxidative pathway which has
been implicated as a mechanism of hepatic injury [Lind,
Gandolfi & Hall 1989]. Other workers have suggested,
however, that it is the marked reduction in both portal
and hepatic arterial blood flows during halothane
anaesthesia which is responsible for hepatic damage in
the guinea pig [Hursh, Gelman & Bradley 1987]. The
guinea pig has also been used to study the potential
contribution to liver damage of a halothane-induced
immune response [Siadat-Pajouh et al 1987].
Other workers have attempted to produce an
immune-mediated model of halothane hepatotoxicity.
Neuberger, Kenna and Williams (1987) immunised rabbits
with halothane antigen-bearing hepatocytes isolated from
litter mates, to induce circulating levels of "halothane
antibodies". The rabbits were then exposed to
halothane; none of these rabbits showed any evidence of
liver cell necrosis. More successfully, Callis and
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coworkers (1987) developed a rabbit model to study the
production of humoral immunity towards a
biotransformation intermediate of halothane. In this
model, rabbits exposed many times to halothane in 75%
oxygen produced an antibody in response to an
intermediate product of oxidative metabolism. Although
the evidence presented is convincing, this model has yet
to be validated by other workers.
How relevant these animal studies are to the problem of
human hepatotoxicity is not known. The lesion in man is
rare and unpredictable, and animal models have not been
in keeping with this clinical picture [Cousins 1980].
All three rat models require the presence of demanding
conditional factors which would not be expected to
pertain to man. These rat models display considerable
sex, age and strain differences regarding susceptibility
to hepatic necrosis. In addition, the
phenobarbitone-hypoxia rat model shows a dose-response
relationship [Jee et al 1980] which is not the case in
man, and the incidence or severity of hepatic dysfunction
does not increase with multiple exposures [Reynolds &
Moslen 1974]. In contrast, the guinea pig model more
closely resembles clinical observations in humans with
regard to halothane biotransformation and lesion
morphology [Lind et al 1987], possible genetic
predisposition [Lunam, Cousins & Hall 1986], and
induction of an immune response following multiple
halothane exposures [Siadat-Pajouh et al 1987].
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Therefore, although the animal models have enabled an
understanding of some of the issues involved, they have
not greatly advanced the quest for the cause of halothane
hepatotoxicity in man.
OTHER INHALATION ANAESTHETIC AGENTS
Enflurane
There is not the same concern regarding hepatotoxicity
after anaesthesia with enflurane as there is with
halothane. Nonetheless, a few case reports of alleged
enflurane hepatitis have been published [Denlinger, Lecky
& Nahrwold 1974; Danilewitz et al 1980; Kline 1980; Ona,
Patanella & Ayub 1980; Paull & Fortune 1987]. In
several of these reports, however, other causes of liver
damage, such as viral hepatitis, could not be excluded.
In a review of 58 cases of suspected enflurane hepatitis,
Lewis and colleagues (1983) considered that 24 could be
explained only as a result of the administration of
enflurane. Analysis of these cases demonstrated that
the clinical, biochemical and histological features were
similar to those seen with halothane-induced hepatitis.
However, the vague and non-specific criteria for
ascribing hepatotoxicity in that review have been
criticised [Dykes 1984]. Furthermore, Eger and
coworkers (1986) reviewed 88 cases of hepatic injury
attributed to enflurane, including the material reviewed
by Lewis, and could demonstrate neither a causal
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relationship between enflurane anaesthesia and subsequent
liver injury, nor consistent histological changes in
liver specimens.
It cannot be denied that unexplained severe liver damage
follows enflurane anaesthesia in the rare patient: the
known incidence is of the order of 1 in 800,000, which is
less than the spontaneous attack rate of viral hepatitis
[Brown & Gandolfi 1987]. This incidence is too low to
suggest a causal association and, in addition, a
molecular mechanism by which enflurane might produce
hepatotoxicity analogous to that produced by halothane is
difficult to propose and support experimentally [Eger et
al 1986]. There are few, if any, parallels between the
metabolism of halothane and enflurane, and the pattern of
enflurane hepatitis does not tend to support an
immune-mediated mechanism [Eger et al 1986]. However,
Christ and colleagues (1988b) have suggested a possible
hypersensitivity basis for enflurane hepatitis, involving
the covalent binding of an oxidative metabolite to liver
microsomal adducts. The case for enflurane hepatitis
currently remains not proven, but further studies such as
that undertaken by Christ may add weight to the argument
for its existence.
Isoflurane
Two case reports have been published attributing hepatic
injury to isoflurane, but in neither report did the
results show a definitive causal relationship between
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isoflurane and liver dysfunction [Gregoire & Smiley 1986;
Carrigan & Straughen 1987]. Stoelting and colleagues
(1987) reviewed 45 cases of hepatic dysfunction after
isoflurane anaesthesia reported to the Food and Drug
Administration in the United States of America. They
concluded that causes other than isoflurane could account
for the postoperative liver damage in 29 patients, while
in the remaining 16, isoflurane might have been one of
several possible causes of injury. McLaughlin and Eger
(1984) described a patient given repeated isoflurane
anaesthetics in the presence of abnormal liver
biochemistry; isoflurane was not implicated in the
aetiology of the hepatic injury and, in fact, liver
function improved during the course of the anaesthetics.
Current evidence suggests that it is highly unlikely that
isoflurane is even rarely responsible for postoperative
hepatotoxicity [Stoelting 1987].
Sevoflurane
First synthesised in the early 1970's, sevoflurane is a
halogenated methyl isopropyl ether, which at present is
marketed for clinical use only in Japan [Wallin et al
1975]. The extent of biotransformation of sevoflurane
is similar to that of enflurane, but its low solubility
and rapid elimination confine this to the period of
exposure [Holaday & Smith 1981]. Findings from studies
of its effect on liver blood flow are not consistent,
demonstrating an increase [Manohar & Parks 1984],
decrease [Wouters et al 1989], or no effect [Pilato et al
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1989], although different concentrations of sevoflurane
were used in each of these studies. Original animal
studies suggested that sevoflurane was not hepatotoxic
[Cook et al 1975], but subsequent investigations do not
support this; it may cause hepatic injury of a degree
similar to isoflurane in enzyme-induced hypoxic rats
[Strum et al 1987], and its administration to guinea pigs
may also result in liver damage, probably by altering
liver blood flow [Lind et al 1989].
Desflurane (1-653)
Desflurane is a new volatile anaesthetic agent
structurally very similar to isoflurane, which is
currently being evaluated for clinical use [Jones,
Cashman & Mant 1990; Jones et al 1990a]. Although it
undergoes some oxidative biotransformation [Sutton et al
1990], it resists metabolic degradation more than other
volatile agents [Koblin et al 1988; Koblin et al 1989;
Jones et al 1990b]. Desflurane has not been reported to
cause hepatic injury in hypoxic, enzyme-induced rats
[Eger et al 1987], rats anaesthetised repeatedly [Eger,
Johnson & Ferrell 1987], or pigs [Holmes et al 1990], or
to influence biochemical tests of liver function in human
volunteers [Jones et al 1990b].
Nitrous oxide
In conventional anaesthetic practice nitrous oxide is
commonly administered in combination with volatile
anaesthetics. Might nitrous oxide be hepatotoxic and
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contribute to the hepatic damage associated with other
anaesthetic agents? Ross and coworkers (1984)
demonstrated in phenobarbitone-pretreated rats exposed to
14% oxygen, that nitrous oxide produced no effect in the
absence of halothane, but potentiated the hepatotoxicity
of 0.75% halothane. In a more profoundly hypoxic rat
model (F];02 0.075), however, nitrous oxide has been shown
to cause centrilobular necrosis [Fassoulaki et al 1984].
Indeed nitrous oxide was found to be more hepatotoxic
than enflurane or isoflurane, which did not produce
hepatic necrosis under identical conditions. This
toxicity is unlikely to result from biotransformation of
nitrous oxide as there is no evidence of metabolism of
nitrous oxide by the liver [Ross, Monk & Duffy 1984].
Fassoulaki and colleagues (1984) have suggested that
nitrous oxide, like other anaesthetics, causes a
disruption in hepatocellular calcium homeostasis,
resulting in damage.
There is one human report of jaundice following
anaesthesia in which the only inhalation agent used was
nitrous oxide [Hart & Fitzgerald 1975]. The clinical
and laboratory features were very similar to those
attributed to halothane anaesthesia. Although halothane
was not administered to the patient, the anaesthetic
gases were delivered from an anaesthetic machine fitted
with a halothane vaporiser which was switched off. It
is more likely that halothane was responsible for the
jaundice, resulting from inapparent circuit contamination
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[Varma, Whitesell & Iskandarani 1985]
SUMMARY
The historical background, clinical features, morphology,
epidemiology and aetiology of halothane hepatitis have
been presented. Animal models of halothane
hepatotoxicity have been described, although their
application to humans is of doubtful significance. Two,
probably distinct, forms of liver damage associated with
halothane have been identified. The much more common
mild form may result from reductive biotransformation of
halothane, possibly influenced by genetic factors, or
reduced liver oxygenation, whereas the rare fulminant
form is most likely to be immune-mediated. The role of
altered calcium homeostasis has not yet been established.
In addition, a common mechanism for liver dysfunction
associated with the halogenated volatile anaesthetic
agents has been proposed. The hepatotoxicity of
enflurane cannot be excluded; while hepatic dysfunction
after isoflurane and nitrous oxide is considered
unlikely, further attention is necessary. It is too
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CHAPTER 2
SERUM ENZYMES IN ACUTE LIVER INJURY
Many biochemical tests have been introduced which are
said to assess liver "function" - an inaccurate term.
Some liver tests can detect cell injury or the response
to injury, while others indicate impairment of a
particular aspect of liver function. A good function
test must satisfy the following criteria: specificity,
sensitivity, reproducibility, and ease of performance.
Furthermore, to infer hepatotoxicity by a suspected
agent, it is important that the biochemical test
correlates well with histological abnormalities
[Zimmerman 1978]. Assessment of chemical hepatic injury
in early studies was based on an impaired ability of the
liver to synthetise urea, cholesterol and its esters, and
plasma proteins including clotting factors, and to
maintain normal blood levels of glucose and amino acids.
These measures, however, are too insensitive, nonspecific
or cumbersome to be useful in monitoring the severity of
damage, comparing the relative toxicity of different
agents, or assessing the potentiation or inhibition of
toxic phenomena by various treatments. Much more useful
is the measurement of serum enzymes which has been the
standard biochemical approach to the assessment of
hepatic injury during the past 30 years.
More than 50 enzymes have been identified in serum or
plasma. For most of them, abnormal values have been
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found in patients with hepatic disease. Their
application to the diagnosis of hepatic injury requires
analysis of their specificity for, and sensitivity to,
liver damage. In this regard, enzymes identified in
serum fall into four groups (Table 2.1). In one group
of enzymes, increased serum levels reflect cholestasis
more sensitively than parenchymal injury. A second
group contains enzymes that are more sensitive to
parenchymal injury than reduced biliary flow, while a
third group consists of enzymes that are insensitive for
hepatic injury but serum levels of which may be increased
in disease of other tissues. In a fourth group are
enzymes whose serum levels are characteristically
depressed in hepatic injury. It is the enzymes in the
first and second groups that are most useful for the
investigation of liver disease in general, and those in
the second group that are used most widely in the study
of toxic hepatic injury.
As with all other methods for assessing liver function,
serum enzyme tests have some limitations. Some of the
enzymes that are considered to reflect liver injury may
actually derive from other organs; that is, they may not
be specific for hepatic disease. A further problem
common to measurement of all serum enzymes is that
increased serum levels may not reflect tissue damage.
Rather they may result from:
(a) an increase in the tissue source of enzymes
because of an increased rate of production per
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cell or an increase in the number of cells, or
(b) impaired disposition or excretion, or
(c) leakage from cells with altered membrane
permeability.
In spite of these limitations, measurement of serum
enzymes remains the cornerstone in the investigation of
chemical hepatic injury. Some of these enzymes warrant
further consideration.
Table 2.1
Examples of serum enzymes in liver disease
Enzymes that detect hepatocellular necrosis
Standard tests: Aspartate aminotransferase
Alanine aminotransferase
Lactate dehydrogenase




Enzymes that detect cholestasis




Enzymes increased in disease of other tissues
Creatine phosphokinase
Enzymes with reduced serum levels in liver disease
Choiinesterase
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ENZYMES THAT DETECT HEPATOCELLULAR NECROSIS
Aminotransferases
Alanine aminotransferase (ALT; serum glutamic-pyruvic
transaminase; SGPT) and aspartate aminotransferase (AST;
serum glutamic-oxaloacetic transaminase; SGOT) are the
most frequently measured indicators of liver disease.
These enzymes catalyse the transfer of the a-amino group
of alanine and aspartate respectively to the a-keto group
of ketoglutaric acid, resulting in the formation of
pyruvic acid and oxaloacetic acid [Kaplan 1987]. The
increase in serum ALT and AST activities is related to
damage to, or destruction of, tissue rich in
aminotransferases, or to changes in cell membrane
permeability that allow ALT and AST to leak into the
circulation.
Neither ALT nor AST is specific to the liver. AST is
present in large quantities in liver, cardiac and
skeletal muscle, and kidney, and to a lesser extent in
brain, pancreas, lung, leucocytes and erythrocytes
[Strunin 1977]. Although ALT is present in greatest
concentration in liver, it is also distributed widely in
the body [Zimmermann & Seeff 1970]. AST is present in
both mitochondria and cytosol of the liver, but ALT is
limited to cytosol. The isoenzymes of AST from
mitochondria and cytosol are immunochemically distinct
and may be assayed individually. Eighty per cent of AST
in liver biopsy specimens from normal adults is of
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mitochondrial origin; in contrast, AST in serum is
primarily cytosolic enzyme, possibly because of the
greater lability of mitochondrial AST in serum.
However, large increases in mitochondrial AST are found
early in diseases associated with massive tissue
necrosis, perhaps reflecting a sudden release of
intracellular contents into the circulation, and for this
reason, specific assay of mitochondrial AST may be useful
in predicting the extent of liver necrosis [Stolz &
Kaplowitz 1990].
Although serum aminotransferase activities are increased
in almost all forms of liver disease, they are not
specific for hepatobiliary disorders [Kools & Bloomer
1987; Mclntyre 1983]. Increased activities may be found
also in patients with cardiac and skeletal muscle damage
[Wroblewski 1959], although grossly increased activities
(>1000 U 1~1) usually indicate hepatic origin. It is
therefore not surprising that increased serum
aminotransferase activity correlates poorly with abnormal
liver histology [James et al 1975; Kaplan 1987; Galambos
& Wills 1978]. A further complication is the finding in
healthy populations that a significant percentage of
those tested have abnormally increased activities of
serum aminotransferases. Kahn and colleagues (1982)
found 5.5% of 10,034 asymptomatic blood donors had
abnormal AST activity, while Friedman and coworkers
(1987) could find no cause for increased ALT activity
(>100 U 1~1) in 22 of 92 healthy blood donors.
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One further note of caution is that aminotransferase
activities may be falsely diminished or inhibited under
certain circumstances. For instance, serum levels of
AST are diminished in uraemia but increase after
dialysis, suggesting that a dialysable substance in the
blood of uraemic patients inhibits AST [Cohen et al
1976]. In addition, serum AST activity diminishes after
24 hours when stored at room temperature, although the
enzyme is stable for 28 days when serum is refrigerated
or frozen [Stolz & Kaplowitz 1990].
Lactate dehydrogenase
Lactate dehydrogenase (LDH) is distributed widely in the
body, particularly in skeletal and cardiac muscle, liver
and erythrocytes. Although LDH is a sensitive indicator
of cell damage, it is not specific for liver disease.
Increased serum activities of this enzyme have been found
in such disparate disorders as myocardial infarction,
carcinomatosis, haemolytic anaemia, leukaemia, infectious
mononucleosis and progressive muscular dystrophy, as well
as in intrinsic hepatic disease [Zimmerman & Seeff 1970].
Five isoenzymes can be detected electrophoretically but
fractionation yields no further useful information in the
diagnosis of hepatobiliary disease [Hargreaves 1986].
Consequently, measurement of LDH activity has limited
application in the diagnosis of hepatic disease.
Because these standard enzyme tests show poor specificity
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and variable sensitivity in detecting hepatocellular
damage, a number of other serum enzyme tests which might
offer greater organ specificity have been developed.
These include isocitrate dehydrogenase (ICDH), sorbitol
dehydrogenase (SDH), ornithine carbamyl transferase (OCT)
and argininosuccinate lyase (ASAL).
Isocitrate dehydrogenase
ICDH is a cytoplasmic enzyme which is relatively specific
for liver disease, but is less sensitive than the
aminotransferases [Rosalki 1976]. It has been shown to
be particularly sensitive in detecting minor episodes of
hepatic damage caused by drugs and alcohol [Ellis et al
1978]. However, disseminated malignancy without
detectable hepatic involvement can lead to increased ICDH
activity [West et al 1964]. As it does not provide the
specific reflection of hepatic disease initially
believed, it offers no diagnostic advantage over
aminotransferase measurements.
Sorbitol dehydrogenase
Virtually all sorbitol dehydrogenase is found in the
liver; only relatively low concentrations are present in
the prostate and kidney [Wilkinson 1976]. Its serum
activity becomes rapidly and distinctly increased in
acute hepatic parenchymal damage, and it would seem to
provide a useful biochemical test in the early detection
of acute liver disease [Zimmerman & Seeff 1970].
However, aminotransferase measurements have greater
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sensitivity, and values of SDH activity may be normal in
cirrhosis and other chronic liver disorders [Asada &
Galambos 1963]. Its instability in serum further limits
its diagnostic usefulness [Wilkinson 1976].
Ornithine carbamyl transferase
OCT, an enzyme involved intimately in the synthesis of
urea, is found almost exclusively in the liver; there is
virtually no activity in other tissues [Reichard 1961].
Serum activity is very low in normal individuals but is
markedly increased in patients with hepatic necrosis
[Reichard 1961]. Tegeris and colleagues (1969) induced
selective tissue damage in dogs and swine, either
chemically by the nephrotoxic agent uranyl nitrate or the
hepatotoxin CC14, or surgically by bile duct or coronary
artery ligation. They measured the activities in serum
of several liver enzymes including AST, ALT and OCT, and
demonstrated that OCT became increased only when the
hepatic parenchyma was damaged. This increase occurred
just as early and was much greater than that of the other
enzymes assayed. Furthermore, in rats administered
chemical hepatotoxins, OCT activity was found to be as
sensitive as histopathology for detecting liver damage
[Drotman & Lawhorn 1978]. Despite the apparent
advantages of OCT over aminotransferase measurements,
however, it has not replaced them in clinical use.
Argininosuccinate lyase
Argininosuccinate lyase mediates the degradation of
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argininosuccinic acid to arginine and fumaric acid. The
reaction is reversible. ASAL occurs in liver, kidney
and erythrocytes [Takahara & Natelson 1967]. In the
liver, the enzyme is involved in the urea cycle and tends
to act as a lyase. In the kidney, however, the
equilibrium is reversed so that the enzyme acts as a
synthetising enzyme to form argininosuccinic acid
[Campanini et al 1970]. Serum concentrations of ASAL
have been determined in patients with parenchymal liver
disease. Its measurement has been found to be more
specific and sensitive for hepatocellular integrity than
the more commonly applied biochemical liver tests
[Campanini et al 1970; Sims & Rautanen 1975]. Like OCT,
however, ASAL has not proved to be more useful in
practice than the aminotransferases, and is not widely
used.
ENZYMES THAT DETECT CHOLESTASIS
Alkaline phosphatase
Alkaline phosphatase is the name given to a group of
enzymes which catalyse the hydrolysis of a large number
of organic phosphate esters at an optimum alkaline pH.
They are found mainly in bone osteoblasts and the
canalicular membranes of hepatocytes, but are also
present in small intestine, kidney, white blood cells and
placenta [Kaplan 1987]. Two distinct types of alkaline
phosphatase are present in the liver, although their
precise roles are unknown [Stolz & Kaplowitz 1990].
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Serum electrophoresis allows the separation of the
isoenzymes produced in these various locations
[Hargreaves 1986]; in most clinical situations this
amounts to separating liver from bone alkaline
phosphatase. Serum alkaline phosphatase activity may be
increased in bone, kidney and intestinal disorders as
well as in hepatobiliary disease, and increased activity
is observed also as a normal physiological response in
children (due to influx of enzyme from osteoid tissue
during bone growth) and in late normal pregnancy (due to
release of placental enzyme). The major value of serum
alkaline phosphatase in the diagnosis of liver disorders
is in the recognition of cholestasis. Increased serum
activity of liver alkaline phophatase does not
necessarily, however, indicate the presence of liver
disease. Brensilver and Kaplan (1975) studied 317
patients who had increased serum alkaline phosphatase
activity. Although the source of the increase was liver
isoenzyme in 253 patients, there was no evidence of liver
disease in almost one-third of these patients.
Measurement of alkaline phosphatase activity, therefore,
has little application in the detection of acute
hepatocellular damage.
Gamma-glutamyl transferase
Gamma-glutamyl transferase (GGT) is present in cell
membranes in many tissues, including kidney, pancreas,
liver, spleen, heart, brain and seminal vesicles
[Goldberg 1980]. Increased serum activity of this
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enzyme is found predominantly in diseases of the liver,
biliary tract and pancreas. There are two main clinical
values of GGT. It can be used to confer organ
specificity to an increased serum activity of alkaline
phosphatase, as GGT activity is not increased in
disorders of bone [Kaplan 1987]; secondly, isolated
increased GGT activity with normal other biochemical
indices of hepatocellular function may be an indicator of
alcohol abuse or alcoholic liver disease. Increased
serum GGT activity, however, is not always associated
with hepatobiliary disease. In addition,
hyperbilirubinaemia can interfere with measured activity
of GGT in vitro, impairing the diagnostic usefulness of
this enzyme test [Combes et al 1977]. In a large
prospective study, 68% of hospital inpatients who had
abnormal levels of GGT activity had diseases which did
not involve the liver [Burrows, Feldman & McBride 1975].
Although GGT provides a sensitive index of hepatocellular
dysfunction, it has poor specificity and offers no
advantage over measurement of aminotransferases and
alkaline phosphatase in the detection of acute liver
disease.
5'-Nucleotidase
Despite its presence in several other organs, increased
serum activity of 51-nucleotidase is purported to be of
hepatobiliary origin only [Kaplan 1987]; in clinical
hepatic disease, activity of 5'-nucleotidase correlates
with serum alkaline phosphatase activity. Its major
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advantage over alkaline phosphatase is enhancement of
specificity. It is used mainly to confirm that
increased alkaline phosphatase activity is of hepatic
origin, although measurement of alkaline phosphatase
isoenzymes and gamma-glutamyl transferase activity have
generally replaced this use. It may be useful in the
diagnosis of cholestasis during pregnancy and childhood
as its activity is not increased physiologically in these
states, unlike that of alkaline phosphatase [Stolz &
Kaplowitz 1990].
Leucine aminopeptidase
This enzyme, which is probably involved in the regulation
of protein metabolism and turnover, is found in virtually
all human tissues [Kaplan 1987]. Increased activity is
found only in pregnancy and hepatobiliary disorders.
Its activity is increased in most types of liver disease
but greatest increases are seen in biliary obstruction,
and thus its major application would seem to be in the
recognition of cholestasis. Clinically, its primary use
is to specify the origin of increased serum alkaline
phosphatase activity; in this respect it appears similar
to 5'-nucleotidase and GGT [Stolz & Kaplowitz 1990].
As these latter tests are more convenient to perform, and
offer broadly equal sensitivity and specificity for
hepatobiliary disorders, leucine aminopeptidase is now
rarely measured.
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ENZYMES WITH REDUCED SERUM LEVELS IN HEPATIC DISEASE
Pseudocholinesterase
Serum pseudocholinesterase concentration is
characteristically depressed in patients with hepatic
disease. Low concentrations are observed also in
patients with a low serum concentration of albumin. It
is believed that the low pseudocholinesterase
concentration reflects impaired hepatic protein
synthesis. However, serum pseudocholinesterase
concentration cannot be used as an index of acute hepatic
dysfunction as its half-life is some 15 days [Strunin
1977]. Furthermore, the test is not sufficiently
consistent to be useful in the differential diagnosis of
liver disease, and adds little to the more commonly used
laboratory measurements.
Enzymes commonly measured in routine clinical practice
include AST, ALT, alkaline phosphatase and gamma-glutamyl
transferase. These tests are generally simple to
perform, are relatively quantitative and inexpensive, and
often are included in the output of multiple channel
automatic analysers. Furthermore, there is enormous
experience with their serum levels in a wide variety of
liver disorders. Along with measurement of serum
concentrations of bilirubin and albumin, they are useful
general tests in the initial investigation of liver
disease. Their poor hepatospecificity and variable
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sensitivity, however, limit their specific application.
Individual tests are generally unreliable indicators of
impaired liver function, and therefore a battery of liver
tests is usually performed. By measuring several serum
enzymes, sensitivity and specificity are enhanced, and
the predictive accuracy for the presence of liver disease
is improved also if more than one test is abnormal. The
measurement of more hepatospecific enzymes such as SDH,
OCT and ASAL provides little additional information in
the routine investigation of liver disease. These more
specific tests are often less sensitive for liver disease
than the aminotransferases, and, in addition, they may be
more complicated to perform, and cost more in terms of
laboratory time and materials used. For these reasons,
coupled with the relative lack of experience with their
serum activities in liver disease, they have not replaced
the conventional liver enzyme tests in widespread use.
They have greater application, however, in the study of
acute, toxic liver injury, when measurement of enzymes
that are sensitive and specific indicators of
hepatocellular necrosis allows earlier, less invasive,
easier and possibly more accurate detection of
hepatotoxicity than by histological methods [Zimmerman
1978].
None of the enzyme tests examined here in detail meets
all the requirements (ie, sensitivity, hepatospecificity,
ease of measurement and reproducibility) necessary to
allow accurate diagnosis and monitoring of minor,
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drug-induced hepatocellular damage. More recently,
attention has focused on glutathione S-transferase as an
alternative test of hepatocellular damage which, in
theory, should be highly sensitive and hepatospecific.
GLUTATHIONE S-TRANSFERASE
The glutathione S-transferases (GST) are multifunctional
proteins which serve as intracellular binding proteins
and as catalysts for the reaction of electrophilic
compounds with glutathione [Mannervik 1985; Jakoby 1985;
Wolkoff 1980]. This conjugation reaction is the first
step in the formation of the mercapturic acids, a pathway
that is a major excretory route for the elimination of
foreign compounds [Chasseaud 1979; Mannervik 1985]. In
addition, GST bind a number of compounds that they do not
metabolise (non-susbtrate ligands), and they have been
suggested to act as intracellular transport proteins for
compounds that have limited solubility in water [Boyer
1989]. As many GST substrates are environmental
pollutants, drugs or carcinogens, the primary role of GST
is thought to be one of detoxification [Beckett & Hayes
1987]: indeed, evidence exists that GST protect against
chemical carcinogenesis [Chasseaud 1979; Smith, Ohl &
Litwack 1977; Sparnins, Venegas & Wattenberg 1982].
STRUCTURE, NOMENCLATURE AND CLASSIFICATION
GST activity is widely distributed throughout the animal
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kingdom and in all species multiple forms of the enzyme
are a prominent feature [Mannervik 1985; Jakoby 1985].
These can be purified using chromatographic and
electrophoretic techniques [Beckett & Hayes 1987;
Mannervik 1985]. Early workers assumed that separate
enzymes were responsible for the metabolism of different
substrates, and the enzymes were variously named aryl,
alkyl, aralkyl and alkene glutathione S-transferases.
However, it became apparent that the GST displayed
overlapping substrate specificities. Consequently, the
original nomenclature was replaced by designations based
on the physical or structural properties of the proteins
rather than on their enzymatic properties. The various
hepatic rat GST isoenzymes isolated were named E, D, C,
B, A and AA in order of their elution from a
carboxymethyl cellulose column [Jakoby 1978]. This
system of nomenclature also proved inadequate, as rat
liver was soon discovered to contain many more forms of
GST than had been identified originally.
Each form of GST comprises two subunits of similar size,
with a total molecular mass (Mr) of 45,000 - 55,000.
Both homodimers and heterodimers have been described
[Mannervik 1985]. The different forms of GST are best
described by their subunit composition, as the individual
subunits function independently. Rat GST have been
studied extensively. At least seven subunits exist,
designated according to their mobilities during sodium
dodecyl sulphate - polyacrylamide gel electrophoresis as
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Ya, Yb (b, and b2), Yc, Ye, Yf (or Yp), Yk and Yn (or Yt)
[Beckett & Hayes 1987; Boyer 1989]. The large number of
GST isoenzymes in the rat has caused considerable
confusion in the past when different means of naming them
were used. In an attempt to avoid confusion, a more
recent system of nomenclature has been adopted, in which
each distinct GST subunit is denoted by an Arabic
numeral, and in which subunits are numbered sequentially
in the order that they are discovered and characterised
[Jakoby, Ketterer & Mannervik 1984].
On the basis of immunochemical analysis, rat GST subunits
can be divided into at least three groups or families.
Group I comprises subunits Ya, Yc and Yk; group II
contains Yb-,, Yb2 and Yn; and group III is composed of Ye
and Yf subunits. Subunit hybridisation can occur in the
rat, but only between subunits in the same family. At
least 12 GST have been described in rat liver as a
consequence of such hybridisation [Hayes 1984, 1986].
Although GST are present in many tissues in the rat, a
marked tissue-specific distribution of GST subunits
exists [Hayes & Mantle 1986a]. For example, Ya is found
only in liver, kidney and small intestine, whereas Yb is
present in high concentration in most organs except
kidney. Yf is distributed widely in extrahepatic
tissues, and although not observed normally in rat liver,
its concentration is increased markedly during the
development of experimental, chemically-induced, hepatic
carcinoma. For this reason, much attention has focused
71
on its potential to serve as a preneoplastic marker for
hepatocarcinogenesis [Satoh et al 1985c].
Table 2.2








[a] [b] [c] [d]
Liver Alpha 1-1 YaYa I 25,500 10 . 0
Liver Alpha 1-2 YaYc 9 . 9
Liver Alpha 2-2 YcYc I 27,500 9 . 8
Liver Mu 3-3 YbiYb, II 26,300 00
Mu 3-4 YbiYb2 8 . 0
Liver Mu 4-4 Yb2Yb2 II 26,300 6.8
[e] 5-5 26,500 7 . 3
Testis Mu 6-6 YnYn II 26 , 000 5.8
Kidney Pi 7-7 YfYf III 24,000 6 . 9
Liver Alpha 8-8 YkYk I 25,000 6 . 1
[a] Mannervik et al 1985; Mannervik & Danielson 1988
[b] Jakoby, Ketterer & Mannervik 1984
[c] Bass et al 1977
[d] Hayes & Mantle 1986a
[e] not yet classified
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Human GST
In man, the glutathione S-transferases can be divided on
the basis of their isoelectric points (pi) into three
groups - basic, neutral and acidic [Mannervik 1985;
Beckett & Hayes 1987; Warholm, Guthenberg & Mannervik
1983]. Within each group there is a range of pi values;
the isoelectric points range from 9.0-7.3 for the basic
GST, 6.5-5.5 for neutral, and 5.3-4.5 for the acidic
group. Immunochemically, the basic, neutral and acidic
GST correspond to the rat GST groups I, II and III
respectively [Hayes & Mantle 1986a, 1986b];
physicochemically they most closely resemble rat Ya, Yb2
and Yf subunits respectively [Hayes & Mantle 1986a,
1986b; Stockman, Beckett & Hayes 1985; Hayes et al 1983].
Table 2.3
Human glutathione S-transferase isoenzymes
Source of
GST
Class Enzyme Group Subunit Mr pi
Liver Alpha bib, Basic 25,900 8 . 9
Liver Alpha BiB2 Basic 25,900 8 .75
Liver Alpha b2b2 Basic 25,900 8 , . 4
Liver Mu p Neutral 26,500 6 , . 1
Liver Mu <i> Neutral 26,500 5 . . 5
Lung Pi X Acidic 24,800 4 . . 8
Erythrocyte Pi P Acidic 24,800 4., 7
Placenta Pi n Acidic 25,200 4 . 8
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The nomenclature used to describe human basic GST was
based initially on the purification scheme devised by
Kamisaka and colleagues (1975). These workers isolated
and characterised five basic transferases from human
liver, designated a, J3, gamma, 5 and e on the basis of
increasing isoelectric points. More recently, other
workers have isolated a neutral form (transferase p)
[Warholm, Guthenberg & Mannervik 1983] and three acidic
forms (transferases lambda [Dao et al 1984], ti [Mannervik
& Guthenberg 1981] and rho [Marcus, Habig & Jakoby 1978])
from human tissue. There is evidence to suggest that
transferase ti is identical to transferase rho [Guthenberg
& Mannervik 1981], although Vander Jagt and coworkers
(1985) have shown that small size differences exist
between the subunits of these transferases.
The subunit composition of the GST isoenzymes in man has
been identified for only three of the basic GST; that of
the neutral and acidic forms remains unknown. At least
two distinct basic subunits exist, and B2, both with
Mr 25,900. These can hybridise to form B-|Bi, B-,B2 and
B2B2 subunit combinations [Stockman, Beckett & Hayes
1985], known formerly as "basic", N/Al and N/A2b
respectively [Hayes et al 1983]. These forms appear to
correspond to transferases e, 6 and gamma respectively,
described by Kamisaka and coworkers (1975). The term,
ligandin, used in earlier literature [Bass et al 1978;
Sherman et al 1983a; Tsuru et al 1978], appears to refer
to both Bi and B2 subunits (Table 2.4). There is
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controversy as to whether basic GST can hybridise with a
subunit of an acidic form. Although Singh and
colleagues (1985) demonstrated that this may be possible,
most other workers agree that such combination cannot
occur [Stockman, Beckett & Hayes 1985; Soma, Satoh & Sato
1986; Hussey et al 1986b]. Much, therefore, remains to
be learned about the quaternary structure of the GST
isoenzymes in man.
Table 2.4
Equivalent nomenclature for human basic GST
Reference [a] [b] [c] [d]
B1B1 basic e ligandin
B-|B2 N/Al 6 ligandin
B2B2 N/A2b gamma ligandin
[a] Stockman, Beckett & Hayes 1985
[b] Hayes et al 1983
[c] Kamisaka et al 1975
[d] Bass et al 1978; Sherman et al 1983a; Tsuru et al
1978
Until recently it was considered that major species
differences existed in the occurrence of the multiple
forms of GST. Further characterisation and comparisons
of GST from three mammalian species (rat, mouse and man)
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has, however, suggested that mammalian GST should be
divided into three classes, based on enzymatic,
immunological and physicochemical properties. Further
support for this classification has been obtained by
elucidating the amino-terminal amino acid sequences of
the various GST and identifying the similarities between
species in each class. The three classes now recognised
are alpha, mu and pi [Mannervik et al 1985]. These
would appear to correspond to rat GST families I, II and
III, and human basic, neutral and acidic GST respectively
(Tables 2.2 and 2.3).
TISSUE DISTRIBUTION
GST are cytosolic proteins, with the exception of a
microsomal form that has been identified in rodents
[Morgenstern, DePierre & Jornvall 1985]. Several
isoenzymes of GST have been demonstrated in each of the
animal species investigated. However, when different
organs in the same animal are examined, it is generally
found that not all of the multiple forms of enzyme are
present in every tissue. In the rat, the organ studied
most intensively is the liver; at least 12 different
isoenzymes occur in the cytosolic fraction. GST have
been identified also in other rat organs including
testis, seminiferous tubules, epididymis, kidney, lung,
heart and gastrointestinal tract, although definitive
characterisation has not been possible for all sources
[Mannervik 1985].
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Accurate description of the tissue distribution of human
GST isoenzymes is hampered by the possibility of
heterogeneity in each of the three groups characterised,
ie acidic, neutral and basic. GST are found in greatest
concentration in liver, kidney, duodenum, testis and
adrenal [Sherman, Titmuss & Kirsch 1983b], although they
have been demonstrated also in other tissues, most
notably placenta [Mannervik & Guthenberg 1981] and
erythrocytes [Marcus, Habig & Jakoby 1978]. Human liver
contains predominantly basic GST; neutral GST are found
in the liver in approximately 60% of individuals
[Sherman, Titmuss & Kirsch 1983b; Hussey et al 1986b;
Warholm, Guthenberg & Mannervik 1983]; acidic GST are
found only in low amounts in normal liver [Awasthi, Dao &
Saneto 1980], but their concentration increases greatly
in the presence of hepatic tumour [Soma, Satoh & Sato
1986]. Basic GST have been isolated also from human
kidney [Sherman, Titmuss & Kirsch 1983b], whereas the GST
present in lung, placenta and erythrocytes are acidic in
nature [Beckett & Hayes 1987]. Using
immunohistochemical staining, Redick, Jakoby and Baron
(1982) demonstrated that GST were not distributed
uniformly throughout the liver lobule, but that they were
present in greatest concentration in the centrilobular
region, with much lower concentrations in the midzonal
and periportal regions; this contrasts with the mainly
periportal distribution of the aminotransferases.
Human GST are subject to marked polymorphism [Hussey et
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al 1986b]; genetic variation has been proposed to account
for this. Using starch-gel electrophoresis and
histochemical staining, three gene loci, GST-1 (mu class,
neutral), GST-2 (alpha class, basic) and GST-3 (pi class,
acidic), have been described [Board 1981]. More
recently, two products from the GST-1 locus have been
discovered, termed GST-1 type 1 and GST-1 type 2 [Suzuki
et al 1987], and there are also at least two products
from the GST-2 locus [Boyer 1989]. Therefore, human GST
are thought to be the products of at least three, and
possibly five, separate gene families. The presence of
three genetically distinct types of human GST has been
confirmed by Warholm and colleagues (1983).
MEASUREMENT OF PLASMA GST
Intracellular enzymes released into the peripheral
circulation following tissue damage can be measured in
two main ways. The much commoner method is to measure
their catalytic activity, but an alternative is to
measure their concentration using immunological methods
such as radioimmunoassay (RIA). There are advantages
and disadvantages to both techniques. Enzymic activity
measurement is generally rapid and easy to perform, but
is susceptible to sources of error in the presence of
circulating inhibitors. It can also be difficult to
distinguish among different isoenzyme forms.
Immunoassay methods are not affected by either of these
limitations, but they are often slow and tedious to
perform, and the availability of the necessary antisera
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may be limited. Plasma levels of GST have been measured
using both techniques.
Enzymic activity
GST activity was first demonstrated in rats, using
bromsulphthalein [Combes & Stakelum 1961] and
3,4-dichloronitrobenzene [Booth, Boyland & Sims 1961] as
electrophilic substrates. Both these substrates are
specific for the rat Yb., subunit, and display virtually
no activity with other subunits, including human GST
[Beckett & Hayes 1987]. Another substrate,
l-chloro-2,4-dinitrobenzene (CDNB), which is active with
most forms of GST, was introduced some 10 years later
[Clark, Smith & Speir 1973]. Unfortunately, the
specific activity of different isoenzymes with CDNB
varies significantly, making it difficult to obtain
sufficient sensitivity to allow precise measurement of
plasma GST activity. Two further sources of serious
error apply to GST activity measurement. Firstly, many
non-substrate ligands including bilirubin and bile salts,
the plasma concentration of which may be increased in
liver disease, can bind to GST thus inhibiting their
activity [Kamisaka et al 1975] . Secondly, acidic forms
of GST from lung, placenta, erythrocytes and other
tissues also conjugate CDNB with glutathione, resulting
in poor organ specificity. In addition, haemolysis can




With the introduction of immunoassay methods, specific
forms of GST can be measured in plasma, with greater
sensitivity than enzymic activity methods. The first
RIA technique, which measured rat ligandin (YaYa), was
developed by Bass and coworkers (1977) to investigate the
tissue distribution of ligandin. Later these workers
demonstrated that measurement of plasma GST YaYa
concentration was a more sensitive index of experimental
hepatocellular necrosis than the measurement of serum
aminotransferase activity [Bass et al 1978]. Species
specificity however, precludes the use of the rat RIA in
man.
Tsuru and colleagues (1978) first described a RIA for
human ligandin (alpha class; basic GST), and showed
increased ligandin concentrations in a variety of liver
disorders. However, there was considerable overlap
between the concentrations measured in controls and in
those with liver disease. Unfortunately, the poor
sensitivity of this method was such that the lower limit
of the reference range could not be defined; rather the
plasma ligandin concentration in control patients did not
exceed 5.3 ng ml-1. Sherman and coworkers (1983a) have
also described a RIA method for human ligandin, in which
serum ligandin concentrations correlated significantly
with histological severity of disease. Again though,
this particular RIA was not sufficiently sensitive to
define the lower limit of the reference range, and the
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minimum detection limit of 1 ng is rather high.
In the same year a RIA was developed in man for the
detection of GST B2B2. This method had sufficient
precision and sensitivity to define both an upper and
lower limit of a reference range (0.5 - 2.6 pg 1~1) ; it
had a detection limit of 12 pg [Hayes et al 1983].
Subsequently, a RIA method for measuring GST B-|Bi was
described which had similar sensitivity [Beckett & Hayes
1984]. The range of GST BiB, concentrations in healthy
volunteers who had no clinical or biochemical evidence of
liver disease was found to be 1.2 - 4.1 pg 1_1 . Both
B1B1 and B2B2 GST are equally effective as immunogens.
The antisera produced to these immunogens are highly
specific (Table 2.5).
Table 2.5
Specificities of antisera used in the radioimmunoassay of








b2b2 100 0 . 2
Erythrocyte A O <0.1
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Antisera raised to GST immunogens show little
cross-reactivity with GST B2B2/ while the converse is
true for antisera raised to a B2B2 immunogen. However,
considerable cross-reactivity of GST B-|B2 occurs with
antisera raised to either B^ or B2B2 GST, indicating
that GST B-|B2 is a hybrid enzyme comprising a monomer
from each of B-|B-| and B2B2 GST. Erythrocyte GST shows
no cross-reactivity with either of the antisera raised to
hepatic GST, allowing specific measurement of hepatic GST
even in haemolysed plasma [Beckett et al 1985b].
The radioimmunoassay methods developed for the
measurement of GST B^ and B2B2 in plasma are much more
sensitive than those described by other workers. Both
assays have good organ specificity; there is little or no
cross-reactivity with the neutral or acidic GST, and even
gross haemolysis produces no change in GST concentrations
when measured by RIA [Hayes et al 1983]. GST B^ is
now measured in preference to B2B2 as it provides greater
sensitivity, and measurement of both types offers no
additional useful information. As with other
immunoassay techniques, the chief limitation of these
methods is the long incubation period required (66 hours)
which contrasts with the few minutes it takes to perform
measurement of serum aminotransferase activities.
Clinical studies have been performed to assess the
usefulness of plasma GST measurement compared with
standard biochemical liver tests.
82
GST AND LIVER DISEASE
Adachi and coworkers (1980) measured serum GST activity
in a variety of liver diseases including acute, fulminant
and chronic hepatitis, using CDNB as substrate. GST
activity increased significantly in cases of acute
hepatitis, primary hepatoma and metastatic liver disease,
with extremely high activity occurring in some cases of
fulminant hepatitis. Serum GST and aminotransferase
activities correlated well in acute and fulminant
hepatitis, and primary liver carcinoma, while in chronic
hepatitis and cirrhosis the correlation was poor. Serum
GST activity decreased much more rapidly than did that of
ALT or AST in cases of acute and fulminant hepatitis. The
authors concluded that serum GST measurements would
provide valuable diagnostic information in acute liver
disease. Interpretation of their data is difficult,
however, not only because of the poor sensitivity of the
enzymic method of GST measurement, but also because many
patients had an increased serum concentration of
bilirubin which can inhibit serum GST activity.
Although there existed a reasonable correlation between
GST activity and serum ligandin concentration measured by
radioimmunoassay, the numbers involved were very small
and the correlation itself was not particularly strong.
Therefore, their assumption that measurements of GST
activity and ligandin concentration in serum have almost
the same clinical significance is not well founded.
Early animal and human studies in which plasma ligandin
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concentrations were measured by radioimmunoassay had
shown that GST provides a more sensitive index of acute
hepatocellular necrosis than does serum aminotransferase
activity [Bass et al 1978; Sherman et al 1983a].
Furthermore, in patients with chronic active hepatitis,
plasma GST concentration correlated strongly with the
histological severity of disease, unlike ALT activity
[Sherman et al 1983a]. More recently, plasma GST
concentrations have been measured in patients with acute
and chronic forms of liver disease.
Beckett and colleagues (1985a, 1985b) measured GST BtB-,
and B2B2 concentrations by specific radioimmunoassays in
patients with paracetamol poisoning, to investigate the
time course of hepatocellular damage, and to monitor the
response to treatment with N-acetyl cysteine. Seventeen
of the 18 patients studied had abnormal GST
concentrations; in contrast, aminotransferase activity
was increased in only seven patients. The high
incidence of abnormal GST concentrations (94%), is
consistent with the results of a large study of
histological changes following paracetamol overdose, in
which 98% of patients showed histological evidence of
liver damage, but only 44% of patients showed an
abnormality of plasma AST activity [James et al 1975].
The increases in GST concentration occurred much earlier,
and were considerably more abnormal than the
abnormalities of aminotransferase activity. Similarly,
GST concentration fell rapidly after peak values were
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reached, in contrast with the activities of the
aminotransferases; plasma half-life of GST B-,B-| and B2B2
was calculated to be approximately one hour [Beckett et
al 1985b]. Therefore, the rapid release of GST into
plasma following hepatocellular damage, and its
relatively short plasma half-life, allows early detection
of injury and early recognition of when resolution
begins.
Measurement of plasma GST concentration has proved less
valuable in monitoring the course of acute viral
hepatitis. Sherman and colleagues (1983a) measured GST
concentration and AST activity in sequential plasma
samples to examine the changes in liver function that
occurred in 68 patients with acute viral hepatitis. At
the time of presentation 67 patients had increased GST
concentrations, and AST activities were increased in all
patients. In patients positive for hepatitis B surface
antigen, GST concentration had returned to normal values
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within 8 weeks, when 20% of patients still had increased
plasma AST levels. Similarly, in patients with non-B
hepatitis, 62% had persistently increased AST activity
when GST concentration had returned to normal. The
rapid disappearance of GST from plasma was attributed to
its short plasma half-life, which it was concluded,
weakened its use as a diagnostic test in acute viral
hepatitis. GST measurement may, however, be a useful
prognostic indicator, as its disappearance from plasma
correlates with recovery from the acute illness [Beckett
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& Hayes 1987]
Patients with chronic active hepatitis have consistently
increased GST concentrations [Tsuru et al 1978] which
correlate well with abnormal liver histology [Sherman et
al 1983a]. Results from patients with cirrhosis are
somewhat equivocal, some workers finding increased GST
activity [Tsuru et al 1978], while other investigators
have reported normal values [Adachi et al 1980] even with
coexisting raised plasma AST activity [Sherman et al
1983a]. On the other hand, GST is a useful test in
detecting subclinical liver damage in hyperthyroidism and
in hypothyroid patients receiving thyroxine replacement
therapy [Beckett et al 1985c]. GST also appear to be
readily released into the peripheral circulation in
patients with primary hepatocellular carcinoma, but not
in those with hepatic metastases or with primary
extra-hepatic tumours [Ohmi & Arias 1981] .
GST have been investigated also in experimentally-induced
chemical hepatotoxicity. Aniya and Anders (1985b)
studied the effects of several hepatotoxins on hepatic
and serum GST activity in rats. A marked decrease in
hepatic GST activity, and an increase in serum GST
activity, was observed after administration of CCl4 or
bromobenzene. These alterations in GST activity were
dependent upon pretreatment with phenobarbitone or
ethanol. Hepatic damage caused by bromobenzene and CC14
is associated with active metabolite formation via
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cytochrome P-450, and is potentiated by phenobarbitone or
ethanol treatment. It was suggested that reactive
metabolites produced from bromobenzene and CCl4
biotransformation contributed to the observed alterations
in GST activity. The increase in serum GST activity was
accompanied by an increase in both serum AST activity and
serum bilirubin concentration. As with other studies
measuring serum GST activity, the poor sensitivity of the
enzymic assay and the potential inhibition of GST
activity by increased serum bilirubin confuse the
interpretation of this data.
LIVER ENZYME TESTS AND ANAESTHESIA
Although minor changes in liver biochemical tests are
considered to be common after general anaesthesia, the
incidence of mild hepatic damage which is clinically
undetected is not known [Cousins 1980], and few studies
have examined prospectively the incidence of such
abnormalities.
Standard liver enzyme tests
Despite the relatively low specificity of the
aminotransferases for minor degrees of hepatocellular
damage, ALT and AST have often been used as markers of
liver damage after anaesthesia. However, using such
measurements in man, several prospective studies of liver
function after halothane anaesthesia have provided
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conflicting results. Some studies have demonstrated a
greater frequency of increased serum aminotransferase
activity in patients receiving repeated halothane
anaesthetics than in those receiving non-halothane
anaesthesia [Trowell, Peto & Smith 1975; Wright et al
1975; Fee et al 1979]. In contrast, Allen and Downing
(1977) could demonstrate only minimal changes in
aminotransferase activities, while McEwan (1976) found
fewer disturbances of liver function after halothane than
after non-halothane anaesthesia.
The differing results from these studies require further
consideration. In the study by Fee and colleagues
(1979), the difference in frequency of increased enzymic
activity between patients who received halothane and
those who received enflurane disappears when obese
patients and those exposed to halothane in the preceding
6 weeks are excluded. In their investigations of
biochemical liver disturbance after anaesthesia, McEwan
(1976) studied 41 patients and Trowell, Peto and Smith
(1975) studied only 39; these numbers are too small to
allow interpretation of their observations with
confidence. The remaining studies by Wright and
coworkers (1975), and Allen and Downing (1977), appear to
disagree upon the effect of repeated halothane
anaesthesia on serum aminotransferase activities, despite
examining patients under similar circumstances.
However, Wright and colleagues measured serum
aminotransferase activities every 3 to 5 days after
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operation for two weeks or more, whereas Allen and
Downing measured AST only up to 72 hours after operation.
Only two patients in the former study had developed
increased aminotransferase activities by the 3rd
postoperative day; in the remaining 13 patients AST
increased only in the second week after operation. It
is possible, therefore, that Allen and Downing might have
recorded a greater frequency of increased AST activity
had they continued measurement for a longer period. It
seems likely that the inconsistencies in these studies
may reflect difficulties in defining a sensitive
indicator of mild hepatocellular dysfunction.
Aminotransferase activities after operation are
influenced also by the nature of the surgery. Clarke,
Doggart and Lavery (1976) measured the activities of ALT
and AST in patients undergoing four different types of
surgical procedure - minimal surgery such as cystoscopy;
body surface operations such as herniorrhaphy; gastric
surgery; and biliary surgery. No abnormalities were
detected after minimal surgical procedures lasting up to
one hour. After body surface operations,
aminotransferase activities showed minor, transient
derangements, while both gastric and biliary surgery
resulted in more marked alterations which resolved by the
4th day after surgery. ALT and AST activities increased
within one hour of starting surgery, although the
investigators considered that these changes were probably
not related to liver function.
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Schemel (1976) has highlighted a further problem in using
aminotransferase activities to diagnose liver dysfunction
after anaesthesia. He found that 11 of 7620 healthy
patients with no intercurrent disease scheduled for
elective surgery had clearly abnormally increased AST,
ALT or LDH activities before operation. Surgery was
deferred in these patients. All eleven patients proved
to have overt liver pathology by further testing, and
three subsequently developed jaundice. It is
interesting to speculate whether this biochemical
evidence of liver damage would have been attributed to
the anaesthetic agent had surgery proceeded.
Specific liver enzyme tests
Thompson and Friday (1978) measured serum OCT activity in
two comparable groups of adult male patients
anaesthetised with halothane or enflurane for vagotomy
and pyloroplasty, and demonstrated a biphasic increase in
OCT activity in both groups. OCT activity increased
significantly in the afternoon following operation, and
again on the 5th to 7th postoperative day, when compared
with values before operation. These changes tended to
parallel increases in ALT activity, although ALT activity
did not exceed 60 U 1~1 in any patient. Despite
studying only 24 patients, minimal but reversible
increases in OCT activity were demonstrated in 75% of
subjects after halothane and enflurane anaesthesia,
although no difference was observed between the two
agents.
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Another group of investigators estimated the activities
of seven liver enzymes, including ASAL, before and after
cholecystectomy in patients anaesthetised with either
halothane or methoxyflurane, or with nitrous oxide and
analgesic supplements [Kalow, Rogoman & Sims 1976].
They found that ASAL activity increased after operation
in around 50% of patients in each anaesthetic group.
Its activity was maximal by the 6th postoperative day and
remained abnormally elevated for up to 10 days.
However, the type of anaesthetic technique employed did
not influence the magnitude of the average increase in
ASAL, AST or ALT in the period after operation,
suggesting perhaps, that the surgery itself exerted a
greater effect on liver enzyme activities than the choice
of anaesthetic technique.
Glutathione S-transferase
Aniya and Anders (1985a) injected chloroform into the
peritoneal cavity of rats pretreated with phenobarbitone,
and measured hepatic cytosolic and serum GST activity by
enzymic assay. A marked increase in serum GST activity
was observed 5 hours after chloroform treatment. This
was accompanied by a decrease in hepatic GST activity,
suggesting a leakage of hepatic GST into the peripheral
circulation. Serum activity had returned to near
control values by 24 hours. Treatment of rats with
SKF 525A or cysteine prevented the chloroform-induced
increase in serum GST activity. As these agents inhibit
the covalent binding of chloroform metabolites to
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macromolecules, it was proposed that the leakage of GST
into serum resulted from chloroform metabolites becoming
bound covalently to liver proteins. It is interesting
that pretreatment with SKF 525A or cysteine has been
observed to inhibit the development of hepatic necrosis
after halothane anaesthesia in the phenobarbitone-hypoxia
rat model [Jee et al 1980] .
Two groups of workers have examined the effect of
halothane on hepatic GST activity in rats. Dale and
Nilsen (1984) measured GST activity in the livers of rats
exposed to repeated subanaesthetic concentrations of
halothane and enflurane. Repeated exposure to
concentrations of 50-1000 ppm were used to avoid the
effects of general anaesthesia and to increase the
metabolised fraction of the inhaled anaesthetics. GST
activity in hepatic cytosol decreased to around 85% of
control values only in rats exposed to the higher
concentrations of halothane or enflurane for several
days. Ivanetich, Thumser and Harrison (1988)
demonstrated that multiple halothane anaesthetics (1.25
MAC for one hour on 3 alternate days) initially
decreased, and subsequently increased, total liver
cytosolic GST activity in vivo. Maximal depression
occurred 10 days after the first halothane
administration; maximal activation was apparent some 15
days later. Isoflurane, enflurane and methoxyflurane
appeared to inhibit hepatic GST activity in a
time-dependent manner similar to halothane. It is not
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known if these agents similarly activate GST as this was
not investigated. No significant alteration in GST
activity was noted after a single halothane anaesthetic
(1.25 MAC for 3 hours). The effect of halothane on the
activity of several hepatic GST isoenzymes in vitro was
examined also. GST isoenzymes 3-3, 3-4 and 4-4, which
correspond immunochemically to human neutral GST,
exhibited reduced activity, while that of isoenzyme 1-2
increased; the activity of isoenzyme 1-1 (YaYa, rat
ligandin) remained unchanged throughout. Therefore, in
the rat, it would seem that the reduction in hepatic GST
activity after halothane anaesthesia results from
disappearance of neutral, and not basic, GST.
This and the previous study have some important
limitations. In neither study was the serum activity of
GST measured; it is therefore not possible to comment on
whether or not the reduction in hepatic GST activity
resulted from leakage of specific transferases into
serum. Furthermore, in both studies the activity of GST
was measured using CDNB as substrate. The variation in
specific activity of different isoenzymes with CDNB makes
it difficult to obtain sufficient sensitivity to
measure accurately individual GST isoenzyme activity.
The finding that activation of hepatic GST activity could
occur after halothane exposure has not been confirmed by
other studies, which have shown no increase in hepatic
GST activity after administration of halothane or other
potential hepatotoxins [Aniya & Anders 1985a, 1985b; Dale
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& Nilsen 1984]. This activation must be of questionable
physiological significance as the process was readily
reversible, and exhibited only low extents of activation,
even with massive concentrations of halothane. Therefore,
the measurement of hepatic and/or serum GST activity does
not provide much useful information in assessing the
changes in hepatocellular integrity which occur following
general anaesthesia.
Plasma GST concentrations have been measured by specific
radioimmunoassays to investigate hepatocellular integrity
after halothane anaesthesia in man. In a pilot study,
Hussey and coworkers (1986a) measured GST B., and B2
subunits in 28 patients undergoing general anaesthesia
with halothane. In 23 patients, GST concentration was
increased 1 to 3 hours after the end of anaesthesia,
compared with the concentration before operation. In
most of these instances GST concentration had decreased
to control values by the following day. However, in
three patients a much larger secondary increase was noted
24 hours after the end of anaesthesia. Thirteen
patients (46%) had abnormally increased GST
concentrations after operation, whereas no significant
changes in plasma ALT activity were noted.
Similar changes in GST concentration were observed in a
larger study by Allan and colleagues (1987). They
measured the plasma concentrations of GST B-|Bi in 71
patients undergoing minor urological surgery, who were
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randomised to receive either halothane or isoflurane in
70% nitrous oxide, or halothane in 100% oxygen. GST
concentrations did not change significantly in patients
who received isoflurane, but they increased in most
patients in both groups who received halothane.
Concentrations had usually reached a peak between 3 and 6
hours after anaesthesia, and had returned to normal by 24
hours in all but five of the 54 patients who received
halothane. The occurrence of abnormal GST
concentrations after anaesthesia was greater in patients
who received halothane in nitrous oxide than in those who
received halothane in oxygen alone (35% compared with
24%), but this difference did not achieve statistical
significance; no patient who received isoflurane
developed an abnormal GST concentration.
There appear to be two distinct phases of increased GST
concentration following halothane anaesthesia; one
occurs consistently within 3 to 6 hours of anaesthesia,
while the second occurs at 24 hours in a small number of
patients. The earlier phase may be due to relative
hepatic hypoxia resulting from halothane-induced
depression of hepatic blood flow, while it is possible
that the second, less frequent, phase results from
metabolism of halothane to toxic metabolites [Hussey et
al 1986a; Allan et al 1987]. It is unlikely that
pre-existing liver pathology was responsible for the
changes in GST concentration after anaesthesia, as in
both studies patients with clinical or biochemical
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evidence of liver dysfunction were excluded from
analysis, as were those who admitted to a high alcohol
intake. As basic GST are also present in small amounts
in human kidney, it is possible, although unlikely, that
renal release of GST may have contributed to the
increased plasma concentrations. Although the changes
in median GST concentrations observed after anaesthesia
were small, some individual increases were large, and
abnormal concentrations were recorded frequently,
particularly in patients who received halothane. It
would appear, therefore, that a short, single halothane
exposure can produce transient hepatic damage shown by
release of GST B1B1 into plasma, while isoflurane seems
to be free of this potential.
In summary, measurement of plasma GST concentration by
radioimmunoassay has much to offer in the investigation
of acute, toxic liver injury. It provides a sensitive,
specific and reproducible index of hepatocellular
integrity and its concentration correlates well with the
histological severity of disease. In addition, its
short plasma half-life of around 90 minutes allows early
detection of damage and its resolution. As GST are
distributed mainly in the centrilobular region of
hepatocytes, its measurement may be of considerable value
in the investigation of halothane-induced hepatotoxicity,
as this disorder is generally associated with
centrilobular necrosis. The value of plasma GST
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measurement is at present largely offset by the length of
time required to produce reliable, precise measurements
of plasma concentration; by RIA, it takes more than 48
hours. Further problems include the limited
availability of GST standards, radio-label and antisera.
Until the methods of assay are simplified and greatly
speeded up there is no possibility that GST could replace
aminotransferase measurement in the routine investigation
of liver disease. It does, however, offer a unique
opportunity for the further investigation of acute,
drug-induced liver damage.
This thesis is based on an investigation of the effect of
volatile anaesthetic agents on hepatocellular integrity
in man, and subsequent attempts to modify such effects,
using plasma concentration of GST B^ as a highly
sensitive and organ-specific index of liver damage.
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OR ISOFLURANE ON PLASMA GST CONCENTRATION
It has been demonstrated that significant increases in
plasma GST concentration occur after halothane
anaesthesia, but not after anaesthesia with isoflurane
[Allan et al 1987], suggesting that halothane is
associated with transient, mild, hepatocellular
dysfunction whereas isoflurane is not. As previous
studies had examined GST changes in patients undergoing
surgery of widely varying type and duration, and as the
effect of enflurane anaesthesia on GST concentration was
not known, it was decided to investigate the changes in
plasma GST B1B1 concentration in patients administered
halothane, enflurane and isoflurane for surgical
procedures that were standard in type and duration.
METHODOLOGY
Patient selection
Patients aged between 18 and 70 years in ASA groups I or
II undergoing body-surface operations such as varicose
vein surgery or inguinal hernia repair were studied.
Patients who had received a general anaesthetic in the
previous 6 months, or who had pre-existing clinical or
biochemical evidence of liver disease were excluded.
Patients taking regular medication likely to interfere
with liver function were excluded also. Subjects were
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allocated according to a previously prepared, randomised
list to receive either halothane, enflurane or isoflurane
in an otherwise identical anaesthetic technique.
Anaesthetic technique
No premedication was given. Anaesthesia was induced
with intravenous thiopentone 4-6 mg kg-1, and maintained
with the volatile agent vaporised in 33% oxygen and 67%
nitrous oxide. All patients breathed spontaneously from
a non-rebreathing anaesthetic system. After induction,
intravenous diamorphine in a total dose of 0.07 mg kg-1
was titrated in increments to allow anaesthesia to be
maintained with an inspired concentration of 1.0-1.5% for
halothane, and 1.0-3.0% for enflurane and isoflurane.
Samples
Blood samples for measurement of GST B-,Bi concentration
were taken before induction of anaesthesia (pre), and 3,
6 and 24 hours after the end of anaesthesia. Plasma
concentration of bilirubin and activities of ALT, GGT and
alkaline phosphatase (ALP) were measured before
anaesthesia and 24 hours after anaesthesia. Samples
were separated by centrifugation and the resultant serum
was stored at -20°C before measurement of GST.
Assay procedures
Concentrations of bilirubin and activities of ALT, GGT
and ALP were measured using a Sequential Multiple
Analysis with Computer (SMAC) System II (Technicon
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Instrument Corporation, Basingstoke, UK). The
normal ranges defined by the laboratory which performed
these investigations are: bilirubin 2-17 pmol 1~1; ALT
10-40 U 1-1; GGT 10-55 U l"1 (males), 5-35 U l"1
(females); ALP 40-100 U 1~1 . The concentration of GST
B1B1 in plasma was measured by specific radioimmunoassay
[Beckett & Hayes 1984], the reference range being 0.7-4.0
pg l-1 (derived from healthy, volunteer blood donors).
The interassay coefficient of variation for the GST B^
RIA was less than 10% and the intra-assay coefficient of
variation was less than 5% over the range 2-40 pg 1~1 .
Statistical analysis
Patient and anaesthetic characteristics in each group
were compared using the Kruskal-Wallis test. Changes in
GST concentrations within each group were compared using
the Friedman test. The Wilcoxon signed rank test was
used to compare GST concentrations at 3, 6 and 24 hours
after anaesthesia with preoperative values in each group:
to eliminate multiple testing errors, the Kruskal-Wallis
test was used to compare the changes in GST concentration
observed in the three groups at 3 hours after the end of
anaesthesia. The incidence of abnormal values in each
group was compared using a 4-fold table Chi-squared test.
Comparison of conventional liver function tests after
operation with preoperative values for each group used
the Wilcoxon rank sum test.
101
RESULTS
One hundred and one patients were studied: 30 received
halothane, 41 were administered enflurane and 30 received
isoflurane. Patients whose preoperative plasma
concentration of GST, or activities of ALT, GGT or ALP
exceeded the upper limit of the reference range were
excluded from analysis. As idiopathic
hyperbilirubinaemia occurs in varying degrees in 5-10% of
the population [Stoelting, Dierdorf & McCammon 1988], and
as serum bilirubin concentration is not a sensitive
indicator of hepatocellular dysfunction [Gitnick 1981],
patients who had an increased serum concentration of
bilirubin before operation with no other abnormal liver
biochemical test were included in analysis.
The remaining 70 patients from whom data were analysed
comprised 22 who received halothane (11 M, 11 F), 30 who
received enflurane (16 M, 14 F) and 18 who were given
isoflurane (10 M, 8 F). Comparisons between the groups
revealed no significant differences in age, weight,
height, alcohol consumption and duration of anaesthesia
(Table 3.1). Significant changes occurred in plasma
concentrations of GST after operation in all three groups
(halothane p<0.05; enflurane p<0.0001; isoflurane
p<0.01), and significant differences in these changes
were observed between the groups (p<0.05, Tables 3.2 -
3.5). GST concentration was significantly increased at
3 hours after the end of anaesthesia in the group that
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received halothane (p<0.01), and at 3 and 6 hours after
anaesthesia in the group that received enflurane
(p<0.0001 and p<0.05 respectively). No increase in GST
concentration was observed after anaesthesia in patients
who received isoflurane. In contrast, GST concentration
was significantly reduced at 24 hours in this group; a
decrease was not apparent in the other two groups. Four
patients who received halothane, and three who were
administered enflurane, exhibited large secondary
increases in GST concentration, which exceeded the
reference range, at 24 hours after anaesthesia. One of
these patients who had received halothane also had
increased serum ALT activity (116 U 1~1) at this time.
Many patients, particularly those who received halothane
or enflurane, developed concentrations of GST which
exceeded the upper limit of the reference range; abnormal
GST concentrations occurred in 50% of patients following
halothane anaesthesia, 20% following enflurane and 11%
after isoflurane. The incidence of abnormal GST
concentrations after halothane anaesthesia was
significantly greater than after anaesthesia with
enflurane or isoflurane (p<0.01 and p<0.05,
respectively); there was no significant difference
between enflurane and isoflurane anaesthesia. No
significant overall changes in the concentration of
bilirubin or the activities of ALT, GGT or ALP occurred
as a result of anaesthesia (Tables 3.6 - 3.9).
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Table 3.1
Mean values (SD) for patient and anaesthetic
characteristics for patients receiving halothane,



























Individual values for GST concentration (pg 1~1) for
patients receiving enflurane
PRE 3 h 6 h 24 h
1 2.2 2.9 2.9 2.0
2 2.4 3 . 0 2.8 2.3
3 2.3 3 . 0 2.8 2.0
4 3 . 6 3.4 3 .1 1.4
5 3 . 2 3 . 9 3.7 2.6
6 3.4 3 . 6 3.2 2.6
7 1.6 1.6 1.6 1.4
8 2.5 3.9 2 . 6 2.7
9 1.4 2 . 1 1.9 1.7
10 1.9 2 . 5 2 . 7 1.0
11 1.7 2 . 2 5 . 5 * 1.2
12 2.3 3 . 0 3 . 6 4.3 *
13 1.9 2 . 6 2.4 1.9
14 2.1 2.4 2.4 2.3
15 0.9 1.2 1.6 1.3
16 3 . 7 4 . 0 3 . 0 5.8 *
17 3.4 4 . 3 * 3 . 9 2.8
18 2 . 5 2 . 7 2.2 2.2
19 2.1 2.7 3 . 0 3 . 0
20 3 . 2 3.8 3 . 0 2 . 2
21 1.3 1.3 1.5 1.1
22 2.2 2.2 2.0 2 .1
23 3.0 2.8 2 . 9 4.8 *
24 2.8 3 . 1 2.8 3 . 0
25 0.9 1.8 3.4 1.2
26 2.6 3 . 1 3 . 2 2 . 7
27 3.2 3 . 9 2.9 1.7
28 3 . 0 3.1 2 . 9 3 . 2
29 2.8 4.5 * 4.3 * 3 . 5
30 1.5 1.6 1.9 1.4
.uded from analysis
31 7.7 * 14 . 2 * 7 . 7 * 3.2
32 4.5 * 4.0 4 . 2 * 2.0
33 5.1 * 6 . 0 * 4.4 * 9.0 *
34 3.1 3.4 3.4 2.5
35 5.0 * 4.7 * 4.3 * 2.1
36 3.7 3 . 5 4 . 8 * 15.0 *
37 3 . 2 2.2 3.2
38 4.8 * 5 . 7 * 4.6 * 2.9
39 9.5 * 9 . 6 * 6 . 2 * 5.6 *
40 5.0 * 6 . 3 * 5.2 * 3.4
41 3 . 2 4.1 * 2.8 1.8
* represents a value which exceeds the upper
limit of the reference range
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Table 3.3
Individual values for GST concentration (pg 1~1) for
patients receiving enflurane
PRE 3 h 6 h 24 h
1 2.2 2 . 9 2.9 2.0
2 2.4 3.0 2.8 2.3
3 2.3 3.0 2.8 2.0
4 3 . 6 3.4 3 .1 1.4
5 3 . 2 3 . 9 3.7 2.6
6 3.4 3.6 3.2 2.6
7 1.6 1.6 1.6 1.4
8 2.5 3 . 9 2.6 2.7
9 1.4 2 .1 1.9 1.7
10 1.9 2 . 5 2 . 7 1.0
11 1.7 2 . 2 5 . 5 * 1.2
12 2 . 3 3 . 0 3 . 6 4.3 *
13 1.9 2.6 2.4 1.9
14 2.1 2.4 2.4 2 . 3
15 0.9 1.2 1.6 1.3
16 3.7 4 . 0 3 . 0 5.8 *
17 3.4 4 . 3 * 3 . 9 2.8
18 2.5 2 . 7 2 . 2 2 . 2
19 2.1 2 . 7 3 . 0 3 . 0
20 3.2 3 . 8 3 . 0 2 . 2
21 1.3 1. 3 1.5 1.1
22 2.2 2.2 2 . 0 2.1
23 3 . 0 2.8 2 . 9 4.8 *
24 2.8 3 .1 2.8 3 . 0
25 0.9 1.8 3.4 1. 2
26 2.6 3 .1 3 . 2 2 . 7
27 3 . 2 3 . 9 2 . 9 1.7
28 3 . 0 3 .1 2 . 9 3 . 2
29 2.8 4.5 * 4.3 * 3 . 5
30 1.5 1.6 1.9 1.4
.uded from analysis
31 7.7 * 14.2 * 7.7 * 3 . 2
32 4.5 * 4 . 0 4 . 2 * 2 . 0
33 5.1 * 6 . 0 * 4.4 * 9.0 *
34 3.1 3.4 3.4 2.5
35 5.0 * 4 . 7 * 4.3 * 2.1
36 3.7 3 . 5 4.8 * 15.0 *
37 3 . 2 2 . 2 3.2
38 4.8 * 5 . 7 * 4.6 * 2.9
39 9.5 * 9 . 6 * 6 . 2 * 5.6 *
40 5.0 * 6 . 3 * 5.2 * 3.4
41 3 . 2 4.1 * 2.8 1.8
* represents a value which exceeds the upper
limit of the reference range
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Table 3.4
Individual values for GST concentration (pg 1~1) for
patients receiving isoflurane
PRE 3 h 6 h 24 h
1 2.3 2 . 5 2 . 7 1.6
2 2.7 2 . 0 1.5 2.4
3 3.7 4.4 * 3 . 6 2.4
4 2.0 2 . 5 2 .1 1.4
5 1.9 2.1 2 .1 1.8
6 3 . 3 3 . 3 3 .1 2.4
7 2.9 2 . 5 2 . 7 1.7
8 2.5 3.0 2 . 3 2.3
9 1.4 1.5 1.7 1.8
10 3.6 3.6 2 . 6 2.5
11 3 . 2 2 . 6 2.6 2.1
12 2.9 2 . 3 4 . 0 2 . 3
13 3.8 2 . 8 2 . 3 1.6
14 3 . 5 3 . 6 3 . 8 3.4
15 2 . 4 3 . 1 4.1 * 1.9
16 1.8 1.8 2.1 2.0
17 1.7 2.1 2.1 1.8
18 3 . 3 3 . 9 2.9 1.6
.uded from analysis
19 6 . 3 ★ 8 . 3 * 5.0 * 4.6 ★
20 6 . 9 * 5 . 3 * 4.3 * 26.0 ★
21 4 . 9 * 4 . 6 * 3 . 9 2.4
22 6.3 * 7 . 2 * 3 .1 3.8
23 4.4 * 3 . 7 2 . 5 2.8
24 8.8 * 14 . 7 * 7 . 3 * 5 . 7 ★
25 8 . 0 * 7.4 * 6.8 * 4.3 ★
26 4 . 2 * 4 . 2 * 3 . 5 1.8
27 8 . 0 * 6.1 * 4.6 * 3.7
28 4.3 * 3.6 5.1 * 5.0 ★
29 5.7 * 5 . 2 * 4.2 * 4.5 *
30 8.2 * 4.4 * 3 .1 2.6
* represents a value which exceeds the upper
limit of the reference range
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Table 3.5
Medians (interquartile range) of GST concentrations
(pg 1_1) for patients receiving halothane, enflurane and
isoflurane




























* p<0.05; ** p<0.01; *** p<0.0001
compared with preoperative concentration
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Table 3.6
Conventional liver biochemical tests before and after
operation in patients receiving halothane
PREOP POSTOP
Bil ALT GGT ALP Bil ALT GGT ALP
1 9 15 12 85 11 18 9 80
2 11 11 10 39
3 11 <10 21 80 9 10 <5 88
4 8 18 12 66 11 12 21 71
5 7 <10 7 64 7 10 8 62
6 14 17 7 49 21 * 15 <5 44
7 12 11 10 84 17 14 7 68
8 11 <10 5 64 9 12 5 49
9 11 14 9 66 10 19 12 61
10 10 26 30 73 8 26 31 63
11 6 22 23 100 9 19 22 87
12 14 16 25 78 16 24 26 78
13 17 23 6 51 21 * 23 5 46
14 16 18 <5 65 6 12 5 55
15 9 16 11 57 10 116 * 52 * 70
16 8 13 8 76 10 11 7 66
17 9 <10 21 88 13 <10 21 78
18 18 * 16 16 84 19 * 16 20 66
19 13 13 15 81 13 13 12 74
20 9 19 11 79 9 16 10 71
21 14 23 15 95 26 * 20 18 75
22 9 16 7 69 7 14 9 63
Excluded from analysis
23 12 36 24 61 18 * 30 25 36
24 11 37 45 81 17 35 47 75
25 13 60 * 7 80 11 39 8 76
26 9 17 18 56 9 10 21 53
27 11 26 35 102 * 9 21 23 81
28 27 * 13 18 103 * 29 * 15 18 93
29 15 24 17 53 9 18 12 39
30 19 * 13 7 125 * 34 * 30 15 123 *
* represents a value which exceeds the upper
limit of the reference range
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Table 3.7
Conventional liver biochemical tests before and after
operation in patients receiving enflurane
(* abnormally elevated result)
PREOP POSTOP
Bil ALT GGT ALP Bil ALT GGT ALP
1 17 14 16 82 22 * 11 10 88
2 7 -- -- 46 8 12 8 44
3 12 -- — 64 9 13 7 59
4 18 * 12 1 2 53 15 <10 12 44
5 7 14 12 41 9 29 7 46
6 14 -- -- 80 15 24 47 82
7 9 <10 22 55 9 <10 10 56
8 9 12 17 53 14 13 14 81
9 14 <10 11 68 13 <10 7 65
10 13 11 12 81 20 * 16 12 79
11 13 13 11 98 21 * 22 11 83
12 6 14 31 100 7 16 32 110
13 13 14 19 39 13 16 17 47
14 13 18 10 64 9 14 9 63
15 8 <10 7 58 9 <10 <5 66
16 10 15 25 68 9 10 18 67
17 20 * 20 29 67
18 13 13 7 64 9 <10 <5 64
19 15 16 27 92 25 * 13 25 84
20 11 33 41 85 14 28 31 84
21 7 <10 16 91 9 11 11 85
22 15 14 19 63 19 * 15 21 68
23 11 25 27 74
24 18 * 11 <5 57 20 * 14 10 43
25 10 <10 <5 51 15 10 <5 48
26 8 29 6 42
27 34 * 18 8 61
28 12 19 43 64 8 16 8 71
29 9 11 — 61 7 <10 8 71
30 11 11 < 5 79 11 13 8 68
Excluded from analysis
31 8 30 42 119 * 12 26 30 102 *
32 9 13 12 103 * 13 <10 11 89
33 16 41 * 25 44 11 34 22 42
34 7 10 81
35 10 29 41 63 12 22 3 7 68
36 12 21 56 * 89 16 37 52 84
37 11 35 20 79 7 27 15 81
38 11 32 53 66 10 25 67
39 9 40 50 * 90 11 32 38 * 92




Conventional liver biochemical tests before and after
operation in patients receiving isoflurane
PREOP POSTOP
Bil ALT GGT ALP Bil ALT GGT ALP
1 10 <10 12 50 11 11 10 39
2 12 23 22 93 16 19 20 91
3 8 27 37 78 10 22 35 75
4 23 * 23 17 84 11 14 15 79
5 16 15 13 69 13 12 — 56
6 8 12 15 63 11 13 6 54
7 9 18 26 66 6 16 22 60
8 7 14 8 55 8 <10 12 65
9 19 * — 7 57 17 <10 7 51
10 7 25 24 63 10 22 21 59
11 16 20 7 70 15 14 8 59
12 6 10 11 83 4 <10 12 80
13 11 14 9 73 9 15 8 69
14 13 18 49 100 10 12 38 85
15 8 <10 6 54 10 <10 9 53
16 15 10 8 35 16 10 9 33
17 11 21 14 58 12 13 11 40
18 13 22 23 92
Excluded from analysis
19 10 37 38 56 11 31 33 52
20 10 39 12 113 * 18 * 76 * 28 103 *
21 17 12 12 124 * 23 * 11 11 103 *
22 16 27 36 94 8 22 25 87
23 14 20 39 63
24 22 * 68 * 21 87 25 ★ 51 * 18 83
25 12 33 18 64 15 37 24 73
26 14 27 47 69 14 18 39 55
27 12 32 27 60 16 32 21 63
28 8 23 13 71 8 14 12 72
29 17 26 30 116 * 11 20 24 96
30 6 13 6 67 6 10 8 64
* represents a value which exceeds the upper
limit of the reference range
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Table 3.9
Median values (range) of conventional liver function
tests for patients receiving halothane, enflurane and
isoflurane
Bilirubin ALT GGT ALP
(pg 1-1) (U 1-1) (U 1-1) (U 1-1)
Halothane
PRE 11 16 11 76
(6-18) (<10-26) (<5-30 ) (39-100)
24 h 10 15 10 68
(6-26) (<10-116) (< 5-5 2) (44-88)
Enflurane
PRE 12 14 16 64
(6-34) (<10-33) (<5-43) (39-100)
24 h 13 13 10 68
(7-25) (<10-29) (<5-47) (43-110)
Isoflurane
PRE 11 18 14 69
(6-23) (<10-27) (6-49) (35-100)
24 h 11 13 12 59
(4-17) (<10-22) (6-38) (33-91)
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DISCUSSION
This study has demonstrated marked differences in the
effect of three volatile anaesthetic agents on plasma GST
B1B1 concentration after anaesthesia. These differences
were not attributable to patient selection, as the three
groups were comparable with respect to factors such as
age, sex, alcohol intake, and type and duration of
surgery. Significant increases in GST concentration
were observed at approximately 3-6 hours after
anaesthesia with halothane and enflurane, but not after
isoflurane. These findings are in agreement with the
results obtained from a previous study, in which
halothane and isoflurane only were studied [Allan et al
1987]. Although the changes in plasma GST concentration
were small, a large number of abnormal concentrations
were recorded, particularly in the group which received
halothane. In addition, secondary and more marked
increases in GST concentrations were seen 24 hours after
anaesthesia in a few of the patients who had received
halothane and enflurane, although this was not observed
in patients administered isoflurane.
How do these observations relate to the mechanisms which
have been proposed to account for hepatotoxicity caused
by volatile anaesthetic agents? The data presented
provide evidence for two distinct phases of impaired
hepatocellular integrity after anaesthesia with halothane
and enflurane, but not with isoflurane. The first phase
113
ocurred in the majority of patients within 3-6 hours of
administration of the agent. This is likely to be
caused by the direct depressant effect of these agents on
hepatic blood flow resulting in relative tissue hypoxia.
In contrast, administration of isoflurane, which
preserves hepatic blood flow to a much greater extent
than halothane and enflurane, did not cause an increase
in GST concentration. The second phase occurred 24
hours after anaesthesia, when large secondary increases
in GST concentration were observed occasionally. This
latter phase may result from the production of toxic
metabolites. The changes in GST concentrations seen at
this time support evidence for the existence of the mild
subclinical form of halothane hepatitis that has been
defined by other workers [Touloukian & Kaplowitz 1981;
Neuberger & Williams 1984; Pohl & Gillette 1982; Brown &
Gandolfi 1987]. It is interesting that the frequency of
abnormal GST concentrations seen after halothane,
enflurane and isoflurane correlates directly with the
extents of metabolism and incidence of reported clinical
hepatic dysfunction for these drugs.
It has been suggested privately that the changes in GST
concentration after anaesthesia may not reflect mild
hepatocellular damage, but rather may result from a
circadian variation in plasma GST concentration, or from
reduced GST clearance. Aldridge and colleagues (1991)
have measured sequential plasma concentrations of GST
B-iB-] in 30 healthy volunteers in a 24 hour period. The
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volunteers fasted overnight, and on the following day-
blood was sampled at 0900 for measurement of GST
concentration. Further samples were taken 3, 6 and 24
hours after this initial sample, time intervals that
correspond to those of the present study of patients
undergoing anaesthesia. GST concentration did not
increase at any time; in contrast to the changes observed
in the present study, GST was significantly reduced at 3
hours (p<0.05, Wilcoxon signed rank test; Table 3.10).
The increases in GST concentration observed after
halothane and enflurane anaesthesia are, therefore,
unlikely to have resulted from diurnal variation in
plasma GST concentration.
Table 3.10
Medians (interquartile range) of GST concentrations
(pg 1_1) for nonanaesthetised volunteers
Initial
fasting 3 h 6 h 24 h
1.9 1.7 * 1.9 1.9
(1.4-2.6) (1.3-2.1) (1.4-2.1) (1.5-2.6)
* p<0.05 compared with initial fasting concentration
To examine the second possibility that reduced GST
clearance was the cause of the observed increases in GST
concentration, serum amylase activity was measured in the
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samples obtained from 10 patients who received halothane,
and in whom GST was increased at 3 hours after induction
of anaesthesia. If reduced clearance was responsible
for this increase in GST concentration, then amylase
activities should also be increased. In fact, in all 10
patients serum amylase activity was lower at 3 hours
after anaesthesia compared with preoperative values,
suggesting that clearance is not reduced [personal
observations]. Therefore, it would appear that
increases in plasma GST concentration after anaesthesia
do reflect a mild degree of hepatocellular damage, and do
not result from diurnal variation or reduced clearance.
Nineteen of the 70 patients entered into analysis
exhibited an abnormal plasma concentration of GST after
operation; in contrast, abnormal ALT activity was
observed in only one patient. This discrepancy does not
mean that GST measurement is too sensitive for the
detection of minor hepatocellular damage. Rather, it
may simply reflect the much more rapid release of GST
into the circulation after damage has occurred, and also
the different half-lives of GST and ALT in plasma (about
90 minutes and 48 hours respectively). A greater number
of abnormal values for ALT activity might have been
observed if samples had been taken 48-72 hours after
induction of anaesthesia. This was not undertaken as
many patients had returned home by that time.
In compliance with the study programme, patients who had
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increased concentration of GST or abnormal activities of
ALT or GGT before operation were excluded from analysis.
It could be argued that a degree of bias was introduced
into the results by selecting "normal" patients.
However, an examination of GST concentrations after
operation in the 31 patients so excluded, revealed a
pattern of GST change similar to that seen in those
patients who were entered into analysis.
Changes in plasma GST concentration clearly demonstrate
the stages of hepatotoxicity which may follow
anaesthesia. Their measurement may help in the
understanding of the mechanisms involved in volatile
agent-induced liver dysfunction and should allow
assessment of therapeutic manoeuvres predicted to
minimise such toxicity. The following three chapters
describe the measurement of plasma GST B1B1 concentration
to investigate further three of the proposed aetiologies
for the development of halothane hepatitis, namely
altered cellular calcium homeostasis, biotransformation
and regional hepatic hypoxia.
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THE EFFECT OF NICARDIPINE ON PLASMA GST
CONCENTRATION AFTER HALOTHANE ANAESTHESIA
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CHAPTER 4
THE EFFECT OF NICARDIPINE ON PLASMA GST
CONCENTRATION AFTER HALOTHANE ANAESTHESIA
The role of calcium in mediating or propagating ischaemic
cell injury, and the concept that increased
concentrations of intracellular calcium constitute the
final common pathway of cell injury have been reviewed
[Cheung et al 1986; Thomas & Reed 1989; Farber 1982].
Gelman and Van Dyke (1988) have introduced a similar
"calciogenic" hypothesis for the development of liver
toxicity associated with volatile anaesthetics. They
postulated that damage occurs as a result of disruption
of mechanisms which maintain cellular calcium
homeostasis, and that the difference in toxicity between
agents might result from a different ability of
anaesthetics to disrupt intracellular calcium
homeostasis. In support of this hypothesis it is known
that a number of hepatotoxins, including halothane, can
disrupt intracellular calcium homeostasis resulting in
excessive accumulation of cytosolic calcium [Moore 1980;
Moore et al 1985; Brattin et al 1984; Zucker, Diamond &
Berman 1982; Long & Moore 1986]. Furthermore, in the
guinea pig model of halothane hepatotoxicity, large
increases in total hepatic calcium content occur after
exposure to halothane. The increase in liver calcium
occurs before significant histological abnormality is
observed, and is related to the severity of the necrosis
[Farrell et al 1988].
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The administration of a calcium channel blocker before
the initiation of cell injury may, therefore, prevent a
large secondary influx of calcium into the cell, and
limit the severity of cellular damage. The calcium
channel blocker nifedipine has a cell protective effect
in ischaemic myocardial injury in man [Stone et al 1980]
and dogs [Henry et al 1978], probably by increasing
collateral perfusion in the ischaemic area. Similarly,
the administration of flunarizine to rats, and nimodipine
to dogs, can reduce the extent of experimentally-induced
ischaemic brain damage [Deshpande & Wieloch 1986; Steen
et al 1983]. The phenothiazine chlorpromazine, which
also inhibits calcium fluxes, has been found to confer a
degree of protection against ischaemic liver injury in
rats [Chien et al 1977].
Several workers have demonstrated that the administration
of a calcium channel blocker can reduce the extent of
hepatic necrosis in rats exposed to hepatotoxic agents.
Landon, Naukam and Sastry (1986) found that nifedipine,
verapamil and chlorpromazine prevented or reduced both
the development of centrilobular necrosis and the
increase in liver cell calcium resulting from the
administration of five hepatotoxic agents including
chloroform. Garay, Burnette and Annesley (1984)
demonstrated that pretreatment with oral nicardipine
could significantly reduce the extent of liver damage
after administration of the hepatotoxins carbon
tetrachloride or d-galactosamine: other calcium channel
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blockers such as nifedipine or verapamil were unable to
prevent the subsequent liver damage. More recently,
Goto and coworkers (1990) provided evidence that oral
administration of nifedipine or flunarizine before
anaesthesia could reduce the incidence of
halothane-induced hepatotoxicity in the
phenobarbitone-hypoxia rat model.
Nicardipine is a "second generation" dihydropyridine
calcium antagonist which is structurally related to
nifedipine. It is a potent peripheral, cerebral and
coronary vasodilator with no negative inotropism, and is
without effect on myocardial conduction [Freedman &
Waters 1987]. It has proved effective in the treatment
of exertional angina, vasospastic angina and essential
hypertension [Freedman & Waters 1987], and has been shown
to have a cardioprotective effect in animal ischaemia
models [Alps, Calder & Wilson 1985; Endo et al 1985].
Both oral and intravenous formulations of nicardipine
have been made; when given intravenously, nicardipine
requires to be given as an infusion because bolus
injection is relatively ineffective [Campbell, Kelman &
Hillis 1985].
Because nicardipine reduced the extent of
chemically-induced liver damage in rats, it was decided
to assess its possible protective effect on hepatic




Eighty patients aged 18-70 years, of ASA class I or II,
who were to have minor orthopaedic surgery such as
arthroscopy, gave informed consent to participate in the
study. Patients who had undergone halothane anaesthesia
within the preceding 3 months were excluded. Those who
were receiving regular oral medication other than
thiazide diuretics or benzodiazepines, and those who gave
a history of parenchymal liver disease, contact with
hepatitis or recent blood transfusion were excluded also,
as were patients whose average daily intake of alcohol
exceeded 3 units, and those whose weight was greater than
120% of that expected for a patient of the same age, sex
and height. Subjects were allocated, according to a
previously prepared, randomised, sex-stratified list, to
receive either an intravenous infusion of nicardipine or
a comparable infusion of normal saline.
Infusion plan
The infusion was designed to achieve a stable plasma
nicardipine concentration of about 120 ng ml-1 after one
hour of infusion, based on an estimated plasma clearance
rate of nicardipine of 600 ml min~1 for an adult subject
and an elimination rate constant of 0.2 h~1 [Graham et al
1985]. The contents of a syringe which contained
nicardipine 5 mg in normal saline 60 ml were infused from
a syringe pump at a rate of 1 ml min~1 into a closed vial
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that contained nicardipine 20 mg in 20 ml volume, via a
fine-bore needle to encourage mixing within the vial. The
infusion was led from this vial to the patient, a
technique similar to that described by Riddell and
coworkers (1984), and illustrated schematically below.
Nicardipine 20 mg
in 20 *1 volume
Nicardipine 5 »g in
normal aalina 60 ml
>7 ■1 Bin-1 To patient
Figure 4.1 Schematic representation of solution
delivery in exponentially decreasing
concentration
A patient allocated to have nicardipine would have
received, in the first hour of this treatment, a
combination of a steady infusion of nicardipine 5 mg and
an exponentially decreasing infusion with a total of
nicardipine 20 mg, of which 95% would have been
administered in that time. A constant infusion of
nicardipine in normal saline (0.5 mg ml-1) was given
subsequently for a further 5 hours at a rate of 5 mg h_1.
The infusion was started one hour before induction of
anaesthesia. The electrocardiograph was monitored
continuously and systemic arterial pressure was measured
non-invasively and automatically for the duration of the
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infusion. The infusion was discontinued if the systolic
arterial pressure became less than 75% of the preinfusion
value, or if tachycardia >150 beat min-1 or disorders of
cardiac rhythm occurred.
Anaesthetic technique
Premedication was with oral temazepam 20 mg 2 hours
before operation. Anaesthesia was induced with
intravenous thiopentone 4-6 mg kg-1, and suxamethonium
1 mg kg-1 was administered to enable tracheal intubation
if this was necessary. Anaesthesia was maintained with
halothane and 66% nitrous oxide in oxygen. Ventilation
was spontaneous in all patients. Maximum duration of
anaesthesia was restricted to 90 minutes. Pain relief
after operation was provided by intramuscular
diamorphine, oral dihydrocodeine or soluble aspirin as
necessary; metoclopramide was prescribed to relieve
nausea.
Samples and measurement
End-tidal concentrations of halothane (Penlon halothane
meter) and carbon dioxide (Hewlett-Packard 47210A
capnometer) were recorded every 5 minutes for the
duration of anaesthesia. The carbon dioxide sensor was
attached to the mount of the mask in non-intubated
patients. Patients were withdrawn from the study if
their end-tidal carbon dioxide partial pressure (PE'C02)
exceeded 8 kPa. The mean of the end-tidal
concentrations of halothane and carbon dioxide was
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determined for each patient, and a time-weighted
halothane average calculated (mean end-tidal halothane
concentration x duration of anaesthesia in minutes).
Blood was sampled before starting the infusion, for GST
BiBt concentration and conventional liver biochemistry.
Further samples for measurement of GST concentration were
taken 1, 3, 6 and 24 hours after induction of
anaesthesia. Conventional liver biochemical tests were
also measured in the sample taken at 24 hours. Alkaline
phosphatase was not used as an index of liver function in
this study as patients undergoing orthopaedic surgery
might have increased serum ALP activity from bone.
Blood sampling for nicardipine assay was performed after
one hour of infusion (ie, at the end of the exponential
infusion) and at 30 minutes, 1, 2, 3 and 6 hours after
induction of anaesthesia.
Assay procedures
Activities of ALT and GGT, and concentrations of
bilirubin were measured using a Sequential Multiple
Analysis with Computer (SMAC) System II. The normal
ranges defined by the laboratory which performed these
investigations are detailed in the previous chapter.
The plasma concentration of GST B^ was measured by
specific radioimmunoassay as in earlier studies. With
greater experience of the assay in man, and using a
larger volunteer population, the reference range for GST
B-,B-] concentration was redefined as 0.7-4.2 pg 1~1 . The
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interassay coefficient of variation and the intra-assay
coefficient of variation for the GST radioimmunoassay
remained unchanged from earlier studies (<10% and <5%
respectively). Samples for nicardipine assay were
separated by centrifugation and the resultant serum
stored at -20°C until assay was performed by the standard
high pressure liquid chromatography method [Wu, Massey &
Kushinsky 1984]. Analysis of nicardipine-containing
serum was performed by Syntex Pharmaceuticals Ltd, Palo
Alto, California.
Statistical analysis
The patient characteristics, the mean end-tidal halothane
and carbon dioxide concentrations, the duration of
anaesthesia, and the time-weighted halothane average for
each group were compared using Student's t test. The
Wilcoxon signed rank test examined changes in GST
concentration from the preoperative values at 1, 3, 6 and
24 hours after induction of anaesthesia in each group.
Differences in GST changes at these times between the two
groups, and postoperative conventional liver function
tests relative to preoperative values, were compared
using the Wilcoxon rank sum test. Correlation of
changes in GST concentration with total dose of halothane
administered, duration of anaesthesia and mean end-tidal
carbon dioxide concentration was with Spearman's rank
coefficient. The same test was used also to investigate
the relation between GST changes and plasma nicardipine
concentration for males and females separately.
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Fisher's exact test compared the incidence of abnormal
GST values in each group.
RESULTS
Eighty patients were entered into the study: 42 received
nicardipine (27 M, 15 F) and 38 received placebo (26 M,
12 F). The infusion was discontinued in 11 patients:
eight had received nicardipine and on each occasion the
infusion was stopped because of hypotension, while the
infusion was discontinued also in three patients who
received normal saline - two because of tachycardia and
one whose operation was cancelled. These patients were
excluded from subsequent analysis. In addition, data
were not analysed in patients who had an increased
concentration of GST, or abnormal activities of ALT or
GGT in the sample taken before operation. As in the
study described in the previous chapter, patients who had
an increased serum bilirubin concentration before
operation with no other abnormal liver biochemical test
were included in analysis.
The remaining 53 patients from whom data were analysed
comprised 29 who received nicardipine (17 M, 12 F) and 24
who were given placebo (13 M, 11 F). The groups were
comparable in respect of age, height, weight,
% expected weight, daily alcohol intake, dose of
thiopentone received, and mean end-tidal concentrations
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of halothane and carbon dioxide (Table 4.1). In no
patient did end-tidal carbon dioxide exceed 8 kPa, and
only four patients had values greater than 6 kPa.
Duration of anaesthesia was significantly longer in
patients who received nicardipine than in those who
received placebo (p<0.01), and consequently, the
time-weighted halothane average was greater in that group
(p<0.05, Table 4.1).
The individual plasma GST B-|Bi concentrations for
patients receiving placebo and nicardipine infusions are
shown in Tables 4.2 and 4.3. GST concentration
increased significantly from preoperative values at 3 and
6 hours after induction in each group, and a significant
reduction was observed at 24 hours in the group that had
received nicardipine (Table 4.4). Administration of
nicardipine resulted in a greater increase in GST
concentration at 3 hours after induction than did placebo
(p<0.05): this difference was attributable almost
entirely to males receiving nicardipine, in whom a
greater increase in GST concentration occurred at 3 hours
than occurred in females receiving nicardipine (Figure
4.1). The plasma concentration of nicardipine was
significantly lower in males than in females after the
first hour of the infusion and at 2 hours after induction
of anaesthesia (p<0.05 both times, Table 4.5). At these
times the plasma concentration of nicardipine was
inversely related to the increase in GST at 3 hours
(p<0.01 after one hour of infusion; p<0.05 at 2 hours
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after induction, Figure 4.2). The magnitude of change
in GST concentration after operation was not related to
total dose of halothane administered (time-weighted
halothane average), duration of anaesthesia, or mean
end-tidal carbon dioxide concentration in either group.
Four of the patients who received placebo (17%) had a
plasma GST concentration after anaesthesia which exceeded
the upper limit of the reference range compared with ten
patients who received nicardipine (34%), but this
difference was not statistically significant (p=0.124).
The concentrations of bilirubin and the activities of ALT
and GGT after anaesthesia were not significantly
different compared with the values before operation. No
patient exhibited abnormal activity of ALT or GGT after
operation, although in four patients, one of whom
received placebo, serum bilirubin concentration increased
significantly after anaesthesia (Tables 4.6 - 4.8).
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Table 4.1
Mean values (SD) for patient and anaesthetic
characteristics in patients receiving placebo and
nicardipine infusions who had normal preoperative liver
biochemistry
Placebo Nicardipine
Age (years) 34 (12) 30 (8)
Height (cm) 171 (10) 174 (11)
Weight (kg) 68 (9) 71 (13)
% expected weight 100 (12) 103 (12)
Alcohol (U day-1) 1.4 (0.8) 1.6 (1-1)
Thiopentone (mg) 414 (63) 428 (86)
[Halothane] (%) 1. 1 (0.3) 1.0 (0.2)
PE.C02 (kPa) 4.9 (0.8) 5 .1 (0.7)
Duration of
anaesthesia (min) 39 (11) 54 (21)
Time-weighted
halothane average 40 . 3 (13.7) 53 . 1 (21.5
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Table 4.2
Individual plasma GST concentrations (pg 1_1) for
patients receiving placebo in whom the infusion was
completed
PRE 1 h 3 h 6 h 24 h
1 3 . 9 4.2 4.1 4.1 12.0 *
2 3 . 1 2 . 0 2 . 7 5 .1 * 2.3
3 2 . 0 1.6 2.4 2.4 1.5
4 2 . 5 2 .1 2 . 6 2 . 2 2.0
5 2.5 1.8 2 . 5 2.8 2.8
6 2.8 3 . 2 3 . 3 2 . 7 1.7
7 0 . 5 0 . 6 2 . 3 2 . 0 3 . 5
8 1.6 1.4 1.9 2.5 1.5
9 2.4 3 . 0 3.8 3 . 0 1.7
10 3.4 3 . 3 3 . 2 3 . 3 2.4
11 3.0 3 .1 3 . 5 3 . 5 2.7
12 2.3 2 . 6 2.3 3 . 5 2 . 0
13 2.2 2 . 7 2.4 2 . 0 1.8
14 1.8 1. 5 1.7 1.7 1.7
15 2.8 2 . 6 3.4 3.8 2.6
16 1.6 1.3 1.5 1.4 1.4
17 1.4 2 . 1 2.0 2.2 1. 8
18 1.8 1.6 2 . 9 2 . 6 2 . 5
19 2 . 2 2.4 3.6 3 . 3 1.7
20 1.7 1. 6 1.7 1.6 1. 4
21 2.3 3.5 2.8 3.1 2.0
22 1.7 1.2 2 . 2 2.8 2.1
23 2.1 2 . 1 3.0 2 . 2 8.6 *
24 4.2 2 . 7 4 . 6 * 2.8 1.2
Excluded from analysis
25 5 . 9 * 4.7 * 4.7 * 4.9 * 2 . 5
26 5 . 9 * 6.7 * 6 . 9 * 7.1 * 4.2
27 27 . 6 * 24.7 * 29 . 2 * 17 .4 * 6.3 *
28 10.9 * 7.6 * 9.4 * 7.8 * 7.4 *
29 4.8 * 3.6 3 . 3 3 . 4 2.4
30 5 . 5 * 4.7 * 6 . 2 * 6 . 2 *
31 5.1 * 4.1 4.1 4.1 2.8
32 6.6 * 4.3 * 6 . 0 * 4.4 * 1 . 7
33 5 . 6 * 5.3 * 6.8 * 5 . 3 * 3.8
34 6 . 8 * 5.5 * 6 . 7 * 5 . 0 * 5.5 *
35 6 . 2 * 5.0 * 6 . 0 * 3 . 6 1.7
* represents a value which exceeds the upper
limit of the reference range
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Table 4.3
Individual plasma GST concentrations (pg 1~1) for
patients receiving nicardipine in whom the infusion was
completed
PRE 1 h 3 h 6 h 24 h
1 3.2 3.0 4 . 7 * 3 . 6 3.4
2 2.1 1.9 2.8 4.2 1.8
3 1.9 1.7 2.8 5 . 0 * 1.5
4 0.9 1.1 1.4 1.9 0 . 9
5 3.0 2 . 6 3 . 2 2 . 0 1.5
6 2.8 2.8 3.2 4.3 * 2 . 3
7 2 . 3 2.0 2 . 9 2 .1 1.5
8 1.8 2 . 0 3 . 2 2.4 1.6
9 2.4 2.4 2.8 2 .1 3.4
10 2 . 7 2 . 3 4 . 2 3 . 6 5.8
11 3 . 5 4.0 5 . 5 * 3 . 9 2 .1
12 4.1 3.5 4 . 6 * 3.5 3 . 0
13 1.3 1. 2 1.2 1.4 1.7
14 2.6 2 . 0 2.2 2 . 5 1.2
15 3.6 2 . 9 4 . 2 4.4 * 6 . 3
16 1.3 1.4 2.0 2.2 1.4
17 1.6 1.8 2.4 3.2 1.8
18 2.6 2 . 9 3.4 3 . 9 1.4
19 1.5 1. 8 2 . 2 2 . 1 1.4
20 1.3 1.0 1.6 1.5 1.4
21 2 . 5 2 . 9 3 . 2 3.0 2.6
22 2 . 1 1. 6 2 . 3 1.7 1. 8
23 2 . 7 2.7 4.4 * 3 . 5 2.0
24 2 . 2 1.8 2 . 6 2.2 1.8
25 2.8 3 . 5 4 . 9 * 2 . 7 1.3
26 3 . 9 4.0 4 . 7 * 2.8 3 . 5
27 2.0 2.1 4.1 2.2 1.7
28 2 . 4 2.0 2 . 3 2.0 1.4
29 1.2 1.3 2 . 7 2.2 1.3
Ixcluded from analysis
30 7.8 * 7.0 * 7 . 5 * 7 . 3 * 3.6
31 8.7 * 7.4 * 8 . 7 * 6 . 2 * 8 . 5
32 5.1 * 3 . 5 5 . 8 * 3 . 5 2.7
33 5.4 * 4.4 * 4.8 * 3.8 2 .1
34 4.6 * 3 . 9 6 . 4 * 3.7 3 . 7
* represents a value which exceeds the upper
limit of the reference range
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Table 4.4
Medians (interquartile range) of GST concentrations
(pg 1_1) for patients receiving placebo and nicardipine
infusions
PRE lh 3 h 6 h 24 h
Placebo
2.2 2.1 2.7** 2.8** 2.0
(1.8-2.8) (1.6-2.8) (2.2-3.4) (2.2-3.3) (1.7-2.6)
Nicardipine
2.4 2.0 2.9** 2.5* 1.7*
(1.7-2.8) (1.7-2.9) (2.3-4.2) (2.1-3.6) (1.4-2.4)
* p<0.05; ** p<0.01





















Individual changes in plasma GST concentrations, relative
to preoperative values, at 3 hours after induction,
showing male and female subjects separately.




Medians (range) for plasma nicardipine concentrations
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Figure 4.2
Relationship between the plasma concentration of
nicardipine achieved 2 hours after induction of
anaesthesia, and the change in GST that occurred at 3
hours after induction of anaesthesia.
■= male patients; o = female patients. There is a
negative linear correlation (r=-0.43, p<0.05) for the
patients taken together.




Conventional liver biochemical tests before and after







1 5 23 20 6 25 15
2 12 19 17 14 19 16
3 13 18 6 11 10 <5
4 12 <10 14 10 13 10
5 20 * 22 19 17 19 11
6 10 15 6 14 12 7
7 13 20 13 8 14 <5
8 10 10 15 9 <10 8
9 11 <10 6 8 <10 <5
10 6 30 19 8 23 15
11 8 25 15 7 27 26
12 12 <10 <5 11 <10 <5
13 13 17 5 15 23 <5
14 5 -- 12 7 12 11
15 15 16 17 7 10 13
16 14 11 <5 11 <10 8
17 14 <10 10 18 * <10 9
18 14 15 12 16 <10 9
19 11 14 <5 12 10 <5
20 9 <10 15 13 <10 13
21 6 19 8 8 12 8
22 15 10 44 13 14 41
23 9 14 8 12 26 10
24 12 40 30 15 31 22
Excluded from analysis
25 12 40 16 24 24
26 9 20 10 7 34 14
27 8 88 * 78 * 16 53 * 74 *
28 6 108 * 119 * 13 85 * 84 *
29 10 26 22 6 20 22
30 12 37 126 * --
31 — -- -- 13 33 45
32 13 36 12 13 36 10
33 12 48 * 78 * 14 36 67 *
34 10 75 * 50 * 11 53 * 45
35 9 45 * 14 26 37 12
* represents a value which exceeds the upper
limit of the reference range
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Table 4.7
Conventional liver biochemical tests before and after
operation in patients receiving nicardipine in whom the
infusion was completed
PREOP POSTOP
Bil ALT GGT Bil ALT GGT
1 35 * 24 18 51 * 23 23
2 8 10 14 8 10 14
3 17 18 13 23 * 15 15
4 12 <10 10 36 * 10 8
5 4 10 6 6 10 7
6 5 18 16 9 <10 16
7 20 * 19 22 19 * 18 21
8 10 <10 7 15 <10 9
9 10 29 12 5 30 7
10 18 * 14 13 18 * 10 10
11 7 34 19 7 24 19
12 14 19 20 8 14 12
13 22 * 17 8 23 * <10 6
14 8 14 12 8 <10 10
15 11 20 28 6 19 20
16 15 10 10 8 <10 --
17 21 * <10 10 28 * 14 8
18 13 18 15 24 * 17 15
19 37 * 18 9 50 * 12 10
20 12 19 5 17 11 <5
21 11 16 14 9 12 12
22 6 26 11 6 16 —
23 11 19 9 11 <10 6
24 7 17 8 5 <10 7
25 21 * 30 36 18 * 29 35
26 10 34 21 8 23 18
27 19 * 13 11 22 •k <10 11
28 8 <10 16 7 <10 13
29 9 17 14 8 16 15
Excluded from analysis
30 8 39 31 18 * 51 * 36
31 15 51 * 159 * 18 * 43 * 151
32 8 28 16 11 23 15
33 8 31 22 12 26 21
34 12 28 9 10 26 6
* represents a value which exceeds the upper
limit of the reference range
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Table 4.8
Medians (range) of conventional liver biochemical tests
before and after anaesthesia for patients receiving

































This study has confirmed that transient GST release
occurs following anaesthesia with halothane in man, as
has been demonstrated previously [previous chapter; Allan
et al 1987; Hussey et al 1986a]. Although the changes
in median concentrations of GST were small, abnormally
increased GST concentrations were observed in 14 of 53
patients after anaesthesia; ten of these patients had
received nicardipine. Administration of nicardipine was
associated with a greater release of GST after operation
than was placebo, resulting mostly from an exaggerated
GST response in males, but not females, receiving
nicardipine. Plasma concentration of nicardipine at the
end of the exponential infusion and at 2 hours after
induction of anaesthesia was significantly greater in
females than in males, and this was related to a lesser
increase in GST concentration at 3 hours. The larger
increase in GST at 3 hours in males receiving nicardipine
may reflect the combined effects of halothane and
nicardipine causing a greater reduction in hepatic
perfusion than halothane alone. The greater plasma
concentrations achieved in females perhaps conferred a
degree of protection against this combined effect, but
possibly were still insufficient to prevent release of
GST into the circulation. Although plasma
concentrations of nicardipine throughout the infusion
were compatible with those required to give a clinically
relevant effect [Debbas, Jackson & Turner 1985], it may
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be that even greater plasma concentrations of nicardipine
are required for hepatoprotection after halothane
anaesthesia. Such concentrations may, however, cause
undesirable cardiovascular side effects. This study was
unable, therefore, to demonstrate that nicardipine, in
the dose administered, prevented this type of liver
dysfunction in man.
The finding that nicardipine conferred no
hepatoprotection is at variance with animal studies.
However, the dose of nicardipine administered to rats
[Garay, Annesley & Burnette 1984] was 25 to 50 times
greater than the total dose given to patients in the
present study. As suggested above, larger doses of
nicardipine given to man might also have the same
protective effect, but at the cost of increased
cardiovascular side effects. Other workers have shown
that the severity of halothane-induced hepatic damage in
rats is related to total halothane dosage [Jee et al
1980], but this has not been demonstrated in humans.
In the present study, patients who received nicardipine
received a greater total dose of halothane (time-weighted
halothane average), and, therefore, might have received a
greater hepatic insult, than patients given placebo.
However, the magnitude of GST increase after operation
could not be related to total dose of halothane received,
suggesting that this difference between the groups is
unlikely to have influenced the present findings.
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There exists remarkable similarity between the
pharmacological effects of volatile anaesthetics and
calcium channel blocking drugs [Jones 1984]. The
depressant effects on sino-atrial node conduction by
halothane, enflurane and isoflurane have been found to be
similar to those of the calcium channel blockers
verapamil and diltiazem [Bosnjak & Kampine 1983]. It
has been demonstrated that halothane and enflurane have a
degree of calcium channel blocking activity [Lynch, Vogel
& Sperelakis 1981; Lynch et al 1982] while isoflurane
appeared to have a greater effect on intracellular
calcium kinetics [Lynch 1986]. Furthermore, the
negative inotropic and vasodilatory effects of the
volatile anaesthetics are similar to those of calcium
channel blockers [Merin 1987].
If halothane has calcium channel blocking activity, is it
logical to propose that the administration of a second
calcium channel blocker might reduce the extent of liver
injury? Current evidence proposes that there are at
least four different types of calcium entry channel
[Schramm & Towart 1985]. These have been designated
leak channels, stretch-sensitive channels,
potential-dependent channels and receptor-dependent
channels. The two former channels are unlikely to be
classical gated channels but probably represent
mechanisms of calcium entry termed channels for
convenience. The latter mechanisms have been defined
more clearly; the existence of the potential-dependent
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channel as an ion-specific gated channel is now beyond
dispute [Schramm & Towart 1985]. Specific calcium
channel blockers are a heterogeneous group of drugs with
diverse chemical structures [Jenkins & Scoates 1985;
Reves et al 1982]. This heterogeneity of structure
implies that there is no one receptor which mediates the
effects of the calcium channel blockers. Snyder and
Reynolds (1985) have suggested that at least two, and
possibly three, distinct receptors for calcium channel
blocking drugs exist, all of which are associated with
the potential-dependent channel. This raises the
possibility that volatile anaesthetics exert their effect
on cellular calcium regulation via a mechanism which is
distinct from that of the specific calcium channel
blockers. In addition, it has been proposed that the
effects of the volatile anaesthetics may be related to
their actions upon intracellular handling of calcium, and
not necessarily upon calcium entry channels [Lynch 1984].
It would appear, therefore, that prevention of calcium
entry into the cell is more important than altered
intracellular handling of calcium in reducing the
severity of cellular injury. The administration of a
specific calcium channel blocker which reduces cellular
calcium ingress might, therefore, be expected to limit
the severity of liver damage after anaesthesia with
halothane. The findings from this study appear to
indicate that this hypothesis is not proven, suggesting
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CHAPTER 5
THE EFFECT OF CIMETIDINE ON PLASMA GST
CONCENTRATION AFTER HALOTHANE ANAESTHESIA
Toxic metabolic products resulting from halothane
biotransformation are thought to be a possible mechanism
of halothane hepatotoxicity [Cousins et al 1987a; de
Groot & Noll 1983]. Halothane is metabolised in liver
microsomes via both oxidative [Cohen et al 1975] and
reductive pathways [Sharp, Trudell & Cohen 1979]. This
biotransformation is dependent on the mixed-function
oxidase enzyme (MFOE) system, of which cytochrome P-450
is the single most important component [Van Dyke 1973].
The H2-receptor antagonist cimetidine has been reported
to interact with liver microsomal enzymes [Desmond et al
1980a]; binding of its imidazole system to the haem
moiety of cytochrome P-450 results in inhibition of
cytochrome P-450-dependent MFOEs [Bauman & Kimelblatt
1982]. Consequently, cimetidine can impair the
metabolism of drugs that are metabolised by the MFOE
system. Drugs reported to be affected in this way
include benzodiazepines [Desmond et al 1980b; Klotz &
Reimann 1980], p-blockers [Heagerty et al 1981; Feely,
Wilkinson & Wood 1981], lignocaine [Feely et al 1982],
theophylline [Jackson et al 1981; Reitberg, Bernhard &
Schentag 1981], warfarin [Serlin et al 1979], verapamil
[Loi et al 1985] and anticonvulsants [Hetzel et al 1981;
Telerman-Toppet, Duret & Coers 1981]. Cimetidine has
been shown to inhibit halothane metabolism in vitro
[Loesch, Siegers & Younes 1987], and animal experiments
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suggest also that cimetidine reduces halothane
biotransformation and consequently lessens the severity
of hepatic injury [Plummer et al 1984; Wood et al 1986].
Therefore, it was thought reasonable to assess the
influence of cimetidine on the release of GST after
halothane anaesthesia, in case halothane metabolism could
be altered to reduce toxicity.
METHODOLOGY
Patient selection and anaesthetic technique
Informed consent was obtained from patients aged 16-70
years, ASA class I or II, undergoing minor orthopaedic
surgery. Reasons for exclusion were the same as those
detailed in the previous chapter. Patients were
assigned randomly to one of two groups, to receive either
cimetidine 800 mg orally the evening before operation
with a further 800 mg given at the time of premedication,
or equivalent placebo tablets. The technique of
anaesthesia was exactly similar to that described in
Chapter 4.
Samples, measurement and assay procedures
End-tidal concentrations of halothane (Penlon halothane
meter) and carbon dioxide (Hewlett-Packard 47210A
capnometer) were recorded every 5 minutes throughout
anaesthesia, and a time-weighted halothane average was
calculated for each patient. Blood samples were taken
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for GST assay before operation and at 3, 6 and 24 hours
after induction of anaesthesia. Measurements of
conventional liver biochemical tests were made on the day
before and the day after anaesthesia. Measurements of
GST BtBi and bilirubin concentrations, and ALT and GGT
activities were as described in Chapter 4.
Statistical analysis
Student's t test compared the demographic data and
anaesthetic characteristics for each group. The GST
changes from the preoperative values at 3, 6 and 24 hours
after induction were compared using the Wilcoxon signed
rank test; the Wilcoxon rank sum test examined
differences in GST changes at these times between the
groups, and conventional liver function tests before and
after anaesthesia. Spearman's rank coefficient was used
to determine whether the GST changes could be related to
the total dose of halothane administered. The incidence
of abnormal GST values in each group was compared using
Fisher's exact test.
RESULTS
Fifty-three patients were studied; 26 received placebo
(16 M, 10 F) and 27 received cimetidine (18 M, 9 F).
Eight patients were excluded from analysis: three were
withdrawn because of excessive duration of anaesthesia
(>90 minutes), three had abnormal preoperative liver
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biochemistry, one refused to have further blood samples
taken and surgery was cancelled in one. Data from the
remaining 45 patients were analysed: 24 had received
placebo (14 M, 10 F) and 21 cimetidine (14 M, 7 F).
The groups were comparable in respect of age, height,
weight, % expected weight and alcohol intake (Table 5.1).
The mean dose of thiopentone, and the mean end-tidal
concentrations of halothane and carbon dioxide were
similar in the two groups. The total dose of halothane
administered, reflected in the time-weighted halothane
average, appeared greater in the placebo group, but this
failed to achieve statistical significance (p=0.064)
(Table 5.1).
The plasma GST B-iB., concentrations for each patient
receiving placebo and cimetidine are shown in Tables 5.2
and 5.3. GST increased significantly at 3 hours after
induction of anaesthesia in both groups, and at 6 hours
in the group which had received cimetidine (Table 5.4);
the administration of cimetidine did not influence the
magnitude of increase in GST after anaesthesia.
Although some patients in both groups showed an increase
in GST concentration which exceeded the upper limit of
the reference range, there was no significant difference
in the frequency of such abnormal values between the two
groups (p=0.266). One patient who had received placebo
exhibited a large secondary increase in GST concentration
at 24 hours after induction of anaesthesia, but no
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patient who had received cimetidine showed a comparable
change. There was no correlation between GST increase
and total dose of halothane administered, or mean
end-tidal carbon dioxide concentration. Concentrations
of bilirubin and activities of ALT and GGT after
anaesthesia were not significantly different relative to
preoperative values in each group (Tables 5.5 - 5.7).
In particular no patient developed an abnormally
increased activity of ALT or GGT after operation.
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Table 5.1
Mean values (SD) for patient and anaesthetic
characteristics in patients receiving placebo and
cimetidine who had normal preoperative liver biochemistry-
Placebo Cimetidine
Age (years) 33 (12) 32 (13)
Height (cm) 171 (7) 173 (11)
Weight (kg) 68 (11) 70 (ID
% expected weight 99 (13) 101 (13)
Alcohol (U day-1) 1. 5 (1.0) 1.5 (1.2)
Thiopentone (mg) 412 (78) 425 (59)
[Halothane] (%) 1. 2 (0.3) 1. 0 (0.3)
PE.C02 (kPa) 5.1 (0.7) 5.2 (0.8)
Duration of
anaesthesia (min) 46 (17) 43 (20)
Time-weighted
halothane average 53 . 6 (24.2) 41.1 (20 . 1
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Table 5.2
Individual plasma GST concentrations (pg 1~1) for
patients receiving placebo
PRE 3 h 6 h 24 h
1 3 . 3
2 3 . 0
3 1.6
4 1.9






11 2 . 0
12 2.2
13 2 . 3
14 3 . 5
15 2 . 5
16 3 . 7
17 1.6




22 3 . 1
23 3 . 2



















5.2 * 5.0 * 2.5
2.3 2.1 1.3





4.4 * 3.1 2.9
2.5 2.4 9.6 *
8.0 * 6.8 * 2.8
* represents a value which exceeds the upper
limit of the reference range
151
Table 5.3
Individual plasma GST concentrations (pg 1_1) for
patients receiving cimetidine
PRE 3 h 6 h 24 h
1 3.6 3 . 3 1.6 2.1
2 2.4 2.6 4.1 2 . 0
3 1.8 2.8 2.2 2.2
4 2.0 2.6 3.0 2.0
5 3.8 4.9 * 4.2 1.9
6 1.5 2.2 2.7 1.8
7 2.1 2.6 2.3 2.1
8 2.5 3.6 6.8 * 3 . 3
9 4.2 6.5 * 5.1 * 6.9
10 4.0 4.3 * 3.6 3 .1
11 3.6 4.4 * 3 . 6 2.9
12 2.2 2 . 9 3.2 2.2
13 3.1 3.3 2.3 1.6
14 3.2 3.3 3.3 2.4
15 3.0 3.7 2.8
16 4.2 8 . 5 * 7.0 * 3 . 0
17 1.7 2 . 6 2.8 1.3
18 1.9 3.8 2 . 6 1.9
19 4.2 5.4 * 3 . 5 5 . 0
20 2.3 2 . 5 6 .1 * 3.3
21 2.1 2 . 6 2 . 7 2.2
.uded from analysis
22 6.1 * 6 . 6 * 5.0 * 3 . 3
23 3.3
24 16.2 * 20 . 3 * 17 .4 * 27 .1
25 1.1
26 2 . 0
27
* represents a value which exceeds the upper
limit for the reference range
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Table 5.4
Medians (interquartile range) of GST concentrations
(pg I"1) for patients receiving placebo and cimetidine
PRE 3 h 6 h 24 h
Placebo 2.7 3.1** 3.0 2.5
(2.1-3.2) (2.6-3.7) (2.6-3.4) (1.9-2.9)
Cimetidine 2.5 3.3** 3.2* 2.2
(2.0-3.7) (2.6-4.4) (2.6-4.2) (2.0-3.0)
* p<0.05; ** p<0.01
compared with preoperative concentration
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Table 5.5
Conventional liver biochemical tests before and after
operation in patients receiving placebo
PREOP POSTOP
Bil ALT GGT Bil ALT GGT
1 8 10 8 9 13 7
2 9 12 19 15 12 16
3 12 <10 8 14 <10 10
4 42 * 15 11 74 * 20 11
5 25 * 23 14 23 * <10 11
6 9 29 42 19 28 38
7 14 16 15 20 * <10 10
8 7 34 31 6 31 22
9 4 11 6 9 17 8
10 5 <10 6 9 16 8
11 11 26 8 14 19 8
12 12 <10 14 12 10 15
13 16 12 17 -- __ —
14 11 22 20 11 12 17
15 5 13 11 15 <10 15
16 5 31 22 9 <10 18
17 12 11 15 21 * 14 15
18 9 18 33 7 23 29
19 11 22 11 15 24 10
20 8 21 8 5 12 7
21 25 * 17 27 26 * 11
22 8 <10 10 6 <10 11
23 9 18 20 8 15 19
24 8 11 15 13 28 17
Excluded from analysis
25 10 23 24 11 19 21
26
* represents a value which exceeds the upper
limit of the reference range
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Table 5.6
Conventional liver biochemical tests before and after






1 12 <10 9
2 26 * <10 9 18 * <10 6
3 15 10 14 19 * 14 15
4 5 10 21 7 <10 19
5 38 * 20 23 79 * 14 22
6 17 19 8 9 18 --
7 8 <10 7 11 14 5
8 5 23 45 6 25 42
9 12 28 45 9 24 34
10 11 <10 17 12 <10 20
11 19 * 14 34 15 14 34
12 18 * 16 21 15 16 21
13 20 * 11 14 43 * 15 15
14 8 40 18 6 40 16
15 14 <10 10 -- --
16 19 * 33 45 22 ★ 24 28
17 12 18 9 16 <10 6
18 7 13 10 7 <10 11
19 9 40 40 11 36 40
20 12 <10 18 14 25 19




















represents a value which exceeds the upper
limit of the reference range
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Table 5.7
Medians (range) of conventional biochemical liver tests





































This study was unable to demonstrate that cimetidine
influenced GST B^-, release into the circulation up to 24
hours after halothane anaesthesia. No patient who
received cimetidine exhibited a large secondary increase
(greater than twice the upper limit of the reference
range) in GST concentration at 24 hours, although it
would be necessary to study many more patients to be
certain that cimetidine prevented this less frequent
increase. The present study provides yet further
confirmation that halothane anaesthesia is associated
with a transient increase in plasma GST concentration
after operation. Once again the changes in median GST
concentration were not large. However, these changes
are considered significant as abnormally increased GST
concentrations after anaesthesia occurred in 14 of 45
patients.
Halothane biotransformation occurs in vitro and in vivo
and this takes place in the microsomal fraction of the
liver [Van Dyke 1973]. The binding of halothane
metabolites to rat liver microsomes is enhanced by agents
that induce cytochrome P-450, such as phenobarbitone [Van
Dyke 1973] and polychlorinated biphenyl [Van Dyke &
Gandolfi 1976]; it is reduced by enzyme inhibitors such
as metyrapone [Gandolfi et al 1980] and SKF 525A [Van
Dyke & Wood 1973]. In rats exposed to halothane, Jee
and colleagues (1980) demonstrated increased
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hepatotoxicity after induction of cytochrome P-450, and
showed that significant protection was afforded by
pretreatment with enzyme inhibitors. Similarly,
cimetidine has been shown to offer protection against
halothane hepatotoxicity in rats, although the reports
differ on the identity of the pathway of halothane
metabolism inhibited [Plummer et al 1984; Wood et al
1986]. Using measurements of exhaled metabolites CDF
and CTF, and of urinary fluoride excretion, Plummer and
colleagues (1984) suggested that reductive metabolism was
inhibited by cimetidine. In contrast, Wood and
coworkers (1986) demonstrated inhibition of oxidative
metabolism by cimetidine: using urinary fluoride
excretion as the only indicator of reductive metabolism,
however, they were unable to demonstrate inhibition of
this pathway, but acknowledged the limitations of this
method alone.
Other animal studies have indicated that the two pathways
of halothane biotransformation may display different
levels of inhibition. Fiserova-Bergerova (1984)
demonstrated in rats that isoflurane inhibited the
oxidative biotransformation of halothane to a far greater
extent than the reductive pathway. If this were the
case with cimetidine in the present study, then reductive
metabolism of halothane may have continued with
subclinical damage as indicated by increased plasma GST
concentration. However, evidence suggests that
cimetidine can inhibit both pathways [Plummer et al 1984;
158
Wood et al 1986]
The influence of cimetidine on the metabolism of
enflurane in man has been investigated also. Yeager and
colleagues (1986) measured serum fluoride concentrations
in patients given a total dose of cimetidine 600 mg
before enflurane anaesthesia, but could not demonstrate
significant alteration in enflurane biotransformation.
Similarly, Oikkonen, Rosenberg and Saarnivaara (1989)
found that premedication with cimetidine 800 mg did not
inhibit the metabolism of enflurane in seven patients
undergoing major ear surgery. The negative influence of
cimetidine on enflurane metabolism would be explained if
enflurane and cimetidine interact differently with the
MFOE system. Alternatively, this may simply reflect the
low extent of enflurane metabolism which might make it
difficult to detect an effect from a competitive
inhibitor such as cimetidine.
In the present study, cimetidine was not shown to reduce
liver damage associated with halothane anaesthesia (as
indicated by GST release), an observation which is at
variance with animal studies. Possible reasons for this
difference include other potential effects of cimetidine
such as those on hepatic blood flow, and perhaps
inadequate dosage of cimetidine.
Original evidence suggested that cimetidine reduced
hepatic blood flow. Such a reduction in flow and
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resultant ischaemia could contribute to the release of
GST. Feely, Wilkinson and Wood (1981) reported a 25%
reduction in hepatic blood flow, when measured by
indocyanine green (ICG) clearance, in normal volunteers
given a single 500 mg dose of cimetidine by mouth.
Others have described a similar reduction in liver blood
flow measured by this technique [Garg et al 1982; Feely &
Wood 1983]. In contrast, other workers who measured ICG
clearance have reported cimetidine to have no effect on
liver blood flow [Daneshmend et al 1984], or even to
increase it [Loi et al 1985]. Such variability in
results suggests that this indirect experimental
procedure is not a reliable method of monitoring hepatic
blood flow. In addition, the use of the ICG clearance
technique has been criticised by Groszmann (1983), who
concluded that unless the degree of extraction of the
indicator by the liver is accurately determined it is
incorrect to assume that clearance is directly
proportional to blood flow. This statement raises
doubts about the results of all of the early ICG
clearance studies, including those of Feely (1981,1983)
and Garg (1982), where no correction factor was applied.
Further investigation has failed to demonstrate that
cimetidine reduces liver blood flow using various
techniques, such as clearance of galactose [Henderson et
al 1983] or sorbitol [Arditi et al 1983], and more direct
methods including the use of an electromagnetic blood
flow meter [Tyden, Thulin & Nyberg 1983], an ultrasound
doppler system or cineangiography [Ohnishi et al 1985].
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Thus there is no convincing evidence that cimetidine has
any effect on hepatic blood flow.
The doses of cimetidine given in the rat studies [Plummer
et al 1984; Wood et al 1986] were enormous (120 and
180 mg kg-1), and it is obviously not possible to
administer such large doses to man. Most human studies
which have shown that cimetidine impairs metabolism of
other drugs have involved giving a larger total dose of
cimetidine than that given in the present study. This
usually involved pretreatment with cimetidine 1000 mg or
1200 mg daily for 2-14 days [Loi et al 1985; Jackson et
al 1981; Desmond et al 1980b; Heagerty et al 1981; Feely,
Wilkinson & Wood 1981; Henderson et al 1983]. However,
Klotz, Arvela and Rosenkranz (1985) have shown that a
single oral dose of cimetidine 800 mg is sufficient to
interfere with the pharmacokinetics of midazolam
administered concurrently. This single dose achieved a
mean maximum plasma concentration of cimetidine of
2.53 pg ml-1 which is within the therapeutic range
evaluated by Somogyi and Gugler (1983). In addition,
cimetidine 1000 mg was found to increase steady-state
plasma propranolol concentrations after only one day of
medication, in contrast to pretreatment with ranitidine
[Reimann, Klotz & Frolich 1982]. Furthermore,
cimetidine in total doses of 1500 mg and 800 mg
respectively, has been shown to reduce clearance of the
local anaesthetic agents lignocaine and bupivacaine, and
to increase toxicity of lignocaine given as an
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intravenous infusion [Feely et al 1982; Noble, Smith &
Dundas 1987]. The data from these studies suggest that
the dose of cimetidine used in the present study
(1600 mg) is sufficient to alter the metabolism of other
drugs administered concurrently.
If it can be assumed that the dose of cimetidine
administered was sufficient to reduce halothane
metabolism, data from the present study suggest that
products of halothane metabolism are not responsible for
the early release of GST described previously [Hussey et
al 1986; Allan et al 1987], although many more patients
would require to be studied to be confident that
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CHAPTER 6
THE EFFECT OF MODE OF VENTILATION ON PLASMA
GST CONCENTRATION AFTER INDUCED HYPOTENSION DURING
HALOTHANE OR ISOFLURANE ANAESTHESIA
Hepatic hypoxia has been proposed as a possible mechanism
of halothane-induced liver damage [Gelman 1987; Gelman,
Fowler & Smith 1984a]. In rats, reduction in the
inspired oxygen concentration during halothane
anaesthesia leads to increased reductive metabolism of
halothane and more severe liver injury [Cousins et al
1979; McLain, Sipes & Brown 1979; Ross, Daggy & Cardell
1979]. There is no evidence that in humans inspired
hypoxia is a contributing factor to halothane
hepatotoxicity: the importance attached to maintenance of
inspired oxygen and arterial oxygenation make such an
association unlikely. However, volatile anaesthetic
agents depress oxygen availability to the liver, partly
as a result of decreased hepatic blood flow [Gelman
1987], and it is possible that these changes may be
exacerbated by the effect of surgery [Gelman 1976],
leading to global or regional hepatic hypoxia.
In man, total liver blood flow is derived from two
sources, the hepatic artery and the portal vein. Under
most circumstances there exists reciprocity between these
sources, such that an increase in flow through one
circuit leads to increased resistance to flow through the
other circuit, tending to maintain a constant total blood
flow through the liver. Anaesthetics can alter the
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splanchnic circulation by different mechanisms acting on
the various factors controlling splanchnic blood flow.
These mechanisms include alterations in systemic
haemodynamics, changes in sympathetic tone, the release
of hormones and other endogenous substances, and changes
in oxygen requirement.
Specific volatile anaesthetic agents have different
effects on the hydrodynamic interaction between portal
and hepatic arterial vascular beds. Halothane,
enflurane and isoflurane all decrease portal blood flow;
hepatic arterial flow is generally increased or preserved
with isoflurane, and to a lesser extent with enflurane,
and is decreased with halothane [Gelman 1987]. During
halothane anaesthesia, cardiac output is the main
determinant of portal blood flow (the coefficient of
correlation between portal blood flow and cardiac output,
r=0.97), and to a lesser extent, a determinant of hepatic
arterial blood flow (r=0.74) [Gelman, Fowler & Smith
1984a]. The extent to which halothane, enflurane and
isoflurane each reduce total liver blood flow closely
parallels the incidence of reported clinical liver
dysfunction for these agents.
Other factors which may affect hepatic blood flow include
the mode of ventilation and reduced systemic arterial
pressure. Positive pressure ventilation is associated
with a reduction and redistribution of cardiac output.
Splanchnic blood flow is decreased [Epstein et al 1966;
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Cooperman, Warden & Price 1968], and blood supply to the
liver is reduced to a greater degree than the decrease in
cardiac output [Geiger, Georgieff & Lutz 1986]. There
is little, if any, pressure-dependent autoregulation of
blood flow exhibited by either hepatic arterial or portal
vascular beds, with the result that liver blood flow and
arterial pressure have an approximately linear
relationship [Richardson & Withrington 1981]. Positive
pressure ventilation and hypotension may, therefore,
exacerbate liver damage associated with halothane
anaesthesia.
As halothane may cause hepatic damage by reducing liver
blood flow, it was decided to assess the effect of the
mode of ventilation on plasma GST B1B1 concentration in
patients undergoing deliberate hypotension during
anaesthesia with halothane or isoflurane.
METHODOLOGY
Patient selection
Sixty patients aged 15 to 70 years of ASA class I or II,
who were to undergo elective ENT surgery for which
deliberate hypotension was required, were enrolled into
the study. Reasons for exclusion were the same as those
detailed in Chapter 4. The patients came from two
different wards; those from one ward received
intermittent positive pressure ventilation (IPPV) and
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those from the other ward were allowed to breathe
spontaneously (SV). Within each group patients were
allocated randomly to receive either halothane or
isoflurane.
Anaesthetic technique
All patients received diazepam 10 mg orally 1 hour before
operation. Anaesthesia was induced with intravenous
thiopentone 4-6 mg kg-1. Thereafter, patients allocated
to receive artificial ventilation received fentanyl
100 pg and d-tubocurarine 0.5 mg kg-1. Following
tracheal intubation, ventilation was commenced using a
Penlon Nuffield 400 series ventilator connected to a
circle system into which fresh gas was supplied at a flow
rate of 4 1 min-1. All patients received a preset tidal
volume of 7 ml kg-1 at a frequency of 13 breath min-1.
To the fresh gas supply was added either halothane 1% or
isoflurane 1.5-2% (vaporiser setting). After induction
of anaesthesia, patients who were to breathe
spontaneously received d-tubocurarine 5 mg and
suxamethonium 1 mg kg~1 to enable tracheal intubation.
Anaesthesia was maintained with either halothane 3-5% or
isoflurane 3-5% (vaporiser setting) delivered in a fresh
gas flow of 1.5 1 min-1 via a circle system. The
fractional inspired oxygen concentration was maintained
between 0.5 and 0.6 in all patients.
A cannula was inserted percutaneously into a radial
artery after induction of anaesthesia to permit
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continuous measurement of arterial pressure. Within 10
minutes of commencing anaesthesia, hypotension was
induced with an intravenous infusion of trimetaphan 50 mg
and sodium nitroprusside (SNP) 12.5 mg in 5% dextrose
500 ml, infused at a rate of 3-20 ml min-1 to maintain a
mean arterial pressure between 40 and 55 mm Hg [Simpson
et al 1987]. Analgesia after operation was provided
with intramuscular papaveretum 10-20 mg, and
prochlorperazine 12.5 mg was prescribed to relieve
nausea.
Samples, measurement and assay procedures
Blood samples for GST B-,Bi radioimmunoassay were taken
before induction of anaesthesia and at 1, 3, 6 and 24
hours after the end of anaesthesia. Plasma
concentration of bilirubin and activities of ALT and GGT
were measured in the samples obtained before anaesthesia
and at 24 hours. Plasma from the samples was stored at
-20°C before measurement of GST. Concentrations of GST
and bilirubin, and ALT and GGT activities were measured
as described in Chapter 4. Arterial tensions of oxygen
(Pa02) and carbon dioxide (PaC02) were measured during
stable hypotension.
Statistical analysis
As in the preceding studies, Student's t test examined
differences in patient and anaesthetic characteristics,
and the Wilcoxon rank sum and signed rank tests were used
as appropriate to compare GST changes and differences
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between groups. Kendall rank correlation was used to
determine whether GST changes could be related to
arterial oxygen and carbon dioxide tensions, duration of
anaesthesia, duration of hypotension and total dose of
SNP and trimetaphan administered. Fisher's exact test
compared the incidence of abnormal GST concentrations in
patients who received IPPV and in those who breathed
spontaneously.
RESULTS
Sixty patients were studied; 28 were artificially
ventilated (14 halothane, 14 isoflurane) and 32 breathed
spontaneously (14 halothane, 18 isoflurane). Data were
not analysed in 12 patients who had abnormal values of
GST, ALT or GGT before operation. The remaining 48
patients comprised 25 who received IPPV (13 halothane
(9 M, 4 F), 12 isoflurane (6 M, 6 F)) and 23 who breathed
spontaneously (11 halothane (5 M, 6 F), 12 isoflurane
(7 M, 5 F)).
Within the four groups patients were equally matched for
age, height, weight and alcohol consumption. No
significant differences were observed in anaesthetic
characteristics between patients given halothane or
isoflurane who received the same mode of ventilation
(Table 6.1). However, when the modes of ventilation
alone are compared, patients who received IPPV had a
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significantly lower mean arterial carbon dioxide tension
than those in the SV group (4.8 kPa compared with
7.0 kPa, p<0.001). The mean duration of anaesthesia was
also slightly, but significantly, shorter in ventilated
patients (49 minutes compared with 59 minutes, p<0.05).
Significant increases in GST concentration from
preoperative values were observed after anaesthesia in
all 4 groups. GST concentration was increased
significantly at 1 hour in patients who received
isoflurane in the SV group and in both groups of patients
who received IPPV, and at 3 hours in patients
anaesthetised with halothane in both SV and IPPV groups.
A significant reduction in GST at 24 hours was observed
in both groups who received IPPV (Tables 6.2 - 6.4). No
significant difference in GST changes was demonstrated
between patients who had received halothane or those who
had received isoflurane, irrespective of the mode of
ventilation. Therefore, the results obtained using the
two volatile agents were combined, to allow an assessment
of the effect of mode of ventilation on plasma GST
concentration after anaesthesia. Patients who received
IPPV had a significantly greater increase in GST at 1
hour after anaesthesia than did those who breathed
spontaneously (p<0.01, Table 6.5). The quantitative
change in GST concentration was unrelated to any of the
other measured variables.
In the majority of patients in whom increases in GST were
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noted, the GST values remained within the normal range.
Eight patients (4 halothane, 4 isoflurane) in the group
which received IPPV had GST concentrations that exceeded
the upper limit of the reference range. Abnormally
increased GST concentrations occurred in three patients
who breathed spontaneously, two of whom had received
isoflurane. The mode of ventilation did not
significantly influence the incidence of abnormal values
of GST (p=0.075).
Three patients who received IPPV and halothane developed
an abnormally increased serum bilirubin concentration
after anaesthesia. No other abnormalities in




Mean values (SD) for patient and anaesthetic
characteristics in patients in all four groups
IPPV SV
Hal Iso Hal Iso
Age (years) 36 (18) 35 (12) 37 (13) 38 (14)
Height (cm) 171 (10) 167 (8) 166 (12) 167 (9)
Weight (kg) 72 (13) 71 (ID 64 (13) 64 (12)
Alcohol
(u day-1) 0 . 8 (1.3) 1.2 (1.7) 1.8 (2.0) 1.2 (1.2)
Duration of
anaesthesia
(min) 52 (22) 44 (16) 55 (16) 61 (21)
Duration of
hypotension
(min) 34 (17) 24 (16) 34 (13) 33 (12)
Dose of SNP/
trimetaphan
(ml) 155 (219) 174 (146) 220 (206) 202 (204)
Pa02 (kPa) 24 (11) 27 (9) 28 (8) 34 (7)
PaC02 (kPa) 4.9 (1.0) 4.7 (1.2) 6.8 (0.8) 7 . 1 (1.2)
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Table 6.2
Individual plasma GST concentrations (pg 1~1) for
patients undergoing deliberate hypotension, anaesthetised
with halothane or isoflurane, who received intermittent
positive pressure ventilation (IPPV)
PRE lh 3 h 6 h 24 h
Halothane
1 2 . 2 3.6
2 2 . 0 2.0
3 2.5 2.8
4 2 . 2 3.9
5 1.8 4.6 *
6 3 . 5 4.2
7 1.9 2 . 9
8 3 . 2 5.3 *
9 2 . 3 4.9 *
10 1.0 1.7








3 4.2 4 .1
4 2.8 5.7
5 2 . 3 3 . 2
6 2.5 3 . 6
7 4.2 7 . 7
8 1.5 2.4
9 4 . 2 4 . 5
10 3 .1 4.8
11 3.1 3 . 6
12 1.7 2.8
Excluded from analysis

































Individual plasma GST concentrations (pg 1_1) for
spontaneously ventilating (SV) patients undergoing
deliberate hypotension, anaesthetised with halothane or
isoflurane
PRE lh 3 h 6 h 24 h
Halothane
1 2 . 0 2.0 2 . 0 2.8 2.6
2 2 . 8 3.4 3 . 6 3.7 3 . 0
3 3 .1 3.0 3.8 2.8 2.3
4 2.8 3.6 3.8 2.8 2.2
5 2.0 2.0 2.2 2 . 6 2.1
6 3.3 3.3 3 . 6 3.3 2.3
7 2.5 2.4 3.1 2.7 2.2
8 3 . 5 3.5 4 . 6 * 4.5 * 4.2
9 2.0 1.9 2.2 2.7 1.3
10 1.2 1.7 1.9 1.5 2.0
11 2.5 3.8 2.2 1.8 1.6
Excluded from analysis
12 5 . 6 * 5.1* 4.5 * 4.8 * 3 . 6
13 5.4 * 5.5* 6 . 5 * 3 . 8 2.2


































10.9 * 13.2 * 11.5
5.4 * 4.9 * 4.0
4.8 * 5.3 * 3.9














* 6.7 * 3.2
4.7 * 3.8
3.0 2.4




Median values (lst-3rd quartile) of plasma GST
concentration (pg 1~1) for patients in all four groups.
PRE Ih 3 h 6 h 24 h
IPPV
Halothane
2.2 3.7** 2.7* 2.7 1.7*
(1.9-2.3) (2.0-4.6) (2.3-3.0) (1.9-2.4) (0.5-2.4)
Isoflurane
2.6 3.6 ** 2.8 2.5 1.9 *
(1.7-4.2) (2.8-4.8) (2.3-3.6) (1.9-3.2) (1.7-2.5)
SV
Halothane
2.5 3.0 3.1 * 2.8 2.2
(2.0-3.1) (2.0-3.5) (2.2-3.8) (2.6-3.3) (2.0-2.6)
Isoflurane
2.3 2.5 * 2.6 2.1 1.9
(1.8-2.9) (2.3-4.0) (2.2-3.2) (1.7-2.9) (1.5-2.4)
* p<0.05; ** p<0.01
compared with preoperative concentration
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Table 6.5
Median values (lst-3rd quartile) of plasma GST
concentrations (pg 1_1) for patients receiving halothane
and isoflurane, combined to allow an assessment of effect
of mode of ventilation
PRE lh 3 h 6 h 24 h
IPPV 2.3 3.6* 2.8 2.5 1.8
(1.9-3.1) (2.8-4.5) (2.3-3.5) (1.9-3.1) (1.5-2.4)
SV 2.5 2.6 2.6 2.7 2.2
(2.0-2.9) (2.1-3.6) (2.2-3.6) (1.9-2.9) (1.6-2.4)
* p<0.01 between modes of ventilation
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Table 6.6
Conventional liver biochemical tests in patients
undergoing deliberate hypotension, who received
intermittent positive pressure ventilation (IPPV)
PREOP POSTOP
Bil ALT GGT Bil ALT GGT
Halothane
1 10 20 15 13 19 16
2 11 18 8 11 19 15
3 16 20 9 13 11 6
4 13 13 <5 14 <10 6
5 11 <10 10 21 * 12 10
6 9 26 31 11 24 37
7 6 13 10 8 15 10
8 7 19 16 10 22 14
9 53 * 14 7 71 * 13 7
10 10 26 20 6 23 17
11 13 30 8 20 * 26 8
12 10 15 11 13 10 7
13 15 20 9 26 * 24 9
Excluded from analysis
14 9 25 12 12 23 14
!sof lurane
1 12 10 13 10 13 18
2 11 10 7 11 17 23
3 13 12 13 11 15 12
4 6 18 8 7 16 7
5 28 * <10 12 26 * 12 12
6 18 * 22 12 13 <10 8
7 11 17 22 12 15 15
8 9 20 15 10 19 11
9 16 26 14 10 25 20
10 7 15 18 5 15 13
11 11 23 14 14 28 15
12 11 21 12 11 22 11
Excluded from analysis
13 12 48 * 49 11 38 38




Conventional liver biochemical tests in spontaneously-
ventilating (SV) patients undergoing deliberate
hypotension (* denotes an abnormal result)
PREOP POSTOP
Bil ALT GGT Bil ALT GGT
Halothane
1 10 15 17 10 14 14
2 8 19 15 9 15 7
3 19 * 20 21 18 * 21 21
4 25 * 20 17 17 23 17
5 14 11 16 16 17 16
6 11 27 17 9 26 13
7 16 17 19 13 16 19
8 9 14 15 8 23 15
9 17 29 17 14 25 12
10 9 20 19 8 17 16
11 11 23 12 12 13 12
Excluded from analysis
12 8 42 * 6 6 23 <5
13 10 25 33 14 25 32
14 10 22 95 * 11 32 94
:sof lurane
1 11 15 15 6 18 6
2 18 * 14 <5 19 * <10 8
3 9 13 9 7 13 9
4 8 <10 5 7 <10 <5
5 13 25 14 9 28 13
6 9 19 18 7 18 19
7 20 * 14 9 16 10 7
8 13 16 16 13 13 13
9 9 23 8 9 16 8
10 12 33 14 14 19 11
11 6 27 17 7 28 15
12 9 21 20 11 26 19
Excluded from analysis
13 12 41 * 46 12 36 41
14 12 42 * 58 * 10 40 51
15 9 14 10 7 13 8
16 12 75 * 40 8 57 * 39
17 11 62 * 33 10 29 26
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Table 6.8
Medians (range) of conventional liver biochemical tests
before and after anaesthesia for patients receiving
halothane and isoflurane, combined to allow an assessment
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The major finding from this study was that patients who
received IPPV in association with deliberate hypotension
during halothane or isoflurane anaesthesia displayed a
significantly greater increase in plasma GST BtB-i
concentration at 1 hour after the end of anaesthesia than
patients who breathed spontaneously. In contrast to
earlier studies in normotensive patients [Chapter 3;
Allan et al 1987], the present study failed to show any
difference between the effects of halothane and
isoflurane on changes in GST concentration.
Some of the methodology in this study is unfortunately
open to criticism, especially the method by which
patients were allocated to different modes of
ventilation, the administration of fentanyl to patients
who received IPPV but not SV, and the lack of measurement
of inspired or end-tidal concentrations of halothane and
isoflurane. Patients were not allocated randomly to
different modes of ventilation other than by ward of
origin. However, no relevant factors influenced the
choice of admission of patients to the two wards, and no
significant differences between the groups were observed
in patient characteristics or type of operations
performed. The slightly shorter duration of anaesthesia
in patients who received IPPV simply reflects the speed
of the surgical team. The administration of fentanyl to
patients who received IPPV, but not to those who breathed
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spontaneously, is unlikely to have influenced the present
findings. Gelman, Dillard and Bradley (1987) found that
hepatic arterial and portal blood flows, and hepatic
oxygen supply were very well maintained during fentanyl
anaesthesia, in contrast to their findings during
halothane or isoflurane administration. The criticism
that inspired or end-tidal volatile concentrations were
not measured, and therefore that the anaesthetics were
probably not administered in equipotent doses, is more
difficult to answer. This objection would be meaningful
if the development of halothane-associated liver damage
in man was dose-dependent. However, there is no
evidence to support this hypothesis, although Jee and
coworkers (1980) found that the severity of hepatic
damage caused by halothane in rats was related to total
halothane dosage. Therefore, although more accurate
measurement of concentration of volatile agent
administered might have strengthened the study, omitting
to do so is unlikely to have significantly influenced the
findings or their interpretation. These criticisms
notwithstanding, the findings from this study provide
further valuable information in the investigation of
possible mechanisms of halothane-induced liver damage.
It is likely that the transient hepatic dysfunction
demonstrated in the present study resulted from
alterations in liver blood flow. Possible reasons for
the observed difference in GST concentration between the
modes of ventilation include the effects on liver blood
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flow of positive pressure ventilation and arterial carbon
dioxide tension.
Total liver blood flow is reduced by positive pressure
ventilation to a greater extent than the concomitant
reduction in cardiac output [Geiger, Georgieff & Lutz
1986]. It is possible that deliberate hypotension could
exaggerate these changes, but the effects of hypotension
on liver blood flow are difficult to predict. Animal
studies have reported controversial data on splanchnic
and hepatic arterial blood flows during SNP-induced
hypotension; these blood flows have been shown to be
either increased [Ross & Cole 1973; Miller & Delaney
1981; Gelman & Ernst 1978], decreased [Wang, Liu & Katz
1977], or unchanged [Sivarajan, Amory & McKenzie 1985;
Fan et al 1980]. Hepatic arterial blood flow has been
reported to either decrease [Skivolocki, Pace & Thomford
1972], remain unchanged [Sivarajan 1986], or increase
temporarily [Plewes & Farhi 1985] during hypotension
induced by trimetaphan. The hepatic circulation has not
been studied extensively in humans during controlled
hypotension because of the difficulties of measuring
precisely liver blood flow, although Chauvin and
coworkers (1985) found no reduction in total hepatic
blood flow during SNP-induced hypotension in
neurosurgical patients. The effect of a combined
infusion of SNP and trimetaphan on liver blood flow has
not been reported. Total hepatic blood flow is closely
related to changes in cardiac output during SNP-induced
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hypotension. Liver blood flow is reduced only when
cardiac output decreases, possibly because the
adaptations of hepatic arterial resistances are
quantitatively too small to compensate for the decrease
in portal blood flow induced by reduced cardiac output
[Chauvin et al 1985]. Wildsmith and colleagues (1983)
found in patients who underwent controlled hypotension
with combined SNP and trimetaphan infusion, that cardiac
output was reduced in those who received IPPV but not in
those who breathed spontaneously. As these patients
were studied in circumstances very similar to those of
the present study, it is likely that cardiac output, and
by inference, liver blood flow, was reduced to a greater
extent in patients receiving IPPV than in those who
breathed spontaneously. This might account for the
observed difference in plasma GST concentration at 1 hour
between the modes of ventilation.
The mean PaC02 measured at stable hypotension was
significantly greater in patients who were breathing
spontaneously than in those who received IPPV, but this
did not significantly influence the increase in GST
concentration at 1 hour after the end of anaesthesia.
Hypercapnia is usually accompanied by a substantial
increase in liver blood flow [Hughes et al 1979; Thomson
et al 1983] with a consequent increase in hepatic oxygen
supply. These increases, although potentially
beneficial to the hepatic parenchyma, are balanced by an
increase in hepatic oxygen consumption, probably
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resulting from an increase in sympathetic discharge
[Thomson et al 1983]. The hepatic oxygen supply/demand
ratio thus remains unaltered. More recent work in
beagles, however, has suggested that mild hypercapnia
(PaC02 7.9 kPa) is associated with a depression of
hepatic function, in spite of the increases in liver
blood flow [Fujita et al 1989]. It would therefore be
expected that increased PaC02 would be associated with an
increase in plasma GST concentration. The present
study, however, has demonstrated that the increase in GST
concentration is not related to PaC02. This tends to
suggest that the greater increase in GST concentration at
1 hour after the end of anaesthesia in patients who
received IPPV is more likely to be due to the effect of
IPPV on liver blood flow and not due to the effect of
PaC02 on splanchnic haemodynamics.
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CONCLUSIONS AND RECOMMENDATIONS FOR THE USE OF HALOTHANE
CONCLUSIONS
It is now generally accepted that two types of
halothane-induced liver damage exist. A mild form
manifest by elevated biochemical liver tests, which may
occur in up to 20% of patients exposed to halothane, is
thought to be due to toxic products of halothane
biotransformation, possibly determined by genetic
factors, or to hepatic hypoxia resulting from an
imbalance between hepatic oxygen supply and demand;
altered cellular calcium balance is another possible
mechanism. The much rarer fulminant form is associated
with the appearance of a specific circulating antibody
and is thought to result from an immune reaction.
Precise definition of the mechanism(s) responsible for
damage is complicated because no diagnostic test is
available for either form of toxicity. Evidence exists
supporting the involvement of each of the currently
proposed aetiologies. For example, the extents of
metabolism of halothane, enflurane and isoflurane
correlate directly with the incidence of reported
clinical hepatic dysfunction for these drugs, as does the
degree to which each of these agents interferes with the
balance between hepatic oxygen supply and demand, the
extent to which each of them stimulates the release of
calcium from stores in hepatocytes, and their ability to
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form immunoreactive protein adducts.
Much of the work supporting each of the proposed
mechanisms has been performed in animal models often
requiring the presence of demanding conditional factors
which do not pertain during clinical anaesthesia in man.
Therefore, data from these animal studies may not be
applicable to the problem of human hepatotoxicity. In
addition, human studies which have attempted to
investigate biochemical liver dysfunction after halothane
anaesthesia have suffered from the lack of a suitably
sensitive indicator of mild hepatocellular damage. The
studies in this thesis have investigated the more common
subclinical type of liver dysfunction using plasma GST
B-|Bi concentration as a highly sensitive and specific
index of liver damage.
The four studies upon which this thesis is based have
shown consistently that halothane anaesthesia is
associated with increased plasma concentrations of GST
BtBi after operation. Enflurane is also associated with
increased concentrations of GST after anaesthesia,
although not to the same extent as with halothane, while
isoflurane appears to have little effect on GST
concentration. Several patients in each study developed
GST values which exceeded the upper limit of the
reference range, and some of these values were
considerably increased. When the four studies are
combined, 118 patients who received general anaesthesia
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with halothane, enflurane or isoflurane did not undergo
any therapeutic manoeuvre designed to alter the release
of GST after operation; these patients comprise those in
all three groups in Chapter 3, and those who received
placebo in Chapters 4 and 5. The incidence of abnormal
GST concentrations observed in these patients is shown in
Table 7.1.
Table 7.1
Incidence of abnormal GST concentrations in patients who
underwent spontaneously breathing, normotensive, general
anaesthesia




















Almost one-third of patients who underwent routine,
spontaneously ventilating halothane anaesthesia developed
an abnormal GST concentration after anaesthesia; the
incidence was much lower in, admittedly fewer, patients
after enflurane or isoflurane anaesthesia. As diurnal
variation in GST concentration has not been demonstrated
in volunteers, and as clearance of GST is unlikely to be
impaired, the increases observed after anaesthesia are
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considered to reflect impaired hepatocellular integrity.
Measurement of plasma GST B-|Bi concentration has revealed
two, probably distinct, phases of toxicity. The initial
phase occurs at 3-6 hours after anaesthesia, and the
second phase occurs at 24 hours. In all four studies
plasma GST concentration increased significantly from
preoperative values at 3 or 6 hours in spontaneously
breathing patients anaesthetised with halothane. In
contrast, administration of isoflurane to patients
breathing spontaneously did not result in significant
increases in GST concentration at either 3 or 6 hours,
although when arterial pressure was deliberately reduced,
GST increased significantly at 1 hour after the end of
anaesthesia in patients who received isoflurane. It is
not clear whether this increase reflects the combined
influence of isoflurane and deliberate hypotension as GST
concentrations were not measured at 1 hour in
normotensive patients receiving isoflurane. Enflurane
was administered in one study only, but as with
halothane, GST concentration increased at 3 to 6 hours in
the great majority of patients.
The second phase of toxicity occurs at 24 hours after
anaesthesia, when much greater increases were observed in
a small number of patients. For the eleven patients
described in Table 7.1 who had increased GST at 24 hours,
the median value of GST at that time was 9.1 pg 1~1
(range 4.5-16.5) in those who received halothane, and
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4.8 pg 1~1 (range 4.3-5.8) for those who received
enflurane. This later increase at 24 hours does not
occur as consistently as the earlier increase at 3 to 6
hours; in one study no patient who received halothane
developed an increased GST concentration at 24 hours,
whereas almost 1 in 5 patients who received halothane in
another study developed an increased GST concentration at
this time. It would be necessary, therefore, to study
many more patients to ascertain the true incidence of
this secondary increase in GST concentration.
How have these studies assisted in our knowledge and
understanding of the mechanisms responsible for
halothane-induced liver damage? The incidence of
abnormal GST concentrations after exposure to each of the
volatile agents was found to parallel their reported
ability to cause hepatotoxicity (halothane > enflurane >
isoflurane). Thus it was established that measurement
of plasma GST B-iB-, concentration might be valuable in the
investigation of subclinical liver damage after volatile
anaesthesia. Subsequently, three of the proposed
aetiologies for halothane hepatitis, namely altered
hepatocellular calcium homeostasis, toxic products of
halothane biotransformation and hepatic hypoxia, were
investigated in more detail. This involved
respectively, the administration of the calcium channel
blocker nicardipine, the administration of cimetidine,
which reduces the metabolism of several drugs including
halothane, and the use of deliberate hypotension and
190
intermittent positive pressure ventilation, during which
liver blood flow is reduced.
Perioperative administration of nicardipine by
intravenous infusion did not prevent or reduce the
release of GST into the peripheral circulation after
halothane anaesthesia at either 3 to 6 hours or at 24
hours, and nor did it result in a lesser frequency of
abnormal GST values; rather it resulted in a
significantly greater increase in GST concentration at 3
hours than did halothane alone, although this occurred
only in male patients. This suggests, therefore, that
altered calcium homeostasis is probably not the major
mechanism involved, although a supporting role in the
pathogenesis of halothane-induced liver damage cannot be
excluded.
Similarly, the administration of cimetidine by mouth
before halothane anaesthesia did not influence either the
magnitude of increase in plasma GST concentration or the
frequency of abnormally increased GST values after
anaesthesia, although no patient who had received
cimetidine developed a large secondary increase in GST at
24 hours. The findings from this study would tend to
support the view that products of halothane metabolism
are not responsible for the early increase in GST
concentration. The role of halothane biotransformation
in causing the secondary increase in GST concentration
cannot be excluded; many more patients would require to
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be studied to be certain that cimetidine prevented this
less frequent increase.
The technique of IPPV and concurrent hypotension resulted
in a greater increase in GST concentration at 1 hour
after anaesthesia than did the same technique in which
patients breathed spontaneously, irrespective of the
volatile agent administered. The mode of ventilation
did not influence the increases in GST concentration at
any other time. It is most likely that the greater
increase in GST concentration following IPPV resulted
from the greater depression of liver blood flow which
occurs during IPPV than during spontaneous ventilation.
These studies provide evidence supporting the view that
a different mechanism is responsible for each phase of
toxicity recognised in the 24 hours after anaesthesia.
The early phase up to 6 hours most probably results from
an imbalance between liver oxygen supply and demand,
although the role of altered hepatocellular calcium
homeostasis cannot be excluded, whereas the secondary
phase at 24 hours may result from toxic products of
halothane metabolism. The four studies described in
this thesis, therefore, support the proposal that the
aetiology of the mild form of halothane-induced liver
dysfunction is multifactorial, in which products of
biotransformation, altered calcium homeostasis and
hepatic hypoxia all participate.
192
The measurement of plasma GST concentration can therefore
help our understanding of the mechanisms responsible for
initiating halothane-induced liver injury, and may allow
assessment of therapeutic manoeuvres which might prevent
or reduce the severity of liver injury.
RECOMMENDATIONS FOR THE USE OF HALOTHANE
The preparation of this thesis has involved an extensive
survey of the literature on the problem of halothane
hepatotoxicity, and this has enabled an understanding of
the arguments for and against the continued use of
halothane as an anaesthetic agent. It therefore seems
not unreasonable to present a personal opinion on the
current place of halothane in anaesthetic practice. It
should be stressed, however, that the discussion and
recommendations which follow arise not from the
investigations measuring plasma GST concentration, but
rather from impressions gained from surveying the
literature.
For more than 30 years, halothane has enjoyed a
reputation as a reliable and usually safe anaesthetic
which can be used in many clinical circumstances. More
recently however, there has been considerable controversy
regarding the continued use of halothane as an
anaesthetic agent [Bennetts 1986; Blogg 1986; Weis &
Engelhardt 1989]. Much of the discussion has been far
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removed from any scientific basis and as a result has
bordered on the irrational. There is no doubt that, on
rare occasions, halothane is associated with severe liver
damage which can prove fatal. One apparently obvious
solution to the problem of hepatotoxicity is not to use
halothane. However, the problems associated with
halothane anaesthesia must be kept in perspective, and
the hazards of alternative methods must be considered if
halothane is to be eliminated.
The risks of halothane anaesthesia cannot be considered
apart from the overall risks of anaesthesia. The
incidence of death from the most unfavourable studies on
halothane-induced liver failure is approximately 1 in
10,000. This is the same as the overall mortality due
to anaesthesia reported by Lunn and Mushin (1982) and is
similar to the incidence of serious neurological sequelae
following epidural blockade [Usubiaga 1975; Scott &
Hibbard 1990]. The incidence of severe morbidity after
adverse reactions to intravenous agents in the United
Kingdom is estimated to be around 1 in 5000 [Noble & Yap
1989], and more patients die from hypersensitivity
reactions to anaesthetic drugs in general than from
halothane hepatitis [Nimmo 1980].
What, then, of alternatives to halothane? Neither
enflurane nor isoflurane are known to be superior to
halothane in relation to the safety of anaesthesia.
Both these agents have the potential to cause liver
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damage under certain conditions in animals, although
their hepatotoxicity in humans has not yet been proven.
Enflurane and isoflurane both undergo considerably less
metabolism than halothane, and it is alleged that this
reduces their potential for toxicity. However, a common
mechanism may link the hepatotoxicity induced by these
three agents. It is proposed that acyl metabolites of
the volatile anaesthetics (possibly trifluoroacetic acid
for halothane and isoflurane) may become covalently bound
to hepatic proteins and act as antigens, thus
precipitating an immune reaction [Christ et al 1988b].
Although enflurane and isoflurane have less immunogenic
potential than halothane, it cannot be considered trivial
since the degree of haptenic alteration necessary to
provoke an immune response in a sensitised individual is
not known.
Metabolism of enflurane causes an increase in serum
fluoride ion concentration which is potentially
nephrotoxic [Mazze, Calverley & Smith 1977], especially
if the patient is obese or receiving isoniazid [Brown &
Gandolfi 1987; Mazze, Woodruff & Heerdt 1982]; production
of fluoride is much less with halothane and isoflurane
[Baden & Rice 1986]. Enflurane reduces the cerebral
convulsion threshold and may precipitate seizures even in
those with no history of epilepsy [Joas, Stevens & Eger
1971; Steen & Michenfelder 1979; Jenkins & Milne 1984];
frank convulsions have also been reported with isoflurane
[Harrison 1986; Hymes 1985; Poulton & Ellingson 1984].
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Isoflurane is a potent coronary vasodilator, and has been
implicated in causing myocardial ischaemia by diverting
flow away from areas of borderline perfusion towards
areas that are already perfused adequately, a phenomenon
known as "coronary steal" [Reiz et al 1983; Buffington et
al 1987]. Although this is important probably only in
high inspired concentrations, isoflurane is almost
certainly dangerous for some patients with coronary
artery disease under some conditions [Becker 1987]. A
further problem with isoflurane is its pungent odour
which makes it unpleasant to breathe. This would appear
to be responsible for the high incidence of laryngospasm
and arterial oxygen desaturation seen during inhalation
induction with isoflurane [Phillips, Brimacombe & Simpson
1988]. Therefore, despite the perceived advantage of
greater resistance to metabolism, neither enflurane nor
isoflurane appears to be significantly closer to the
ideal inhalation anaesthetic agent than halothane.
More recently sevoflurane and desflurane (1-653) have
attracted interest as possible alternatives to the
volatile anaesthetic agents in current use. Sevoflurane
is potent, pleasant to inhale, non-flammable in clinical
concentrations, and allows rapid and smooth induction of
anaesthesia [Holaday & Smith 1981]. It is metabolised
to approximately the same extent as enflurane, but is
degraded substantially (31% at 37°C) in the presence of
soda lime, raising questions about its potential toxicity
[Strum, Johnson & Eger 1987]. Indeed, sevoflurane has
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been shown to cause hepatic injury in animal models
[Strum et al 1987; Lind et al 1989]. There has been
little attempt to promote the widespread international
use of sevoflurane, suggesting that it offers little or
no advantage over the currently available agents.
Desflurane, which is undergoing evaluation for clinical
use, represents an interesting development in the quest
for the ideal inhalation anaesthetic agent [Miller &
Greene 1990]. It permits more rapid induction and
emergence, and greater sensitivity of control of
anaesthetic depth than all the other volatile anaesthetic
agents [Heijke & Smith 1990] . It undergoes minimal
biotransformation [Koblin et al 1988; Koblin et al 1989]
and is more stable in the presence of soda lime than any
of the presently used volatile anaesthetics [Eger,
Johnson & Ferrell 1987]. To date there are no reports
of liver damage associated with the administration of
desflurane either in animals [Eger et al 1987; Eger,
Johnson & Ferrell 1987; Holmes et al 1989] or in humans
[Jones et al 1990b]. However, specialised vaporisation
systems and the use of closed circuit anaesthesia are
essential due to its high volatility and expense, and
these present practical difficulties in its use. It
would be premature to speculate on the cost/benefit ratio
of desflurane compared with isoflurane or enflurane at
such an early stage in its development.
Total intravenous anaesthesia is another alternative to
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halothane, although protagonists of the technique appear
to be more concerned about the problem of anaesthetic gas
pollution than about toxicity of volatile anaesthetics
[Wright & Dundee 1982]. Although the technique is
valuable in certain clinical situations, it is not
without limitations. These include the lack of an ideal
agent despite the introduction of propofol, difficulty in
controlling depth of anaesthesia, enormous individual
variation in dose requirements [White 1989], and an
increased risk of awareness during anaesthesia.
Furthermore, intravenous anaesthesia with Althesin or
propofol was shown to result in liver enzyme changes
similar to those seen after halothane anaesthesia [Sear,
Prys-Roberts & Dye 1983], and altered liver biochemical
tests have been reported after the administration of
thiopentone [Dundee 1955], methohexitone [Bittrich, Kane
& Mosher 1963] and ketamine [Dundee et al 1980].
Therefore, intravenous anaesthesia does not appear to
solve the problem of hepatotoxicity associated with
anaesthesia.
Halothane is more potent than enflurane and isoflurane
and is less irritant to the respiratory tract. These
properties may confer an important advantage when there
is a need to deepen the level of anaesthesia quickly, as
inability to effectively control the depth of anaesthesia
presents an immediate threat to a patient's life in
circumstances such as regurgitation or airway
obstruction. Therefore, when overall patient safety is
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considered, it would seem that the risk/benefit ratio for
halothane compares favourably with that for alternative
volatile agents and the technique of intravenous
anaesthesia. Halothane has deserved its prominence in
anaesthesia for more than 30 years; it would be most
unfortunate if it were to disappear because of the
protestations of non-anaesthetists whose understanding of
the balance of risks in anaesthetic practice is probably
deficient by anaesthetists' standards.
What, then, is a "safe" interval between halothane
anaesthetics? The Committee on Safety of Medicines
(CSM) originally recommended that repeated halothane
anaesthesia should be avoided within 28 days. This
recommendation was based on the findings of Inman and
Mushin (1974; 1978) who analysed cases of alleged
halothane hepatotoxicity reported to CSM. Of 251 cases
considered, 82% involved multiple exposures to halothane,
and 75% of these multiple exposures involved at least two
halothane anaesthetics within 28 days. However, neither
the physical status of the patient nor the severity of
the surgical illness were taken into account, and the
recommendation appears to have been nothing other than a
cautious guess. More recently, and again without firm
evidence, CSM advised that the minimum interval between
halothane anaesthetics should be increased to 3 months,
and that a history of unexplained jaundice or pyrexia in
a patient following exposure to halothane contraindicated
its future use in that patient [Committee on Safety of
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Medicines 1986]. These recommendations are thought by-
many to impose severe limitations on the choice of
volatile anaesthetic agent, which might in certain
clinical situations be harmful to patients [Adams et al
1986]. In addition, because CSM depends on a system of
open reporting, the reliability of the figures upon which
such recommendations were made has been questioned
[Spence 1987a]. There can be little argument that
unexplained jaundice following a previous exposure to
halothane contraindicates its future use in that patient.
Unexplained pyrexia however, is hopelessly superficial:
many patients develop fever after operation, irrespective
of the anaesthetic used, and its value as a sign of
sensitisation to halothane is of doubtful significance
[Dykes 1971].
It is not possible to define a "safe" interval for all
patients; halothane hepatotoxicity may occur after a
single exposure to the drug, whereas other cases have
been reported several years after the previous exposure
[Neuberger & Williams 1984]. If the fulminant form of
halothane hepatitis results from immunological
sensitisation then there can be no "safe" interval for
patients so predisposed.
In these days of increasing litigation, it would seem
prudent to adopt the following guidelines for the
administration of halothane:
1. A history of unexplained jaundice following previous
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exposure to halothane contraindicates its future use
in that patient; unexplained pyrexia requires
further definition.
2. A minimum interval between halothane anaesthetics of
3 months should apply for most adult patients,
realising that for some patients there is no "safe"
period. The interval of 3 months is not
appropriate for children under the age of 14 years,
in whom the risk of halothane hepatotoxicity is
extremely remote, and for whom halothane provides
many advantages for overall safety.
3. If, on consideration of the available options and
the patient's condition, halothane is to be
administered within 3 months from a previous
exposure, the appropriate reasons for the choice of
halothane should be documented in the case notes.
4. If halothane is to be avoided for fear of provoking
liver damage, the alternative inhalation agent
should be delivered from an anaesthetic machine to
which a halothane vaporiser has not been attached,
in order to prevent the development of liver injury
from inapparent circuit contamination with
halothane: that this is not the practice in most
operating theatres serves only to underline the
double standards which are applied currently to the
use of halothane.
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Halothane is a safe and useful anaesthetic agent. As
with all drugs, however, its use can result in adverse
effects. An understanding of the mechanisms of
halothane-induced hepatotoxicity, and the factors
predisposing to it, will enable full advantage to be
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APPENDIX 1 - STRUCTURAL FORMULAE OF VOLATILE AGENTS
Halothane F H
F — C — C — Br
F Cl
Enflurane F F F
I I I
H — C — 0 — C — C — H
I I I
F F Cl
Isoflurane F H F
I I I





h — c — 0 — c
I I
cf3 h
Desflurane F H F
I I I




APPENDIX 2 - ABBREVIATIONS
The scientific units, symbols and abbreviations used
throughout this thesis conform to those described in:
Units, Symbols, and Abbreviations. A Guide for
Biological and Medical Editors and Authors.
4th edition, Baron DN, ed. (1988). Royal
Society of Medicine Services: London
Other abbreviations used are listed below:
ALP alkaline phosphatase
ALT alanine aminotransferase








CSM Committee on Safety of Medicines
CTF 2-chloro-l,1,1-trifluoroethane
ENT ear, nose and throat
F female
FjC^ fractional inspired oxygen concentration
GGT gamma-glutamyl transferase
GST glutathione S-transferase






IPPV intermittent positive pressure ventilation
LDH lactate dehydrogenase
M male
MAC minimum alveolar concentration
MFOE mixed-function oxidase enzyme
OCT ornithine carbamyl transferase
PaC02 arterial carbon dioxide partial pressure
Pa02 arterial oxygen partial pressure
PCB polychlorinated biphenyl
PE.C02 end-tidal carbon dioxide partial pressure
RIA radioimmunoassay
SDH sorbitol dehydrogenase
SGOT serum glutamic-oxaloacetic transaminase
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PLASMA GLUTATHIONE S-TRANSFERASE
CONCENTRATION AS A MEASURE OF HEPATOCELLULAR
INTEGRITY FOLLOWING A SINGLE GENERAL
ANAESTHETIC WITH HALOTHANE, ENFLURANE OR
ISOFLURANE
A. J. HUSSEY, L. M. ALDRIDGE, D. PAUL, D. C. RAY, G. J. BECKETT
AND L. G. ALLAN
Hepatic injury has been associated with the use of
volatile halogenated anaesthetic agents [1]. Halo-
thane, a volatile anaesthetic agent still used
widely in Great Britain, is the subject of renewed
controversy, with acute fulminant hepatitis oc¬
curring rarely following its use. The incidence
and underlying mechanisms leading to the devel¬
opment of "halothane hepatitis" still remain
unknown, but biotransformation [2], a suscepti¬
bility factor [3], and hypersensitivity [4] have all
been implicated.
With recent reports [5, 6] questioning the
future of halothane in clinical anaesthesia, an¬
aesthetists may turn to alternative anaesthetics
such as the newer volatile agents, enflurane and
isoflurane. However, there have also been reports
of hepatic injury associated with enflurane an¬
aesthesia [7, 8]. It has, therefore, been postulated
that there is a syndrome of "enflurane hepatitis".
Hepatic dysfunction after administration of iso¬
flurane is unlikely [9].
The most widely used method of assessing
drug-induced hepatocellular damage in man is the
measurement of transaminase activity in plasma
[10]. However, these measurements lack sensi¬
tivity and may have poor organ specificity. The
measurement in plasma of the hepatic isoenzymes
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SUMMARY
The plasma concentration of hepatic glutathione
S-transferase (GST) was measured in matched
groups of patients who received halothane,
enflurane or isoflurane anaesthesia for elective
minor surgery. The GST concentrations increased
significantly at 3 h after anaesthesia in patients
who received halothane or enflurane, but not in
patients who were given isoflurane. A secondary
increase in GST concentration, at 24 h, was seen
in a small number of individuals who received
halothane or enflurane. Abnormal GST con¬
centrations were found in 50% of patients
following halothane anaesthesia, 20% following
enflurane and 11% after isoflurane. The small but
significant increases in GST concentrations in
patients receiving halothane or enflurane sug¬
gests an impairment of hepatocellular integrity
following the administration of these anaes¬
thetics. in contrast, isoflurane anaesthesia did
not appear to be associated with this effect.
of glutathione S-transferase (GST) by radio¬
immunoassay is a sensitive and specific method
for the detection of acute drug-induced hepato¬
cellular damage. In chronic liver disease, the
measurement of GST, unlike the aminotrans¬
ferases, correlates well with liver histology (for a
review see [11]). The physicochemical properties
of GST offer certain theoretical advantages over
measurements of aminotransferase in the investi¬
gation of chemically-induced hepatotoxicity.
GST are relatively small enzymes (MW ~ 50000)
and arc present in high concentrations in hepatic
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cytosol. GST are readily and rapidly released in
quantity into the circulation following hepatic
damage; their short plasma half-life (<90min)
allows early detection of hepatic damage and its
resolution. Unlike the transaminases, which are
located periportally, GST are primarily located
in the centrilobular hepatocytes [12]. The
measurement of plasma GST may, therefore,
be of particular relevance in investigating halo-
thane hepatitis, since this syndrome is generally
associated with centrilobular necrosis.
We have shown that significant increases in
plasma GST concentration occur 3 h after halo-
thane anaesthesia, but not after isoflurane an¬
aesthesia [13, 14]. This suggests that halothane,
but not isoflurane, is associated with a mild,
transient impairment of hepatocellular integrity.
In the present study, we have investigated
sequential changes in plasma GST concentration
in three matched groups of patients allocated to
receive anaesthesia with halothane, enflurane or
isoflurane, for surgical procedures that were
standard in type and duration.
PATIENTS, MATERIALS AND METHODS
Patients and samples
Only patients undergoing herniorraphy or vari¬
cose vein surgery in ASA groups I or II were
included in the study. Ethical approval and
informed consent were obtained. Patients with
pre-existing clinical or biochemical evidence of
liver disease or who had received a general
anaesthetic in the previous 6 months were ex¬
cluded. Patients taking regular medication likely
to interfere with liver function were also
excluded.
Subjects were allocated to three groups: pat¬
ients in group A received halothane (n = 30),
group B patients received isoflurane (« = 30) and
patients in group C received enflurane in — 41).
No premedication was given. Anaesthesia was
induced with thiopentone 4—6 mg kg-1 i.v., and
maintained with the volatile anaesthetic agent
vaporized in 33 % oxygen and 67 % nitrous oxide.
Ventilation was spontaneous in all subjects.
During maintenance of anaesthesia, the inhaled
fresh gas concentration of halothane varied from
1.0 to 1.5 °o, and those of isoflurane and enflurane
from 1.0 to 3.0%. Diamorphine was given i.v. in
divided doses at induction and on recovery to a
total dose of 0.07 mg kg"1.
Blood samples were taken before the induction
of anaesthesia and at 3, 6 and 24 h following the
termination of anaesthesia. Plasma concentrations
of albumin, alanine aminotransferase (ALT),
bilirubin, y-glutamyltransferase (GGT) and alka¬
line phosphatase (ALP) were measured in the
samples obtained before anaesthesia and at 24 h
following anaesthesia. Plasma from all samples
was stored at — 20 °C before measurement of
GST.
Assay procedures
Concentrations of albumin, ALT, bilirubin,
GGT and ALP were measured using a Sequential
Multiple Analysis with Computer (SMAC)
System II (Technicon Instruments Corporation,
Basingstoke, U.K.). The concentration of GST
B, in plasma was measured using a specific
radioimmunoassay [15]. The reference range
for GST Bj is 0.7^4.0 pg litre"1 (derived from 135
blood donors). The inter-assay coefficient of
variation for the GST B, RIA was less than 10%,
and the intra-assay coefficient of variation was less
than 5 % over the range 2^40 pg litre"1.
Statistical analysis
The Kruskal-Wallis test, for analysis of vari¬
ance, was used to compare the changes in GST
concentrations observed in the three groups, at
3 h following anaesthesia, in order to eliminate
multiple testing errors. Changes in GST con¬
centrations within each group were compared
using the Friedman test. The Wilcoxon matched-
pairs test was used to compare postoperative
concentrations of GST and albumin with pre¬
operative values in groups that showed significant
changes with the Friedman test. Correlation
analysis used the Spearman rank test. A four-fold
table chi-squared test was used to compare the
incidence of abnormal values in each group. The
demographic data from each group were com¬
pared using the Kruskal-Wallis test.
RESULTS
Patients with preoperative plasma concentrations
of GST, ALT, bilirubin, ALP or GGT that
exceeded the upper limit of the reference range
were excluded from the study. Statistical analysis
of the demographic data for the remaining
subjects in group A (n = 22), group, B (n = 18)
and group C (n = 30) showed no significant dif¬
ferences (table I). No significant overall changes
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in the concentrations of bilirubin, ALT, ALP
or GGT occurred as a result of anaesthesia.
Significant differences in the changes in GST
concentrations following anaesthesia between the
three groups were observed (Kruskal-Wallis: P
< 0.05), and significant temporal changes in GST
concentrations were evident within all three
groups (Friedman; group A P < 0.05, group B
P < 0.01 and group C P < 0.0001). In groups A
and C, that is those patients receiving halothane
and enflurane, respectively, these changes were
caused by significant increases in GST con¬
centrations at 3 h after anaesthesia (Wilcoxon:
group A P < 0.01 and group C P < 0.0001) and at
6 h following anaesthesia (group C P < 0.05). In
the patients receiving isoflurane (group B), no
significant increase in GST concentrations oc¬
curred after anaesthesia. The medians and inter¬
quartile ranges of the GST concentrations at
times before and after anaesthesia in the three
groups are shown in table II. There was no
correlation between the changes in GST con¬
centrations and the total dose (duration x main¬
tenance °0 anaesthetic concentration) of anaes¬
thetic (Spearman rank).
Four patients in group A and three in group C
showed secondary increases in GST concentra¬
tions, which exceeded the reference range, at
Table I. Demographic data for patients in group A, group B and group C who had normal plasma
concentrations of GST, ALT, bilirubin, ALP and GGT before operation
Group A Group B Group C
Halothane Isoflurane Enflurane
(71 = 22) (7! = 18) (77 = 30)
Age (yr)
Mean 42.4 40.2 50.3
SD 17.0 15.8 12.7
Sex (M/F) 11/11 10/8 16/14
Height (m)
Mean 1.70 1.70 1.71
SD 0.10 0.11 0.12
Weight (kg)
Mean 70.4 68.6 71.0
SD 13.7 12.2 15.3
Cigarettes (No. day ')
Median 5 0 0
(lst-3rd quartile) 0-15 0-12 0-10
Alcohol (g week ')
Median 2.5 6.0 0.1
(lst-3rd quartile) 0.1-15.0 0.7-16.0 0.05-
Duration of anaesthetic (min)
Median 45 50 45
(lst-3rd quartile) 30-55 33-60 30-55
Table ii. Medians (lst-3rd quartile) of GST values (fig litre ') f°r groups A, B and C. Significant
increases from basal values (Wilcoxon matched-pairs)'. *P < 0.05; **P < 0.01; ***P < 0.0001
After anaesthesia
Before
anaesthesia 3 h 6 h 24 h
Group A
Halothane 2.9 3.4** 3.3 2.5
(77 = 22) (2.3-3.4) (2.6-4.1) (2.2-4.0) (1.8-3.5)
Group B
Isoflurane 2.9 2.6 2.6 2.0
(77 = 18) (2.0-3.3) (2.1-3.3) (2.1-3.1) (1.7-2.4)
Group C
Enflurane 2.4 3.0*** 2.9* 2.3
(77 = 30) (1.9-3.0) (2.3-3.4) (2.4-3.3) (1.4-2.7)
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24 h after anaesthesia. One of the patients who
had an increased plasma GST concentration at
24 h after anaesthesia with halothane also had an
increased plasma ALT activity (116 u. litre-1) at
this time. The changes in GST front preoperative
concentrations in the samples obtained after
anaesthesia, for all three groups of patients, are
shown in figure 1.
Many patients, particularly in groups A and C,
showed concentrations of GST which exceeded
the upper reference value after anaesthesia (fig. 2).








Fig. 1. Individual changes in plasma GST concentrations
(jig litre-1) from the preoperative sample. # = Changes
within the reference range; A = increase in GST which ex¬
ceeded the upper limit of the reference range (4.0 jjg litre-1).
Group A patients were anaesthetized with halothane, group
B patients received isoflurane and group C patients received
enflurane.
following anaesthesia in all three groups is shown
in table III. Patients receiving halothane had a
greater incidence of abnormal GST concen¬
trations than those receiving enflurane or iso¬

























3 0 6 0
Time after anaesthesia (h)
24
Fig. 2. Abnormal plasma GST concentrations (>4.0|ig
litre ') following anaesthesia with halothane (group A), iso¬
flurane (group B) or enflurane (group C) compared with con¬
centrations in preoperative samples. The maximum increase
in GST concentration for each patient is shown.
Table III. Incidence of abnormal plasma GST concentrations following anaesthesia in patients in groups
A, B and C
Group A Group B Group C
GST Halothane Isoflurane Enflurane
(pg litre ') (n = 22) (n = 18) (n = 30)
Normal
(< 4.0) 11 16 24
Increased
(> 4.0) 11 2 6
i
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0.05, respectively). There was no significant
difference in the incidence of abnormal GST
concentrations between the groups receiving en-
flurane or isoflurane.
DISCUSSION
We have demonstrated marked differences in
the plasma GST response to three halogenated
anaesthetic agents. These differences were not
attributable to patient selection, since the three
patient groups were comparable with respect to
factors such as age, sex, alcohol intake and the
type and duration of operation. Significant in¬
creases in GST concentrations at approximately
3-6 h following anaesthesia were observed with
halothane and enflurane, but not isoflurane.
These findings are in agreement with the results
obtained from a previous study in which only
halothane and isofiurane anaesthesia were studied
[14].
Changes in GST concentrations result from an
impairment in hepatocellular integrity and may be
an indication of mild subclinical liver damage of
a transient nature. Although the increases in
plasma GST were small, a large number of
abnormal concentrations were recorded, par¬
ticularly in the halothane group. In addition,
secondary and more marked increases in GST
concentrations were seen 24 h after anaesthesia in
a few of the patients who had received halothane
or enflurane. This secondary phase of impaired
hepatocellular integrity was also apparent in
previous studies [13, 14], None of the patients
who had received isoflurane showed this second¬
ary increase in concentration.
The relationship between the impairment of
hepatocellular integrity that we have observed in
the majority of individuals following halothane
and enflurane anaesthesia and the rare develop¬
ment of fulminant hepatitis is unclear. Two
distinct forms of liver damage, mild (type I) and
severe (type II), have been defined following
halothane anaesthesia [16]. Hepatic dysfunction
of the type I form is probably more common and
it is thought to be associated with increased
concentrations of serum transaminases [17], How¬
ever, not all studies have demonstrated an in¬
creased incidence of liver enzyme disturbance
following halothane in comparison with other
agents, and small, reversible changes in liver
function are common following all kinds of
anaesthesia [18]. Fulminant hepatic failure fol¬
lowing halothane (type II) is a much rarer event
which occurs mainly in adults with an incidence
of between 1:7000 and 1:30000 [6].
A number of mechanisms have been proposed
to account for the hepatotoxic effect of anaes¬
thesia. Biotransformation with the formation of
toxic metabolites which may bind to cellular
macromolecules and cause necrosis has been
suggested [19, 20]. The reductive metabolism of
halothane, which is associated with hepatic nec¬
rosis in animal models [21], has been demon¬
strated in man [22]. The degree of biotrans¬
formation of the three anaesthetics included in
this study differs. Halothane is metabolized to a
greater extent (approx. 20 °0 of an inhaled dose)
than enflurane (2°0) and isoflurane (0.2 °0) [5]. It
is interesting to find that anaesthesia with halo¬
thane resulted in a significantly greater incidence
of abnormal GST concentrations than did an¬
aesthesia with either enflurane or isoflurane.
The incidence of hepatitis increases with re¬
peated halothane exposure, which would be in
keeping with a hypersensitivity reaction. It is of
interest that hapten formation involving halothane
or a metabolite has been described [4]. There is
also evidence to suggest a susceptibility factor
responsible for a genetic predisposition to halo¬
thane hepatitis in certain individuals [3]. Hepatic
hypoxia per se has also been implicated in
anaesthesia-associated hepatotoxicity [23].
The data presented provide evidence for two
phases of mild transient hepatotoxicity after
anaesthesia with halothane or enflurane, but not
with isoflurane. The first phase occurred in the
majority of individuals within 3-6 h of admin¬
istration of the anaesthetic. In the patients
receiving halothane, this is most likely to be
caused by the direct specific effect of this agent on
hepatic blood flow producing relative tissue
hypoxia [24]. However, an increase of GST was
also observed in patients receiving enflurane,
which is not known to affect hepatic arterial blood
flow.
The second phase of impaired hepatocellular
integrity, at 24 h, which was indicated by marked
changes in GST concentrations in a small number
of patients and an increased ALT activity in
one patient, may result from the production of
toxic metabolites. The changes in GST con¬
centrations seen at this time support evidence for
the existence of the mild form of liver damage
following halothane (type I) that has been defined
by other workers [17]. The proportion of patients
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showing this response was greater in the group
who received the more extensively metabolized
anaesthetic halothane, than in the group who had
received enflurane.
Changes in plasma GST concentrations clearly
demonstrate the stages of hepatotoxicity which
may follow anaesthesia. Their measurement may
help in the understanding of the mechanisms
involved in the hepatotoxicity related to the
inhalation of certain volatile anaesthetic agents.
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EFFECT OF NICARDIPINE INFUSION ON THE RELEASE OF
GLUTATHIONE S-TRANSFERASE FOLLOWING
HALOTHANE ANAESTHESIA
D. C. RAY, G. J. BECKETT, J. D. HAYES AND G. B. DRUMMOND
Liver dysfunction following exposure to volatile
halogenated anaesthetics has long been estab¬
lished [1], The role of halothane in the
development of hepatic injury is the subject of
renewed controversy and research. Significant
increases in the plasma concentration of the
hepatic cytosolic enzyme glutathione S-trans-
ferase B,B, (GST) occur after halothane but not
isoflurane anaesthesia [2, 3]. This led us to believe
that measurement of GST in plasma could be
valuable in the investigation of liver dysfunction
following anaesthesia as the plasma concentrations
of GST allow detection of minor and short-term
hepatic injury which is not revealed using con¬
ventional hepatic enzymes [2, 3].
The role of calcium in mediating or propagating
ischaemic cell injury, and the concept that
increased concentrations of intracellular calcium
constitute the final common pathway of cell injury
have been reviewed [4], Gelman and Van Dyke
have propounded a similar "calciogenic" hypoth¬
esis for the development of liver toxicity asso¬
ciated with volatile anaesthetics [5]. Slow calcium
channel blockers have a cell protective effect in
ischaemic myocardial injury [6] and in ischaemic
brain damage in rats [7], Garay and co-workers
[8] found that the calcium antagonist nicardipine
might significantly reduce the extent of liver
damage in rats after administration of the
hepatotoxic agents carbon tetrachloride or
d-galactosamine.
We have assessed the possibility that nicardi¬
pine given as an infusion before and during
halothane anaesthesia in man might reduce the
release of GST.
D. C. Ray, m.b., ch.b., G. B. Drummond, m.b., ch.b.,
f.f.a.r.c.s. (Department of Anaesthetics); G.J.Beckett,
ph.d., J. D. Hayes, ph.d. (Department ofClinical Chemistry);
The Royal Infirmary, Edinburgh EH3 9YW. Accepted for
Publication: October 24, 1988.
Correspondence to D. C. R. (Anaesthetics).
SUMMARY
To assess the possible protective effect of
calcium channel blockade on hepatic function
after halothane anaesthesia, 80 patients were
allocated randomly to receive an i.v. infusion of
either nicardipine or normal saline. Plasma con¬
centration of glutathione S-transferase B1 sub-
units (GST) was measured as a sensitive index of
hepatic damage. Data from 53 patients were
analysed. Plasma GST concentration increased
significantly at 3 and 6 h after induction of
anaesthesia in the placebo group (P<0.01),
and at 3 h (P < 0.01) and 6 h (P < 0.05) in the
nicardipine group. The administration of nicar¬
dipine resulted in a greater increase in plasma
GST concentrations at 3 h than did placebo
(P < 0.05), mainly because of a greater increase
in males than in females. The increase in GST at
3 h was related inversely to plasma concentration
of nicardipine both at the end of the exponential
infusion (P < 0.01) and at 2 h after induction
(P < 0.05), when males had lower plasma nicar¬
dipine concentrations than females (P < 0.05).
Calcium channel blockade with nicardipine in
the dose administered was not shown to reduce
liver dysfunction after halothane anaesthesia.
PATIENTS AND METHODS
Patients and samples
We studied patients aged 18-70 yr, ASA I or II
[9], undergoing elective, peripheral orthopaedic
surgery expected to last between 30 and 90 min.
Ethics Committee approval and written informed
consent were obtained. Patients who had under¬
gone halothane anaesthesia within the preceding
3 months were excluded. Those patients receiving
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regular oral medication other than benzo¬
diazepines or thiazide diuretics and those who gave
a history of parenchymal liver disease, contact
with hepatitis or recent blood transfusion were
excluded also, as were patients whose average
daily intake of alcohol exceeded 3 units and those
whose weight was greater than 120 °0 of that
expected for a person of the same age, sex and
height [10]. Subjects were allocated, according to
a previously prepared, randomized, sex-stratified
list, to one of two groups to receive either an i.v.
infusion of nicardipine or a comparable infusion
of normal saline.
The infusion was designed to achieve a steady
state plasma concentration of nicardipine approxi¬
mately 120 ng ml-1 after 1 h of infusion, based on
an approximate plasma clearance rate of nicardi¬
pine of 600 ml min 1 for a 70-kg subject and an
elimination rate constant of 0.2 h 1 [11]. The
contents of a syringe containing nicardipine 5 mg
in normal saline 60 ml were infused from a syringe
pump at a rate of 1 ml min-1 into a closed vial
containing nicardipine 20 mg in 20 ml volume, via
a fine-bore needle to encourage mixing within the
vial. The infusion was led from the vial to the
patient. This technique was described by Riddell
and co-workers [12]. In the first 1 h of this
treatment a patient allocated to receive nicardipine
would have been given a combination of a steady
infusion of nicardipine 5 mg and an exponentially
decreasing infusion with a total of nicardipine
20 mg, 95 % of which would have been admin¬
istered in that time. Subsequently, an infusion
was started of nicardipine 25 mg in normal saline
50 ml at 10 ml h 1 for a further 5 h.
The infusion was commenced 1 h before in¬
duction of anaesthesia. The electrocardiograph
was monitored continuously and systemic arterial
pressure measured for the duration of the in¬
fusion, which was discontinued if the systolic
arterial pressure became less than 75 of the
preinfusion value, or if tachycardia >150 beat
min 1 or disorders of cardiac rhythm became
apparent.
Premedication comprised temazepam 20 mg by
mouth 2 h before operation. Anaesthesia was
induced with thiopentone 4-6 mg kg-1 and suxa¬
methonium 1 mg kg 1 was administered to facil¬
itate tracheal intubation if this was necessary.
Anaesthesia was maintained with 66"<> nitrous
oxide and halothane in oxygen. Ventilation was
spontaneous in all patients. End-tidal con¬
centrations of halothane (Penlon halothane meter)
and carbon dioxide (Hewlett-Packard 47210A
capnometer) were recorded every 5 min for the
duration of anaesthesia. The carbon dioxide
sensor was attached to the mount of the mask in
non-intubated patients. Patients were withdrawn
from the study if their end-tidal carbon dioxide
partial pressure exceeded 8 kPa. Postoperative
analgesia was provided by i.m. diamorphine, oral
dihydrocodeine or soluble aspirin as necessary;
metoclopramide was prescribed to relieve nausea.
The patient's age, height, weight, alcohol
intake, the operation performed and the duration
of anaesthesia were recorded, and end-tidal
carbon dioxide and halothane concentrations were
recorded for each 5-min period. The mean of the
end-tidal concentrations of carbon dioxide and
halothane was determined for each patient and
a time-weighted halothane average calculated
(mean end-tidal halothane concentration x
duration of anaesthesia (min)). Blood was sampled
before commencing the infusion, for GST and
conventional liver function tests, full blood count
and screening for the following autoantibodies:
thyroid cytoplasm, gastric parietal cells, anti-
nuclear factor, smooth muscle, mitochondria and
antibrush border. Further samples for measure¬
ment of GST were taken 1, 3, 6 and 24 h after
induction of anaesthesia. Plasma concentration of
nicardipine was assessed at the end of the
exponential infusion and 30 min and 1, 2, 3 and
6 h after induction. At 24 h a final sample of
blood was taken for repeat blood chemistry and
hacmatological screening.
Assay procedures
Concentrations of bilirubin, and activities of
alanine aminotransferase (ALT) and gamma
glutamyl transferase (GGT) were measured using
a Sequential Multiple Analysis with Computer
System II (SMAC) (Technicon Instrument Cor¬
poration, Basingstoke, U.K.). The plasma con¬
centration of GST B,B, was measured by specific
radioimmunoassay [13]. The reference range for
GST B,B, is 0.7-4.0 pg litre 1. The interassay
coefficient of variation for the GST radio¬
immunoassay was less than 10 "0, and the
intraassay coefficient of variation was less than 5 °0
over the range 2-40 pg litre 1. Samples for
nicardipine assay were separated by centrifugation
and the resultant serum was stored at — 20 °C
until assay was performed by standard high
pressure liquid chromatography [14]. Analysis
of nicardipine-containing serum was performed
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Table I. Median (range) values of conventional liver function tests for 16 patients excluded from analysis because of abnormal
values before operation, and median values of GST for these patients
After operation
Before op. 1 h 3 h 6 h 24 h
Bilirubin (|tg litre











by Syntex Pharmaceuticals Ltd, Palo Alto,
California.
Statistical procedures
The demographic data, the duration of an¬
aesthesia, mean end-tidal halothane and carbon
dioxide concentration, and time-weighted halo¬
thane average for each group were compared
using Student's t test. Changes in GST con¬
centrations within each group were compared
using the Friedman test. The GST changes from
the preoperative values at 1, 3, 6 and 24 h
following induction of anaesthesia in each group
were compared by the Wilcoxon signed rank test.
Differences in GST changes at these times
between the two groups were examined by the
Wilcoxon rank sum test. The relations between
changes in GST concentration and duration of
anaesthesia, end-tidal carbon dioxide con¬
centration, and dose ofopioid administered in 24 h
were examined by Spearman's rank coefficient.
This test was also used to investigate the cor¬
relation of GST changes and plasma nicardipine
concentration for males and females separately.
RESULTS
Eighty patients were entered into the study: 42
received nicardipine (27 males, 15 females) and 38
received placebo (26 males, 12 females). The
infusion was discontinued in 11 patients and they
were excluded from subsequent analysis. Eight of
these had received nicardipine and on each
occasion the infusion was stopped because of
hypotension. Three patients receiving normal
saline also had the infusion discontinued, two
because of tachycardia and one whose operation
was cancelled for surgical reasons. Data were not
analysed in 16 patients who were found to have
abnormal liver function tests in the sample taken
before operation (table I). All exhibited an
increased GST and nine also had abnormal
conventional liver function tests. In no patient did
end-tidal carbon dioxide partial pressure exceed
8 kPa, and only four patients had values greater
than 6 kPa.
The remaining 53 patients from whom data
were analysed comprised 29 who received nicardi¬
pine (17 males, 12 females) and 24 who were given
placebo (13 males, 11 females). Comparisons
between the groups revealed no significant dif¬
ference in age, height, weight, percent of expected
weight and daily alcohol consumption (table II).
Two patients in the study were taking regular oral
medication: one was receiving temazepam and
the other bendrofluazide. Both groups received
similar doses of thiopentone at induction of
anaesthesia, when three patients in the placebo
group and two in the nicardipine group received
suxamethonium to facilitate tracheal intubation.
Mean end-tidal values of halothanc and carbon
dioxide concentrations did not differ significantly
between groups. Patients receiving nicardipine
had a significantly longer duration of anaesthesia
than those receiving placebo (P < 0.01) and, as
would be expected, their time-weighted halothane
average was correspondingly greater {P < 0.05)
(table II).
Table II. Demographic data and anaesthetic characteristics
{mean (SD))
Placebo Nicardipine
Age (yr) 34 (12) 30 (8)
Height (cm) 171 (10) 174 (11)
Weight (kg) 68 (9) 71 (13)
Percent of expected wt 100 (12) 103 (12)
Alcohol (u. day ') 1.4 (0.8) 1.6 (1.1)
Thiopentone (mg) 414 (63) 428 (86)
Halothane concn ("„) 1.1 (0.3) 1.0 (0.2)
Pe;„, (kPa) 4.9 (0.8) 5.1 (0.7)
Duration of 39 (11) 54 (21)
anaesthesia (min)
Time-weighted 40.3 (13.7) 53.1 (21.5)
halothane average
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Table III. Median values of GST (pg litre 1) (interquartile range). *P < 0.05; ** P < 0.01 compared



























A significant increase in plasma GST con¬
centration above basal values was noted 3 and 6 h
following induction in each group and a significant
reduction at 24 h in the group receiving nicardi¬
pine (table III). The distribution of changes in
GST from the preoperative values is shown in
figure 1. Nicardipine administration resulted in a
greater increase in GST concentration 3 h after





















Time after operation (h)
difference was almost entirely attributable to
males receiving nicardipine, who showed a greater
increase in GST value at 3 h (P < 0.01) than did
females receiving nicardipine (fig. 2). The median
plasma concentrations of nicardipine at each time
of sampling are shown separately for males and
females in table IV. Males receiving nicardipine
had significantly lower plasma concentrations of
nicardipine than females at the end of the
exponential infusion and at 2 h after induction
(P < 0.05, both times). The plasma concentration
of nicardipine at these times was inversely related
to the increase in GST at 3 h (P < 0.01 at the end
of exponential infusion, P < 0.05 at 2 h after
induction (fig. 3)). There was no correlation be¬
tween the magnitude of change in GST at 3 and
6 h and duration of anaesthesia, mean end-tidal
carbon dioxide concentration or administration of
opioid after operation in either group.
The finding of positive autoantibody titres in





Fig. 1. Individual changes in plasma GST concentrations
after operation, relative to the preoperative value, for the
patients receiving placebo and nicardipine infusions. Arrow¬









Fig. 2. Individual changes in plasma GST concentrations, rela¬
tive to the preoperative value, 3h after operation, showing
male and female subjects separately.
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1 h 2 h 3 h 6 h
Males 115.2 90.8 90.3 79.7 80.6 35.5
(61.0-149.5) (67.4-159.3) (72.1-117.3) (64.9-118.6) (63.2-128.3) (20.2-58.5)
Females 149.8 107.7 99.4 105.4 103.8 34.8
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Fig. 3. Relationship between the plasma concentration of
nicardipine achieved 2 h after induction of anaesthesia, and
the change in GST that occurred at 3 h after induction of
anaesthesia. □ = Male patients; O = female patients. There
is a negative linear correlation (r = —0.43, P < 0.05) for the
patients taken together.
antinuclear factor, and one each to thyroid
cytoplasm, smooth muscle and antibrush border)
could not be related to an unusual GST response.
The concentrations of bilirubin and activities of
ALT and GGT at 24 h after induction were not
significantly different compared with the values
before operation (table V).
Table V. Mean (SD) values of conventional liver function tests
Bilirubin ALT GGT
(|ig litre ') (u. litre ') (u. litre"1)
Placebo
Before op. 11 (4) 16 (10) 14(14)
After op. 11 (4) 14(8) 12 (13)
Nicardipine
Before op. 14(8) 17(8) 14(7)
After op. 16(12) 13(8) 13(7)
DISCUSSION
The underlying mechanisms of "halothane hepa¬
titis" remain poorly understood. Hypersensitivity
[15, 16], toxic products of metabolism [17-19]
particularly non-oxidative metabolism [20],
regional hepatic hypoxia [21, 22] and a familial
susceptibility factor [23] have all been implicated
as contributing factors. Females are reported to be
at greater risk than males of developing hepatic
damage following halothane anaesthesia [24, 25],
although the sex distribution of patients exposed
to halothane anaesthesia is not necessarily equal.
It was for this reason that we investigated
independently the influence of nicardipine in¬
fusion on GST release in the two sexes.
It has been suggested that an increase in
intracellular calcium acts as the final common
event in irreversible cell damage [4]. Such an
increase occurs secondary to disruption of the
mechanisms that maintain intracellular calcium
homeostasis. Recently, it has been postulated that
the difference in toxicity between halothane and
isoflurane might result from a different ability of
anaesthetics to disrupt intracellular calcium
homeostasis [5]. The administration of a calcium
channel blocker before the initiation of cell injury
may therefore prevent a large secondary influx of
calcium into the cell and limit the severity of
cellular damage. Indeed, studies in the rat suggest
that this is the case [7, 8]. We undertook this study
to investigate the degree to which calcium channel
blockade could reduce liver dysfunction following
halothane anaesthesia.
We have confirmed that transient GST release
occurs following anaesthesia with halothane in
man, as has been demonstrated previously [2, 3].
Although the changes in median concentrations of
GST were small, some individual increases were
sufficient to increase the plasma concentration of
GST above the upper limit of the reference range.
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This finding parallels those of earlier studies in
which the administration of isoflurane did not
result in an increase in plasma concentration of
GST [2, 3], We have also shown that nicardipine
is associated with a greater release of GST after
operation than is placebo. This difference resulted
from an exaggerated GST response in males, but
not females, receiving nicardipine. Females had a
significantly greater plasma concentration of
nicardipine at the end of the exponential infusion
and at 2 h after induction than males, and this was
related to a lesser increase in GST at 3 h. The
larger increase in GST at 3 h in males receiving
nicardipine may reflect the combined effects of
halothane and nicardipine causing a greater re¬
duction in hepatic perfusion than halothane alone.
The greater plasma concentration achieved in
females perhaps conferred a degree of hepato-
protection against this combined effect, but
possibly were still insufficient to prevent release of
GST. Although plasma concentrations of nicardi¬
pine throughout the infusion were compatible
with those required to give a clinically relevant
effect [26] and haemodynamic effects were
apparent throughout the infusion (increased heart
rate and reduced diastolic arterial pressure), it
may be that even greater plasma concentrations
are required for hepatoprotection following halo¬
thane anaesthesia. Such concentrations may,
however, cause undesirable cardiovascular side
effects. We were unable demonstrate.that nicardi¬
pine in the dose administered prevented this type
of liver dysfunction.
The finding that nicardipine conferred no
hepatoprotection is at variance with animal
studies. However, the dose of nicardipine ad¬
ministered to rats [8] was 25 to 50 times greater
than the total dose given to patients in the present
study. As we have suggested, larger doses of
nicardipine given to man might also have the same
protective effect. In the same animal studies the
agents used to induce hepatic injury were carbon
tetrachloride and d-galactosamine. The pattern of
hepatotoxicity caused by these agents may not
resemble the centrilobular necrosis seen with
halothane, so a comparison of the protective effect
of nicardipine for different hepatotoxins may not
necessarily be appropriate.
In animal studies the severity of hepatic damage
caused by halothane is related to halothane
concentration, but this has not been demonstrated
in humans. Despite the random allocation design
of this study, the patients receiving nicardipine
had on average a longer duration of anaesthesia
and consequently a greater time-weighted halo¬
thane average than patients given placebo. This
raises the possibility that a greater hepatic insult
was imposed in the patients receiving nicardipine.
However, no correlation was detected between
duration of anaesthesia and magnitude of GST
increase, a finding in aggreement with those of
Allan [2] and Hussey [3], suggesting that this
difference between the groups is unlikely to have
influenced our findings.
As in previous studies investigating GST
release following halothane anaesthesia, some
patients exhibited a large secondary increase in
plasma GST activity 24 h after induction (fig. 1).
These patients were distributed equally between
the two groups and nicardipine seemed of no
benefit in preventing this less frequent increase,
although many more patients would require study
to be certain of this.
In compliance with the study programme,
patients with abnormal liver function tests before
operation were excluded from analysis. It could
be argued that we thus introduced a degree of bias
into the results by selecting "normal" patients.
However, an examination of GST concentrations
after operation in the 16 patients so excluded
revealed a pattern of GST change similar to that
seen in those patients who were entered into
analysis.
GST is a sensitive marker allowing investiga¬
tion of liver dysfunction following use of volatile
anaesthetic agents in man. Further investigations
are required to elucidate the mechanisms in¬
volved.
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PREOPERATIVE CIMETIDINE DOES NOT PREVENT
SUBCLINICAL HALOTHANE HEPATOTOXICITY IN MAN
D. C. RAY, A. F. HOWIE, G. J. BECKETT AND G. B. DRUMMOND
Toxic metabolic products resulting from halo-
thane biotransformation are thought to be a
possible mechanism of halothane hepatotoxicity
[1,2]. Metabolism of halothane occurs in man via
both oxidative and reductive pathways. Van Dyke
has demonstrated that metabolism takes place in
liver microsomes [3]; cimetidine has been repor¬
ted to bind to liver microsomal enzymes, specifi¬
cally cytochromes P450 and P448 [4], Conse¬
quently, cimetidine can impair the metabolism of
drugs that are metabolized by the mixed-function
oxidase enzyme system. Drugs known to be
affected in man in this way include anticoagulants,
benzodiazepines, beta blockers, theophylline, anti¬
convulsants [5] and lignocaine [6]. Animal experi¬
ments suggest that cimetidine reduces halothane
metabolism and consequently lessens the severity
of hepatic injury. Although two groups ofworkers
have demonstrated this reduction, they differed
on whether or not it is the oxidative or reductive
pathway of metabolism that is inhibited [7,8].
Glutathione S-transferase BjBj (GST) con¬
centration in plasma is known to provide a more
sensitive index of drug-induced hepatocellular
damage [9] and correlates better with hepatic
histology than the serum transaminase concentra¬
tions [10], We have demonstrated previously that
halothane anaesthesia produced significant in¬
crease in plasma GST concentration 3 h after
anaesthesia. In some patients a larger secondary
increase in GST occurred 24 h after anaesthesia. It
has been suggested that the peak in GST
occurring at 3 h results from alterations in hepatic
blood flow whilst the increase at 24 h may be
caused by production of toxic metabolites [11].
D. C. Ray, m.b., ch.b., G. B. Drummond, m.b., ch.b.,
f.f.a.r.c.s. (University Department of Anaesthetics); A. F.
Howie, b.SC., f.i.m.l.s., G. J. Beckett, ph.d. (University
Department of Clinical Chemistry); The Royal Infirmary,




To assess the influence of pretreatment with
cimetidine on changes in hepatocellular integrity
after halothane anaesthesia, 53 patients were
allocated randomly to receive either cimetidine
1600 mg orally or placebo tablets before
anaesthesia. Plasma concentrations of gluta¬
thione S-transferase (GST) were measured as an
index of hepatic damage. Data from 45 patients
wereavailable foranalysis. Plasma GS Tconcentra¬
tion increased significantly 3 h after induction of
anaesthesia in both groups (P < 0.01, both
groups) and at 6 h in the cimetidine group
(P < 0.05). Pretreatment with cimetidine did
not influence the magnitude of increase in
GST concentration. There was no difference be¬
tween the groups in the frequency of abnormal
GST concentrations at any time. Cimetidine does
not appear to prevent release of GST from the
liver by halothane anaesthesia in man.
We have assessed the possibility that admini¬
stration of cimetidine before anaesthesia could
prevent the release of GST following halothane
anaesthesia in man.
PATIENTS AND METHODS
The study was approved by the Area Ethics
Committee. Informed consent was obtained from
patients aged 16-70 yr (ASA class I or II)
undergoing minor orthopaedic surgery such as
arthroscopy. Patients receiving regular oral medi¬
cation of any type and those who had undergone
halothane anaesthesia in the preceding 3 months
were not included. Obesity (weight >120% ex¬
pected), excessive alcohol consumption (> 3 units
day"1) and a history of previous liver disease or
recent blood transfusion also resulted in exclu-
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sion. Patients were excluded from analysis if their
duration of anaesthesia exceeded 90 min. Patients
were assigned randomly to one of two groups, to
receive cimetidine 800 mg orally the evening
before operation with a further 800 mg given at
the time of premedication, or equivalent placebo
tablets.
Premedication comprised oral temazepam 20
mg 1 h before operation. Anaesthesia was induced
with thiopentone 4—6 mg kg-1 i.v. and was main¬
tained with 66% nitrous oxide and halothane in
oxygen. All patients breathed spontaneously via a
Lack Mk II system with a fresh gas flow rate of 6
litre min-1. End-tidal concentrations of halothane
(Penlon Halothane meter) and carbon dioxide
(Hewlett-Packard 4721OA capnometer) were re¬
corded every 5 min for the duration ofanaesthesia.
Patients were withdrawn if the end-tidal carbon
dioxide exceeded 8 kPa. The mean of these end-
tidal concentrations was determined for each
patient and a time-weighted halothane average
calculated (mean end-tidal halothane concen¬
tration x duration of anaesthesia in minutes).
Blood samples were taken for GST assay before
operation and at 3, 6 and 24 h after induction of
anaesthesia. Measurements of conventional liver
function tests were made on the day before and
the day after anaesthesia.
Concentrations of bilirubin, alanine amino¬
transferase (ALT) and gamma glutamyl trans¬
ferase (GGT) were measured using a Sequential
Multiple Analysis with Computer System II
(SMAC) (Technicon Instrument Corporation,
Basingstoke, U.K.). Plasma basic GST concen¬
tration (Bj subunits) was measured by specific
radioimmunoasay [12], with a reference range for
GST of 0.7-4.0 pg litre-1. The interassay co¬
efficient of variation was less than 10%, and the
intra-assay coefficient of variation was less than
5 % over the range 0.2-40 pg litre-1.
Statistical analysis
The demographic data and anaesthetic charac¬
teristics for each group were compared using
Student's t test. Changes in GST concentrations
within each group were compared using the
Friedman test. The GST changes from the
preoperative values at 3, 6 and 24 h after induction
of anaesthesia were compared using the Wilcoxon
signed rank test. Differences in GST changes at
these times between the two groups and post¬
operative conventional liver function tests rela¬
tive to preoperative values were compared using
the Wilcoxon rank sum test. Correlation of GST
changes with total dose of halothane adminstered,
and with mean end-tidal carbon dioxide con¬
centration was with Spearman's rank coefficient
[13]. A four-fold table Chi squared test was used
to compare the incidence of abnormal GST values
in each group.
RESULTS
Fifty-three patients were studied: 26 received
placebo (16 male, 10 female) and 27 cimetidine
(18 male, 9 female). Eight patients were subse¬
quently excluded from analysis: three were with¬
drawn because of excessive duration of anaesthesia
(> 90 min), three had abnormal preoperative liver
function tests, one refused to have further blood
samples taken and surgery was cancelled in one.
End-tidal carbon dioxide did not exceed 8 kPa in
any patient. Data from the remaining 45 patients
were analysed: 24 had received placebo (14 male,
10 female) and 21 cimetidine (14 male, 7 female).
The groups were comparable in age, height,
weight, % expected weight and alcohol intake
(table I). The mean dose of thiopentone and the
mean end-tidal concentrations of halothane and
carbon dioxide were similar in the two groups.
The total dose of halothane administered, reflec¬
ted in the time-weighted halothane average,
appeared greater in the placebo group, despite the
random allocation design of the study, but this
failed to achieve statistical significance. Twenty-
two patients in the placebo group and 17 in the
cimetidine group had received previous anaes¬
thesia.
Table I. Demographic data and anaesthetic characteristics for
patients receiving placebo and cimetidine (mean values (SD))
Placebo Cimetidine
Age (yr) 33 (12) 32 (13)
Height (cm) 171 (7) 173 (11)
Weight (kg) 68 (11) 70 (11)
% Expected weight 99 (13) 101 (13)
Alcohol intake 1.5(1.0) 1.5(1.2)
(u. day-1)
Thiopentone (mg) 412 (78) 425 (59)
Halothane (%) 1.2 (0.3) 1.0 (0.3)
End-tidal COz (kPa) 5.1 (0.7) 5.2 (0.8)
Duration of 46 (17) 43 (20)
anaesthesia (min)
Time-weighted 53.6 (24.2) 41.1 (20.1)
halothane average
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Table II. Medians (1st, 3rd quartiles) of GST values (pg litre ') for both groups. *P < 0.01;
**P < 0.05 compared with before op.
Before op. 3 h 6 h 24 h
Placebo 2.7 3.1* 3.0 2.5
(2.1,3.2) (2.6,3.7) (2.6, 3.4) (1.9,2.9)
Cimetidine 2.5 3.3* 3.2** 2.2
(2.0, 3.7) (2.6, 4.4) (2.6, 4.2) (2.0, 3.0)
Some patients in each group showed an increase
in GST concentration which exceeded the upper
limit of the reference range (4.0 pg litre"1) (fig. 1).
There was no significant difference in the fre¬
quency of such abnormal values between the two
groups. One patient in the placebo group exhibi¬
ted a large secondary increase in GST at 24 h, but
no patient receiving cimetidine showed a com¬
parable change. Cimetidine did not appear to
influence the magnitude of increase in GST at 3
and 6 h. There was no correlation between GST
increase and total dose of halothane administered,
or mean end-tidal carbon dioxide concentration.
Concentrations of bilirubin, ALT and GGT were
not significantly different relative to preoperative
values in each group (table III).
DISCUSSION
GST has been shown previously to be released
following anaesthesia with halothane and enflu-
rane but not isoflurane [14,15]. The present study
has been unable to demonstrate that cimetidine
influenced GST release at 3 and 24 h following
halothane anaesthesia. Although no patient re¬
ceiving cimetidine exhibited a large secondary
increase in GST concentration at 24 h, it would
be necessary to study many more patients to be
certain that cimetidine prevented this less fre¬
quent increase.
Halothane biotransformation occurs in vitro
[16] and in vivo [17] and this takes place in the
Table III. Median values for pre- and postoperative conventional liver function tests in each group
Placebo Cimetidine
Pre. Post. Pre. Post. Normal range
Bilirubin 12 16 14 17 2-17
(pmol litre"1)
ALT (u. litre"1) 16 15 20 18 10-40


















Pre. 3 6 24
Time (h)
Fig. 1. Individual values for plasma concentration of GST
(pg litre"1) at each time of sampling for patients receiving
placebo and cimetidine.
Significant changes occurred in postoperative
plasma concentrations of GST in both groups {P
< 0.001 both groups). GST increased signifi¬
cantly 3 h after induction in both groups, and at
6 h in the group receiving cimetidine (table II).
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microsomal fraction of the liver [3]. The binding
of halothane metabolites to rat liver microsomes is
enhanced by agents that induce cytochrome P450,
such as phenobarbitone [3], and reduced by
enzyme inhibitors such as SKF-525-A [18]. In
rats exposed to halothane, Jee and colleagues
demonstrated increased hepatotoxicity after in¬
duction of cytochrome P450 and showed that
significant protection was afforded by pretreat-
ment with enzyme inhibitors [19]. More recently,
cimetidine has been shown to offer protection
against halothane hepatotoxicity in rats [7,8],
although the reports differ on the identity of the
pathway ofmetabolism inhibited. In hypoxic rats,
Plummer and others [7] suggested that cimetidine
reduced reductive metabolism. In contrast, Wood
and co-workers [8] showed that cimetidine re¬
duced oxidative metabolism of halothane in
normal untreated rats, but failed to demonstrate
that cimetidine reduced metabolism by these two
pathways in the hypoxia/enzyme-induced or tri¬
iodothyronine models.
Possible reasons for the differences in the
observations of the influences of cimetidine on
metabolism in animals and the negative result of
this study in man include other potential effects of
cimetidine such as those on hepatic blood flow,
and perhaps inadequate dosage of cimetidine.
Original evidence suggested that cimetidine
reduced hepatic blood flow. Such a reduction in
flow and resultant ischaemia could contribute to
the release of GST. Feely and colleagues [20]
used clearance of indocyanine green as a measure
of hepatic blood flow, to demonstrate a reduction
after administration of cimetidine. The limitations
of this technique have been stressed by Grosz-
mann, who suggested that the extraction ratio
should be measured when utilizing clearance
techniques [21]. This was not performed in
Feely's study. Further investigation has failed to
demonstrate a reduction in liver blood flow by
cimetidine using various techniques, such as
clearance of galactose [22] and more direct
methods including the use of an electromagnetic
blood flow meter [23], an ultrasound Doppler
system or cineangiography [24]. Thus there is no
convincing evidence that cimetidine has any effect
on hepatic blood flow. If the increase in GST
concentration at 3 h results from changes in liver
blood flow caused by halothane, data from the
present study suggest that cimetidine causes no
additional alteration in hepatic perfusion.
The doses of cimetidine given in the rat studies
were enormous (120 and 180mgkg x) and it is
obviously not possible to administer such large
doses to man. Most human studies which have
shown that cimetidine impairs metabolism of
other drugs have involved giving a larger total
dose of cimetidine than that given in this study.
This usually involved pretreatment with cimeti¬
dine for 2-14 days [25-27], Klotz and co-workers
have shown that a single oral dose of cimetidine
800 mg is sufficient to interfere with the pharmaco¬
kinetics of midazolam administered concurrently
[28]. This single dose also achieved plasma
concentrations of cimetidine within the thera¬
peutic range as evaluated by Somogyi [29].
However, when cimetidine was given in a total
dose of 600 mg to patients undergoing enflurane
anaesthesia, the metabolism of enflurane was not
altered significantly as assessed by serum fluoride
concentrations [30].
If it can be assumed that the dose of cimetidine
used was sufficient to reduce halothane metab¬
olism, our data suggest that products of halothane
metabolism are not responsible for the early
release of GST described previously [11,14,15].
Several other theories should be investigated
before the true nature of liver dysfunction associa¬
ted with halothane (as indicated by GST release)
is fully understood.
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